var title_f40_49_41744="Unconjugated bilirubin w anemia child";
var content_f40_49_41744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Approach to the child with unconjugated hyperbilirubinemia who has anemia and/or hemolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 694px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     G6PD: glucose-6-phosphate dehydrogenase deficiency; HUS: hemolytic-uremic syndrome; RBC: red blood cell.",
"     <br>",
"      * Symptomatic G6PD is most common in males of African or Mediterranean descent.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Mandl KD. Jaundice-Unconjugated Hyperbilirubinemia. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41744=[""].join("\n");
var outline_f40_49_41744=null;
var title_f40_49_41745="Shearing forces and pressure ulcers";
var content_f40_49_41745=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shearing forces and pressure ulcers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shearing forces can occur when a patient is moved carelessly or slides down the bed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Taylor CR, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing: The Art And Science Of Nursing Care, Sixth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41745=[""].join("\n");
var outline_f40_49_41745=null;
var title_f40_49_41746="Urticaria pigmentosa";
var content_f40_49_41746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urticaria pigmentosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 400px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGQAQADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBPtA3JG753sDyMkn0FONql1CUkkJi3BwYxkHHQH1Of0FQ28yJIMLtLoXBA7jHf6Yq/D5iyoFVWU53E8EdxxXkz0Ps6WupMkSl1BcqgXcN/+NQac7sVWRShbkKeVx2OfU1MsPlWzLDF5i5LbNxJOepBPP8A+qp7VxzH5flKnyYIyMY4xjoPeudyOyKTVy1HIUG18+WBnOc8+/8An0p7OqLu8xnA4yB39aaqyCIDaV2dwPu/SpN3yfKDz2U4z/8AWqGDVhjMucAEqRyMZ/Oq1yJJVCR7FGOcjkVYlQW0DMqOQASMEk5qmHV4VlRXYMASmOh9TQVHuVJYxKEt3AimKny2Xk49c9jSwpFHHIFkL9NzN0Lf0q5gOhXOAefxJHNOeJFiCoi7XJyNvBPuKpyYW6EESJOwkKo/GQ3PH09amVM4DIu9BjZjAHHFLEg3kEjJHAU8VJImEwckj5l54P8Anmhu5FtTJaDyoAGgUgEYRTkA5JJ598fmaoamMRMqLgDHGfuitq5RZCjEkMuSDnHPQfX/APVXP6kpubb5d64bPPyk7T/I1cXd3CWxwfiWXy5HUAB8dR6dv68Vw4X7T4h0+NmJCy72OM8L8x5/Cuw8RSxTkzW/+rYcAZ4Oen51yujqJPEVuyuQY43YBRknKkZ6Y446/hXtYdaWPmsydlqei+DpWk0zfGgd0nkXkkcbiR+jV1aWx3s+V3lzuIAJC+314rlPCsuyW6i2glpC6468qMjHb2+tdjbhJYyGTcJlG4E4LL0P415mLbjVkexlz5qEX5Es0UjRHy3EbAjrkg+341Heh2tJGYsSAfuEk/gOtPFp5dm0EMvllSAjjGQM8DB/WpjG0hQqWUgk7QPboa51LsdrIU+e3zGSGYfeKcjjuPrUllOZYizRPGFYrg8k47/piiG6EzGMRlmgG5sjIbnoOMUxXuZZIWVQIXBMnmgFl+g+lXoYWb0LToqguwIO3AySNoz0FQtGs7oXXz1H3SU78dMdatBPn2sFDjO5cjr65/z2qrc+VlI2G5SONoIwB3OOlTccbjnRslYo0A6luvPelVmdmBIboWwc4Pp0z+NSwSJMrNBhkXumDz6UM3JESOpPJYrgZzwP8+tS2WkEEZChxI7GQ8qTwP8Ad9P6461o26lctyi/oR/Ws6HzRLKZNqR7sKUbJc9tw7Vq2sJ8sJlUmICkD5hzzwfyrNsuStuOe3dnCqQRtwVXHAPQ4/D8ah+zbQIWbzYiAxjIzge2PcdOvWrEpmLkXXzBQFRQuCBzwemT3/Cq6TTOx3uRGD8uGDEYxycZ/Kj0IVxuSkQVfn28gde3qP8AOKzX2lVjkkBfgkKQApHPA9BjH51ZuJGin8hQQehIXbtyC3XHSsuIySxm5nthHsOAXOewwc/hx9RVx1YpXirliIqrKoUICcbjn5MDAHtV2I4jChCZP4crzjvj/D3qtbtmTAOQwxkNyT3z25zn9KtQQqirGm7yx6Dg/hjqPatpkUdiWJnecbFIVFyWLYKk44x/PtU0sLTToSZfMUb9w4yfeqmnyLNEWV2yygAnnbzgg569unrWpAkkcmXJVQDjJ9R1Of8APJrCWh0qJXQYEjyK+4DBccAcc5/D1p7MdqIieYzEEhTk4I+99BUbP5lwoZVkWSPBR1yRnqSf6VZlFwGH2ePGcDdnaQvU4xSbG1bcrzweZIJHbavG1SenuR6+1U76eaGJ2iVF+UjLtgA1qhlAJDKdsZyck/lnjv8ApWTdxw3DKrKWSNgwwfvEc8/4UJ9Bx8xkUm+2jeRWVnXJ8sY29eeKJ3mfyIbeKQpJ8pdjtwP59abql+trHhhMVk4UAYP1H04q3aOZIFEzI7jAYqe3qfbjtRqXolckSN96oFMkWw5ds7iR/n9KR7EPHFEZJQB82SclvqfTtVmKPO0q3UEZzj8Pam3kgihkZ1aTbhfLAySc9qLmHM27RMy5h8wIEuCxVSp3DGT6/WsfU0kigUIA8mACRkZ9/pXR3ThkEu1lzjKnqD6fh/Wub1WFPO+08hghTBbGRnP+fxrSD1CcdDzfxMqxnEYUZ449+39a5zwzEz6xcyRPt8uFY/uE43Nnt7D9a3fFQ2F98j5JLE7untisnwgrsdRcqRGXjTOO4B/Xn9a93CrRHy2aPsdp4aZhqVzCzYO1GznvyMj8RXb6eWZB5jjzFzls8Dnrk/SvO9EAXV24GySLPPU4bp9cGu9smEUpcszgrkpnk5PX26fSvOzCNqjPWyeXNh0aQjLPG6vhSRgEjlvX8vzojc4fcjIdxUZ549c80RrnZxjadygHAXtx/L8qHnWK5t4AV2SE8de3GO1cK0PUfYkVQXGDht3Izjn0+vApskTskmxyJDnB2kgZ9R3/AFqUlV2CTaCT8xJGDkdM4qSMqYlliKlRkhh19MD27H/61O5lZ9Ctch/3JkCqXYZIXj8Mfd//AFU5IQxwRtUcHcep9T6/UUJ+9tE+aSCYNuwx5OD0JPXj1q2Ig0mQwPPBHJH+cH9aTYO+zILO3S2RggAUE5Tsp7YH403hYi7SSruJG4j19M9asNEXfaDmMfMc/e9uPzqZrYMnluvyE43Hk5H+f0qepfmyFbeS2iR7eJZ3HqMbznn9P61sWKSiFFkYyjGzceGJ6/TsTxxnpWZ4fluHmuI7qMxANiIH+IDsK6C3dkcblQuxBBC8r6A88j3qG7BVb2KF6IoIGaYsu8smWUEbuR/3z7/T1rMggcWv2aRikJUKjRnlMdST7f561t2863qT/u2CI+0B1yDt7j29R9KpuIr6UyBFAAMJH3ck45HsPelfQcdNGZttsS2RFLNxsLFeWPfOPrxWZqZQ+Xt4DbtoYYOOBkD06Y+lbM8bRw7fNLPuULg5G0c5HrnGc/lXM69PJaaVqVzMVLpE5GGzkAE5/E9q3pe9Iwry5YuResJhL/Ed2Q3JxwckZx0zzWhjAzbOGhLc45IH1rNsAqOQmQzggcddo/oD/Or6q88i+XkPksDnqO+SPyz/AIVtUWoqDXKPg3q8iSBF/eBlUZBIH9a0UAmZxjB/i3dPx9O2KzlPmSQKo3I7EMSNuev+cVeUIkuNrEPjkjPOMceuce/SsJI64t2uSyuLc7kQyfLktwckD19enNPi32ljuUuh2lm3yYA7nPv+lPiTZ8kjsFf5l3KTz/LH9afcW7l1RWkMJ+dvlyrdgKxbDRqzMm42uwBZkV2J+Qja/wDn86ZIu1ie2MjavX6VqXUL+WPLEREfKALxj0H16VnvdBRKJIXijQgKR36Z+ozxT5i4x5loMSNVOWUFV5AJ5z7VFawRqwuLRjtkIOz+EgH+H/PNWkgLzeYG2JHyEHAbrwfSrKQKf4FVgc4UHjnk49MVXMLlsSoIGHyDchYjcg/r61I/lqpDFCwHBxkj15+n86YltHGWSIEcs23PJOO3b/JqtFaGG7llZ3aORVLBzxkfyFIzsiO6VixUKQFHJxnb6VxWp3v+m3VqqA7W3KxOSBjkfnj/ABrtL1nTa7EKEBLhSPm+hrkNbt4gzzQsVLhWcjndgZ/P/CtKVr6jm7RPMPFcmWYevUVH4TiCaS8jHc8s7uuDkqvC8+n3ah8TuHuXyc4J4rT8OwiPQ7LaeTGHYnvuJJ7e+K+iwyVj43M5XkXrAhNRtcAYfchZVI3ZA4/DAx9a7zTwtxFG+DvHy9OSAehHt6V5/ukTULORSVRZ1BHHHbp3HSu800MkOWw6jIbnHHsfXmuHMo+8mepkVS9Nx7M2o9oQI2SXf5SB0/L60LIn2csirIE5UR43YPYHPFPiAPJLeW2Dg9z2IqdAI2d0Qb2AG/aPm64H868m57zRBCJWl23MaSwsdykqQVOOjD/CtS2tzHGEht1CAYVAnHQ5JOenWs61SaW9kdXVbXGEUZLbh1OfrWlBE8V1uSXCEgGGRBkAHrj0NDZjK97DJAWCvGQFbHysSMmo3hywySWUc7sDPTvUmoWxuIU8tlRyd29RjIzz0+lADEoA28AYyo+76ZJouO2hGksMYdo3Mw4X5Oijvx+X5VE2ord25fTx5rj5WVs5AzyPrjpU0GkWoZnEZR3YSOA3cfj+netGO3srWXcqbXfk7V5wO1Q2i7xW2oWYM6QtCroQA+ZFwOnTjp/+qtVcxw5gWIyFhhgeCf59iM/yqpKR9m8wGUtFjAjJ3ZxnkfT+daMZYCTOFgRAobOcZHXHbj/PFTe5lPuVpcpCW8tWwx6c5OfSsq/mjWN/IQoA2wBjhnYqecfQ59xW/cySQwAoPM4xGELYH/18dTn2zWJdXGyQxrs3JiUs/AI+7gZ5z149M0kgpSv0Mm+Z4zHFD5W5GCHK9cLnJIP+c1xfxIlit/Dl3GZD9puPKh656yc/orfr6V2eoSeV5DxMGcuWZWTJbAJYgDv0P4V5v8UZ0a202NX5ad5G3dSEUKOfq7frXfg481WJyZhNwoTf9a6HT+HpGuNPhds7xHgFh9zAIY5+ordDNEi/MDuGcKAu4DGenXuPyrl/CzhrdgxwYZGXAHQN839RXV2ypLjJwyZClW6A9Ac1piFyzaFg5+0pRfXQIyqgmNgQg3IASN3HA6Z6+vtU0Bn8iHzIVLCP5yDkKRjAP+e1U183y5x5qK+eP9nI/lz1PtVoRRrA24tK/l7XUsRkAZ7epPFckj1IdjRVTIzB8upUZG4HJ6k5/pU+mTNNbFsD5m2qwHB9Tx61XsM3cCiWFo4niycNk4xx/nrzV+1ubdovJgwIguCV6OvTqev86wYSVk0IG2qSoO44G3dkj8D1qlKd4wVABO3aVH9PWrs0ewMOvykjJPBqMwPt4VTjqWJ2jmhNIRWjZm3k4OQcluFxz6VPGhKjflQpBJboBnA4z+nbNU47WWI3BhkLoGysZGePQU201O6eYCS3IZvmTzCOfb8BQmbODl8JeMlusqCSRBLjjBxg+n14qG+fbNCUH7yQngc8Y9c1oyWsLyNJIV3nBD4GQQOPpxTZ4F8wDA3EA46AD6dulO5imrow7tRcW6iQHaOCFPHB4HuK4rWZGU3MewJCCBGxPLE8n8q7TUDJ9imLxNEqYG0dduefwrhfFb8m3iJjtlhIYqOQT939M1vQV5Cr+7Bnk3iJVeacrlizFRuYdScV2KxpEqoqBFRQoTpgAdK5eaH7RrVvGUGJJ1yMdg24j9P1rsSAepIyf8819LQ0ifC5g71EilOxUKSPl3DnOO/b39q7HS2DQFZlLq6kSheVJxyCPfFcjewBo5AoO1lIJ3d/Suu0NyxQhlL7dxB9QB+vI/WuLMtkz1Mheso+hs7JWkt5IiPs33XGeQABjHv/APXq3cLKLac2/wA8oBKoR949hk9KWyJeOFOkm0B0zynr9cHirKkJMVDZOeRjJUev44/zmvEufVSTVhsDSbEPImC4YbhhTitWCKIP54G2V1Cu+SRxyMc9eaxdBuX1B5y0QCoflPbHTNdE8bmB/lSUqu3axIyDnjNKTMJxcZWZRv2W1gknGTjA6cDoOeuKkjUSxlsHHRR2pbyykmgnLRpg8gDsOh6VnyzeSkoSCWVo8K6KQwAOeR69ahsuMLrTc0VfKlolUZbJKqT+Xb171L807cgHZ8uQBjv0HH59PrVadDLAQlyqxhPlLcDPrgdqnheZpIG8+FoYk3zlOhIHbipehFrq5eSNYGB3OxyN7ZACnGAG9fpVuT7RPYybomEhbKITkAnovHHT+tRW8yyq5s/JklTGRG+COpGRn3qW7upbS3t3aKfyonVZJWQ/LngMMdTkmi9zFqTkl1I4IXt4VjSRGWNmVt7Y2D06+/SqF3HHMfM27WiHR/mwT0fHb/A+1XrQMZLrfnDSfuXUfeXvnPv6+tTSYEX+tOHb7uM8jp798fjTTBu0tTk7+4gKfuQmVBdXXOM7SDgHgcg5+prxrx7ceb4meAuWjtoIo+vAZvnbA7dRXs2rNGsZLSbn2kIg6YBIJ9snPPrXg99cG81O7u5smS4mZ93YAnAGB7AV6uWRvJy7Hl51VSpxgur/ACO88MzItzdRIQWBRypOMHBz+gFdUJEj80EY2/JnHXOPzznqOnFcbpTNBrERQjmJuMY5GCOfwP5139skRZPJOyNwBtUdAARxVY5cs2+5eUy5qKT6MbLII4llUnfuUYbgtk4q7FMYz/qHiOSHIwQR6fz6VStWke3DSRkNgqVbnj+EkevGfxq6yfabZ4iu+JhhxnjnGe/ToDXmyfQ96MF+JKRNcIFgiTeMA544NadibeO4ITMUrfKEOQRj0U/nUOmh4okG8EqAmSfm4A6HqBWlCivctPE2G2hQWOcHjoT1rNinK110IdRkkigkkWMyuoxsyOSenuD71XieR5A7xbWwvAOcmreqrJM8arOYMDd0yT65qGOKOGFSokYHALep+lQTG3Iu5mxWkqXc/kSZ8wgjcenY8f56U+5WYiKaGEmRGAAzgrzg8Va8sJMZEiAOzb16855NOdElkjlWRkKZYqCfmGP8/pTRs563Zb8uZAzbcPnKgnIqmrt5RMwRWbkKwxx6n/PercdzGksVrIyvcOC6kdAR7VJLIjxTCN4pJFBHbg/5NBz3a0aMDU5RJKuEBibO5xngjGPrnmuB8WuAshZlZiOqjPTj/Cu9uYJVZYWkWOOKLhUGAWIx+VeceLowsRCMHiQLs5wXGOc+2f5V04bWQsQkoaHnemosviSLJBRFeXp1IGB+prrVPyjC46HI4xxXMeG4mbXb2bBAjh29OpLA/wBOldQm0D5fTJ9K+opK0EfBY2TdZkcu9Q38IHBx35/XpXS+HB/oqJ5eSsYdW5+bjHIrnsquGBwBxgcA10XhvdJbWrgkeWckdcjkYPp2/SuHMfgR6mQv9615fqb1kiLfMgDCRog5BHBBIz/IVozyi3XLIXLMCNq8du9Qp5albhyS1tH8/rsb2/CrF9MIbZ5kjaXBHQdR7V8+3qfZWvYsacsaXSwFOoBA6YFblkXwxOR3wQMf5/8ArVh6fclb5Q4Aed9quOmAuRkHv1rodo2ruO5io3KOT/n8qUmclVWepG8XmIDztwHztwcelZtrZyxkuzpI+5sOeMjHfHU81oTu8UJMLgvnAOBhT0Le4rKtIBqEdyHf/SVHls/QNjoahsqnHR3ehNPaTyywSRSxhYmBYFDg/wCJqWwi8y7aMxyqyjzBK/CfhjuDmoLWxudOhkS4mEp42n7xA/8A11pCO4jtZGDtI4BONpwc47+lK5U0krJ3XQbAY4PEKwm0jRrhQRJj7zZ4zj3rSvFugNm8NE67UWQ/xZKnPtyPpVOyFzHrMjyfu2WLA+XeoyeCQO1XW1MT3ohAPkLDvMhGVIx1z9e1Cfc56ifMmlfQzoBdZWK5BjmjKHdHjDHJ4B9ME8/SkvIHaVorV2jld2csoDc7O+fr17kCtG6CJJFHLG7pK6g4HygngD8sfpTJIXthO0oU7d21lxl1/hGe2M4ovYlO/vdzzv4hTtp/h+5uImHnxQMsb9DnIAzj03DFeJRoRGI1HyjoM8f54r1X4v3hSzitwwLyzFHUD7oXDf0UV5svJ5PJBC7hxxz1r6HLY2pcz6nz+bz5qyj2X5nURnybqBvmJV1HJ7EgV3WnsP7QQFiLcA704AJ7HntXCXIIhYquVAz9Mf8A6q7PTgJroOW3EHMLHngqOD6jk0setmb5JK94m/KI5ZGjOAE/iByQCPl49eGOeR+dMslZHaJmQvEpJYkjIBGCR3zn+dSLJHKpLIBsYLlF5PGD+HXrU/ltIjrGEEhULkjgY7j8vzxXivax9TGOvkOs1+0SrE58qUrgjJDMM9en+SK1Z3VITI8g2IACdgJHb5h61Usrfb86TKpVWQF14x1yT1rVR4ygFwuWLYY7Th/8QexqGZ1ZJS01M66lxbJtIMLfLtAIJ57du9SIiQqi5ZR0xnJAP8vrV+MZheIxxhIySPMPccjFUGO2Z5AiOZOAGHyj2B7fWpZMZc2hHEiyRlZFGRnGDkc96nhCONp5dBkY6e/0FNQAksWA9cjkj8uaSC3j+0efG7cqBhhwQfagbtrchtn/ANJuZbiOKOWMqquxxle2SabCkFpcmWNkXzWBy+TknOf5/pUNxZz3+oTw3AYwxAhEX+It0ye+OPpzU02nQRQxow8uSMbtyt93HXk+tPoW+XZvcz7yJilzvLOJc7mzgrnA/lXm3jCJ7Z/nIIC+WgHRFA459Sf0r0XUrgG3SSAl0dQFjH8RJChvfGK4DxhtW0lRt3yA4YknPHX+ddOF+JGWJVoNnGeEYCI755CDI8wQsP4iFyfwy3at4Rk5LMoIPB9D/X61neGEI0gnbt3zytn0Gcf0xWizfPxvYjt+lfVQTUUfneJleq/UYyjbxnI5FdD4et3m0140flkkj3Hjvx+Iyf0rAO7AIBOeSPbnNdN4XkUWbhv4JCM98Hr/ACP51wZl/C+Z6+Qv/aH6P80dZayKsBMxJ8oCJ3IGWAxjj/gX602G2Nh5ccS74YwxIxy+TwPwzTYVcRxysWV1Vsoh5yRgfyq5cSxyWTbZVjdlCozHmvm2z7heQy0tzO0TXC4uhklsYUDOR/8AX/nW+kQZ4ZPNXYeQQcdsEj1/zms7SbFIRKTJIWZuXk4OB6en/wCutF1tInsy24TfNsYDORjng9ulNyOSryuVokaTr9sezUbZFHDsMjGec1oW6qqMI12gjPPBY47iqxsA+ofaHZmbA2pEQMfWrDhpGYqVdxjIzwPUDuf/ANVZtmMuXRR+ZIu12MnMaN0J7nuasww+WuWMgTPCqeWBx0rJkgNzbyQzzZV26jIAI6AVowreWqQRqDcNvCEu+cLn+nFSZ1I2VkzWtlidZdiqu/5DLuyD19apWOnxWsEMS/vZFLIXIwVJzwvY4q86SS28tvb7Y7mPBjKjGQOpI9KS4kmtrJZFiErhGJVegOM5988j3960RwqbV0nv/kY+poS0cTna4lWSPbn72OD+fWq93CNjNdF2DKFYRYCllwTn0wSePatoojb1YSRu8ZbjsxHcn6fmBVC9jzaIThWZdvTOBj9eec1B106myPn34k3Hn6vY26EkQ27SsF/vSOSN34KK5LG9mBHBzjPfnpXQ+P8AcPGmqIQCY/LjODn+AE8/ielYWNzNtbjODmvq8IuWlG3b8z5bHzc8RP1t92h1UrFc7QOmOMc11nhnD2UEkgB+QJnHAIH/ANauVkJLMdvT/PFdL4U/eaW0as2+FmHTvk4B/OscwVqVzvyOV67T2sdRAp+4doc8DbyTyR+OOlWPLJVgR8z5UycdMdfrxUMI3zSsm5i/IBHTp0/Q1djwiK8p2qwyCeQfX8xXhS1Pr78uhNprM1iI2EpVY8ebwAecH8e+K07fy41/eOxRcFizZLnHP4E81SjiZUMcZyiH5R75yf61dkn8yOKTaqEDJTgkAcH8KzOar7z06lMX6TXMsSoCq8IWPzNnnHt7VFIh+WVhIoUjaypx9CBx361dmlT7UoCxlmAyWAAYA8Y9DWc0M0dpdq05RiW28HAH0pFwt002GzuXuJUaHcF2kbTjPqfwqaK9jVbhY4xGsA2kjn8OagWIyX67pHVhCDhB8pP9a0zbwOhhKowOAQT1HqfT60bFVHGNkyCwv0nlS3dTHcSDdtXJwO34U2SY3UF5bsvlOjeX7njg59c1Lo7eZdOl7GkdyoZVVFGdgHUn0/pRLHDZl2cqod9zkt7YGPxxQQ+VTaS10/pGHc6WLeKIxtl0jSLLfdVQe3pmvM/GkioHWRhuzkKeCDg9fyzXqeuyyoY2Uboi22TacH6j2FeQ+OJhLDLcYZJAmdhXBQFSBkduM/nXXg1zT1M8XJ+yu+pQ8Ogpo1kckl03ndyTuY/41o43Dghl4GSMH6VT02JodJsY2H3YIxwcD7oNX1IKZO7J5O48Hivq0rI/O5yvJsr8ByDkDqQuee/4VueGyoViM7vM+7uzuGQMH8z+VY75yQoB6knpg+lbvhiJWHLBhvfleMcA5P8AnuK8/Mf4Nz2ci/3n5P8AQ7DSWEr3AVV2pKEyxyDx/n8qsxKjwIbi3w29VKBR8vbcKp6PY+VZmDzG8sly2Mkrk9AfxrV02LzYLYXDSsAxc9sdhmvmZbn3HMkrlxoozE8bvtSQcAnnp2HepNPlTzIkdo5LlEIUgZYDHPXtShhAwNycqThDxwfSnIqkySQRIWIKByBnPqPbNI5HqmmNubJ3nWSOaSB4x8pjPLg9SR7U6feY38gB3Kt8xO0v9P8AH6VBpiSRWJjuZAJ5TkkNnrnge3ritB40lC/wkAYKY6VInKzs9bGXp80sGnNLeeZHcg8IRyfTrU+n3moTozRvGVR87hnAHUqffoahuLZpJ4rG7d5ZRJ5sZVeAP9o1vadZASqF2qHBJRujdskfWpsVWnCMXJpXevkWtGum+xwz3smPvoHZsBxn+vSrF/dSRy2LW0cgF1iPY33F4yD9elNXTxJbMZXZom2KqLzz1yKbC00d1dpI4lCsrRIwLNF6cVqtrM8p8kpOa+7+vUq6kk+LSTbbxu0jCTcekWDxg98gGszVrq5trcBfLmuJbkxj64JCj3GFH4VavFlfUNmHZI41ZM8hyfvKf0/MUl4YYjCp3yTQESuQBwcHn6kCpaOqnaKjfU+atYuft2uatcvwJLmUjPUAOV/9lFUAG3DZkNjv/n/OKWE5VZMktIS4zjuc09lLHCnORnLDBz/X/wDVX18IqMeU+NnLnk5HSScMcng8/wCfxrpPBzhLe8TcQI7jLcckFQR/WuemG1sj7xOT/XP4VveClQ3GoA5AfynPORwCOR24FYY5Xotnbk8rYqK73OyiQidlB+6NrDuBj/8AXSy3KxxCZFMo3BgFGQD/AJPNRZf7bK0KvhpBHICeBheMc981btFjEEAEZjCghl6lfT8a+ckz7iNlqzRtLiMxGUkJhQdp6joenpjr70lrLYgn7NLh5OFRzk+vH+RTYbDzNSM8pBjVCGBPTPv9Ktf6Bp1v9pTGC2wFBn8j2qbGEnHaN232Ix5mInjWJoyxDbvT6f571P5CTRBxJvjf5Suent/SpN0TqoiJMcnIVR0/H1x61VthKry/aWXycnyzHxnnrjtUmd21faxn3FhNHfwSWzBYI127TJggf1rQijkEuU2GNlwzt3z3/pTNRtEvxG/2jEkZLJsOAwHXPoPemwW0tjabLVJJmQkornlyefwpo1c+eCu9dv6ZdjjS2t3ePY124O0t1fHQHPsapajpcswE8pST92FliY8ZHNXfMkW8hjix8o3zKVwQp6c/Wma7MpBF0NsJXYTjv2oMacpqat1MW9laW3QSKUZk3MB1Hb/69eNePZWMN6rjY4CxM2Mbjg8/TnH5167qNobdLg27N+9PylskJlcZ9TjH/wCqvI/HLOboK7745fJj3lcBzuI4x0HX1rtwS/eCx7UaLcexKVVY/LUKBGACMcYAA5/KnIu4kcADt71Lt/1p6gng+v04ppGBuI2rgDge3T6V9UmfnTAHaDz8oGOee3atnwtIUjuGCllXe5Xp/d9KxJAeuOc8H1/zmug8LQhreYk7NzSAj2O0fpXn5jb2PzR7WRK+KS8mddpZu4ntkkQNDL5jFhj5Rn5f0x+VbVpNA5kjD/MpG4Dpzzgf4VjWMGyGNJHYwIq7ix7dBz2rQnvreyQSS5Cg4YoM5Ppn1r5eW59rJcy0RdniWRlVFUqrZ24zj9atZBCG3b5264HFUJYo1t5JIEd7iVAgXJG7Pp+FWP313aLHagw7WAcsp6UrmMlotdCWJWSZjceXuHyYUdOP89KLeDyZc2zFgSPMBOST2GanaZvO8hgskxXJAHAB/pSIGkuzB9maONQCJcgAn8O9KyMuZ21JgQqngFT1+bOMdqt6fKkZMspIY8NuPAHoPp6VVitJAy7HTBA425x6fXNN05X1Fp7aZCyxyMuzIBOOfy/OhbmM1GUXrp1Nax1Tzbm4gnAHkrvSQLwR1H17Uaq/kss0Sn7UWEakdwT83Pcgc+1TW9itvHF+65JGwn+7x8v0H9Ks3fmBEDxqkeOFJ5VejH8e1aJaWZwucFUTgtBrDyXLSGPdtCgbccY6VxXi27Sz0zUrho2/d2zTmQ9GwjYAx7AfpXUrvnnuISCFwEPmf7v8OPrj8K4b4rFrfwbquC2Psnkq2MZO5VA/Wqpx5pqPdlwl7KMpPex8+wb1hjBx0UdTxxnH4VKeGJPYcH8PSlwrMdgGeR04Hpx0pTnHHGcYzxX1vmfKXZ0kqMcDHtgtWx4SAN5qCICjGNVDbuQTuArKd/vAjBB4JPStvwb5jX195SjJSMY7AbjyPeubG39hI78q/wB6h8/yZ2SRyJcI4zsPO085Lcg/mDWgiuJBgBSDsJHrx1FQ3E6pbK7oG/d/MQed30FTWM8ayKqy5lKlRvGd2Rk5/Gvm2z7XdXNHTQtx58iRsMttc5zvx2/+vTbizYyhIcQw42uMeo5Ap9nEYDhjznH549KvGQqXidyCckfNx9c9jUepyym4zvExtLtIoHngErO+NzZPP4UXWpGKaWGQlMx7klI+Qk9Pcc9qn2OkpKKhVuMnGcdqo3yXV85tpIj9nG11c8g4/g/SkdEbTnzTZdidnKRzrGsuN2OCDz2NTTMLWJpZWbOMKSckk/5FUYPNtb+SKVlmAQPb/wB9fX8h/KrwWeW4aN0V7L5WQk8++R65o3M5pJ+W/wDw39dyvoMt09vAZIZGDMY5ZGHzr1Oee3apJ4J31DNyYzZop46ZJxgn0rXmYy22xRsVfmDZ5JFVtQj8+DEmGQjHzdQeOaepkq3NNyta5yOqLM8oCxnygjFGBwO4ryjxbbf8TCwgj27RcRAKW5+Xkj9Dz716zrVrci1W2WfZHEo3uOpwSSOnpxXluvqTrlogRSUd5eeT91s/+hfpXfl6ftULNZpYaTXZiKjFvlUA4zx2pu3BY85PpU0jAcBRg9j9f5VEykBt3JHBA496+oR+fyeoxlLkkE9CefX2rovCCObYuDgF2yMZzyKwGDBmPy84BJ44zXV+EQPsEZbnJYgH/ePNebmr/cL1R7nDyX1p+j/NG6kcLH7LdhpRMSwUH+6RgVtW/S4+2CN0STeqRjORjr+Gax57gRXMM3l88KVz82WyM+wxXVWasFKsdxYYXnpg/Tpz+lfNu/U+uqy5YpmSLaSa7F7IGKquILYkdehYntWzbmWGESXaKj42nDcE9uTS31j9rtfLYhdr4O0/eAPQfWoPEd0BYTQpEHkkwvC5wOKmVzFS9q4x/pInVNhLOxZmUBiOO3A/Woo3nW8hRIC0Trgvu4j5zg/WrEH7y1gllzGVTgFeQeP8/lUK2khu5pZbh2WTG2FTjbxyaWqMlyptSNFvM3t5gVSW528gU57SNb9LxmKm3jIWNRgE9QffsKrwRpa2a5lYwKcBiMlgO5q/YLcSSSSTMrE/LGmMhec5B9frSWpjJ8qbT0Lei+ddWInnXAmQFGR+c98+nNXp1jEiySfcjyW+YnHWnn/j3bfGqnOcA9T/AJ/nVW2uI7mQyxbtkkhBJXHKkqT+lbLRWPOk3OTmlZFSDT4t7S73ZlmNxuboG/qMH+dea/GAG18A3UDFmaW72KwPADTb8fgBivUXV5LZwxBzztY+nWvLvj8RH4ZsNuSv22MAHvhXNaYZXrQXmjSrVfsppvo/y/4J4eASoIz8vY9s0oA3hm65/wD1Y/rSAhnJAJYDg8c08YXIPBbjnGMfX/PavqfQ+aT7nTN94cAY64PXtmui8AEC/utu1R+7GOOeWPXv2rn3jwNoYcjHpj2ro/AESPcXzE7lEkYX+Z49a5cf/Al/XU9HKVfFR+f5M64Wyw2EaKux4zynUdM/4Vas/L3yKFVpFJJB5Yeo9qS6AaQkYYueN3cdBx6nNR6MzPd3CskYw2GC9Sc9fpjHFfNbH2t3KLbNuGR7hWxlGxhd3UHn/PNTRxMibZZBggA7hmltrczEndtR+4ABHuKvpbxRgDzQ6Z5BOfxH6UHn1Kii7IzmVEzsAkkbj0wOxx+NRozDPJyBwcdT2NCTtJdgLGypuKMXGGAHQgdwatDZFIEVgVOAcjp+PpUlu8dGU5pILe6gjcASyk4I9+cn2q/sxKeQMAAcZNZgaOS8tZrshrne6xSIuRwP04FabzBJiLtdkKx796gtnkDr+v400KonovL9egxWwQEeORUba2eO/pSyuVO1o93ynG7op6Vna7pmZ4Ht52WeVtmeQrADIzj8fxqa2mlSyMepyLviJyfb60x8icVOLv5dTF8TssdtIdyqrjafTJIx/SvIdZG3xDGhKuEifv3GAOPxr1vxIEurMhJNsa/MGbqOMjj8jXkOoj/ippu6rbEMe/Lj/A16OWK9VHPmzccG7k+ccnCksOpBJNI4B54zjsev+RSyHJxznvk8gf5FRofu8kZHAPavpEfCt6i5y3GCQcFT7+oruvBiJ/ZsDfKsYU9OASWJzXERgElhjIbp3/z/AIV3vg+NBpVtnhXTjAwSeeteVm/8Jev+Z9Dw9/Hk/L9UbGmsz24uPLXezuQoHJAO0H8q6O2x8vIJB5buTn0rFtJiurpbSI+wRNIWVepJrfWSKOM7STJxhR3J6fyNfPaH02IbvtuV9PuoXwkSLHEGYKvvk5NWFaKSYKyqcAgDGMYx/iKiWFUlVlhzICQpPzE578dutSypJDbsbdDvzk5P3snkGho5pNN6dSrM8Vo8UEKyOJX+UKM4Hc+wp8UrNPJEdqR4AVs8n1P8uf8ACrJikUOVw2MbSB0HeqUDtIzyNC6Mp2YK/fI6H171Fi0+ZaGjbJuOC+SORz0rWiRBAQh5kB3djnrn6VhpbojxyiNUMQJVl6KOMnFbmkSLLEksYY7hkF/lI9qcUtjjxG3Mi0b1IxNHBvluI4VkCYyzj/E5qle74XhbzZcXDxhFVfuNyTn69D9a3be1BcSuqq7LjK9R7D2z/Ks6eJkYBmdnxhm6bv8AOK1lHTU4aVSPNZETneVeLkFtxB5AOO1eOfHqZpdHgjCf6nU1DFfmwDExB/En9K9gt7eSGCcmcyPI0jKx5KZzgAe3FeU/HOzMHhy1mZixa8hklkz99vLKZ/8Are9aYTSvH1Lqcvsqi8jxGJigVtwBPHp27+1O+Utt2nI7A/1/OkBxnBOAOT79zSsQWCjBHc57V9Uj57Q6dt6gZzlRx8vU/wD6v511XgKOSOK4kXPMjk7emAgGAfqf51yzMFbAyxx04z/n2rsvBRddMsxFks80jnnggNg8+vSuLMXaj6np5Kr4n0X/AADoLe5aSG2LqFYorhQOnbGe5yG59q29OTFvvjRRJIwLEDn1z/SsQfvLxI1XakakEZ6H8PrW3G3kPbpskbedpdeQvfJ/KvnpM+uqLSyL7W7yQqqOw+UMGUn73p9Kbax3kTvHdxhl/hweSD7VoWc0Uqq6k4DFfTJHBpmp3HkvArwlguFyvzbB6n2qTgVSV+SxzupX/lzH7OUliQhQ+7G1u4b0HvVyBAzAorSKxyMNkfn3ptzDp6TzryjXIJKt/GPTP+TT44wLfybLMZRcR7B93moudjceRKKt6ktxp/2qAx7drAHDRnGcj+dWbWzeKxitt3n7U2szdWH+PtT1UNH5jDI77SQw/Cn2l5vHmp8yt/GVBHHU/WqW5yynNxstl+Y20CGIbdzeXwm9fmAxwR+BrOvpPtenymJkcCTbtPRhwDz39a2gxiXzAm5XbA28D6fWqi2UVsZUhJCsSQrHOc8HFUKnUSlzPfocPrS+bJbtBK/2ezbynGMEgDHP5V5Zcus2s3MqBsCJV6c/fYf+y16x4hgjtIZJw2AQqsS3ocfma8olAOrXxQcZVMY+p/m1eplSvVMs+mvqmnkOwQxx15wRjnjrSHgYyeMYJI9uKlBOTw2F9OAPSm854XJIAyBX0R8MNLHH8Qx97B613HhaRvsdkG3KmIgGA6tnlfqc1xangttPuWJ/WvQPCZRNK0wuqsBllJPRgcDP4V5Ob/wl6n0XDjSrzXl+qOvt7b94PNBJweSPXt9OcVbSGV7pZfl8vy8YIBG7senQD+dNRhIsmN+1TuZhxjtj/wDVVmJ2ZHJAjjHK5474HH6mvnkfQTmyR0YSx7fLRDzsPVvft7VLHJG+9I2aTy/kYg4we4+nNUbGGeG0b7RcmednJz1wT0GPTBqa1MscIVnbnOSowQM9ifyzRdmMorVJ3JrnIiOSxYcAZHI+n+elU72za5lt90sgijcMSjbdxA71Ncu4hIA+YD5Qfu9ayLOS7acQyTbY+Rtb7z4/iHtU9dTWlB25k7WOjdVYLjhSQcZ5OOtXLC5iivRbGVBcshkETcsy/wB761TtPLCucNuPyjA6Y9P89q1LaCLf9o8pfPUYLkc4+vpQk29DgrNJNSNePfsBbIbv2P0rDuV1AWyGVY5ZvtJDhWIURnJJ+uCK2bY72O9gDnAX9RWZrryW1lI9rEZJ94KRluJSSMgfhnitpq6OKg7T5bLUgjmlFw8BG7dGXBB/iBxt+vI/WuA+N8BfwPdZBIRoJAG9PMX9Rmu2zGJjcKG3nCMwPOME8du9cb8XnE/w+1ckq22EEAcdJEOf04ow0v3kPVfmdNWNoSfk/wAj55U5UkA4xnLDkD0pjZ3k4JGf8/WkyCxX5VA59B/nNO4ZyQGDBs5OOf8AOK+sR802dQEywADfMcj/AOv7V2Xg1wmjW8uSnLopz94lznn8vyrjZIXfJGAcgDJxXU+H0aTw/blV2Sj5lz1HzHn8i35iuHMn+7Xqexkcb136fqjr7IqjTXEzgRAhi3YDpx+Vb0UauF8lsOWDBmJ2/Tj1Fc/p5CKm4ZUjkbeff8s/5xXQafvZtrgjAznjkdiK+ee59VXVlc2be3jd0IZVkwSoA7Y5FMu4FEyDbnC4YDJzTrCzgt428sBgG3DnIDdyPT6VA7JjC9QDjnOfb/PpSaPMTvPRmZfWou1lErK8fDRKpKkMPeq63rW7wRXMJ3yj/WIPlDAdPy/OrRmViNzAM0mxQTn8eKrnelztP1BY8r171J6ENuWRpWcq3McbKTtOSuVw3oRj2otd1tLK1xt8gEkFV6DHeoRHIt0jGYqCCRGB94Y6j3FXQ5XB6gHcvOcmnqc07LRbMfuS9Rki3bYzubJxjuMfpUc8Z2u+cNjcecn/APVSrPHFIsLt+/fLJxgtjrk/TFVruYlZMjLBuUHB/P6GgiMXey2OV8WrHPZKjgFWYPx6Ag/zxXkcDEy3cjceZMxCj0GAf5frXp/jCRoLKVtxIRenevNbaJ1gjLZygy+Bgbs5P869vKIaykcHEFS1KFPuxwAKkKCWxj2qNnGOQAAenHNPYHcSAenr0PcfzqEREMCcYPQDPI9a95HyLJCwaTIYAdT06/5/nXbeFZrf+wt8zlGieSJMHrls4/IVxEY2ru5PG7p1/wA5rrfArKzXVvIFDRusyk89Rtz+n615uaQ5qDfZr/L9T28gqcmLS7pr9f0PS9HkiuLPfGSw3ENgdwef1q35UdySrEtwUJBwCDxisvT4o4gQMp5nzOBxk4A/r+lXLditwNuEWPkg8jHsPU4r5jQ+qqx95uJoJsihCRIpjjI6Ecimsz8qQFVRknt7U4OjwqucrjoopzvHFB50rJtU5G7p04NDObW+xlXV7GpCvtx6t0NJI8EEKzTBIkxsL46cgAZqvcyiSWMBgy8/KExnn+lWrK2aWd/NkEsRxsUL+p9/5VJ1uKjG70L+jtMDK90yIVfCY7j3961tPuJ59TEY2rZqpVgw+YvxgiqawLyYgpPYnj8Kt6czh0QxHC/ebjAPGP8A9dEVqedXaleVv+Ab8RCODtznO2qN6RcwR3PlgLjIjcfMjAnDf/Wq9EgCgMQe/POfpWdDJdCZ478KVwW3offp+tdElpY82mtXJdDPhif5hlsNyE6kegH5VyXxUjjbwHr4wQ5tH47gAZyf++a62bzItUkgD/JInmxpt+6AcE5+pFcr8SgkvhXxEqMoK2Eiy46nCMevbqKinZTj6nc05Rfmj5uOGiZgGIUcnP8AKo2I8zhQAW496aCpXAJXA6EgflTim5geMkDOB+tfXJHzL1Onlc8ZXPIyDkH8a7Hw6jQ6Lblf9ZKi7snI56fp/OuQkVNzHODjgY6cV6FoMMa6XZiTCjy0UZPfGOvTtXn5lK0F6nt5HFurJ+RsWcDzRQfOMIQx5z0NaUE0VjI5jLloDyCCzDcc/lUenQO28b3UbwVJPGQe1aItPMbznIjmA2tIpwT9f518/c+lqVFflk9C9HfwlVhMqLM679p4P4VXvQWAEL7SCW24z+Gfelt44WjeKRhM8WDlhyp9f1/Wo57TfE6q7o2MB1/hz3HrUs44qEZaFaytoIruaZdxM+N+MgEjj+VRTqyTq3m5J+TDfdz/AJ71NBEbdAkzGSVUw8xUAn3IHHrzVe8kfaMJzu+Xnnp/9ahHVG7lvcspOs4XIUXMI3BScEds8djVaC7u7bRXP2WSa7/54uwDAbuOf61As4lvoUHmRvGxB+X5XyO5/lTb+a4i/wBJMcqG1G4sV3eapPIAp3ZapaqLXn/wPRm8gIwZOdwwMEZ/Kuc1+/mt7sJa2byTNGWMq/wgjHPY9a2IZLq5gt5w8QDIS2BycjjHp78Vi3stysQS4EfmY+bYfTqcUJamdGNpO9jifGEzNBbwXDlpD8jZyuQSCSR+GK53gtwfbPIOfStLxDcNNrEgckiH5TnoCcH+lZZcCQEkNznOMV9Tl1Lkorz1Pkc7xHtcS0to6f5iFdu3I4ONoweP0prLnpjJJP15qQ5AJG/r09enam5GSpUEZ4xnj/Oa9A8YhzkAFdxz169q1PDd0bfV493yRyKYyRzz1H6is11Vh6nGD9KVXMTrIVJaNhINvcg54P4VlXh7Sm4d0bYSt7CtGp2aPZdOuTcxJIwZSGPA7DnH50l/BPc6nDD5gitovnZs4MnoB9O9Y+gSg2pTzcSNCrK467SfT15FaF1Ctxpwtp5C2BsZs4LV8c1Z2sfolrNSTOlhQsB5jAsevbJ+tZN5Zz3Dstxch7cncY/LCgY6c+xGasQPEnlQRuecFQxORjPWi8k2RE4Uryefas2ZU1KEtCijgyKyOdqcZA5Na0Jd1OeSACCRgY7isC3IiVBtJy3LKcdcn8RWloqzTxSyTSTIJDlAy4ZF6AYpWNa0LK9zXku3jtiUjLsBkRqMHirWlFl82VVHmyYAQ8cj+8c/hVBoDDEMDzCihgv3mcjtmtLwvcPfWKXDwmAliAhXBIBxj3FNK7PPrJRpuS2NfTrq62L56qJOWZV5VefWpJ5pZmmjER2xjAOBtYntn9Kcg+yQTO+BCql5SBnt0A78Zp9lKs9ok0IaOMkFVYbdwHQ/St0nojyZNXc0tDL1GQC4RQDuKk49uhP0zgVxvxLR4vB+rbI1PmWc7TtjgDym5PuSAK9AS18uX94zTO2SCwHCk9B7CuN+J23/AIQfXVZwX+wXCoDx/C1EFaav3OmnUVrR10Z8uFSFGScAbs+v+f60YCNlcjcB1PB/z6U4deNhJHJ/z9KjY5Zl9wCR/n36V9WfOHUTsxEiMCWYYBJ75xn9a9TtoXW1jhiTYUK+Yp5ynPyj8BXnFjbLdanaQ5YB5UB9NobJ/QV61YxE30sgwEVQEx3Ynof0/wC+jXkZnO3Kj6LIo2U5+hcsfOltoJUURs43NG3BHrWgkqIVWcA72x0zz3FMtxuUsoyvB6ev+TVu1bzXyAMcpk8f5/CvGPWqyvdtEyNGhJZjjOF45z/hVaG4kLLDOnluxIj2ncGUdDnt9KtNDIkaumw7WORgj69O9R3ImE8Rj/1WfmHH5/0qWc8WmU74ypewlI/3bgo5BwV9CB3qnes8hSOKFXJcK+TjaMHn3POK05FJxu+QqMqe9VUgLTHOMHBwfz4oOinJJegyOMp1Uoc4PPUehqdJHEbFecU5RFqNmyRSlkztyhwQQeeexoePflvnGPlJPTpjmgTlfSW5lpNeWtq8d5Ks0kjnyWCYI74PriuW1Se4h/0m8aORYIW3SAYZyewHYcfjW7qUl4dQjRT/AKKImZ8r1P8ADj3zXCeMblilrH8wZtw4JGOmR+Q6/wCNdGGpOrNRXU6K1WOHoyrO21/+Ac48jyM0rgM7ncTnoeen/wBemqOd2BgA87qYeSME42gfy/8ArflQwX72Nq5xyc496+vhZKyPzipKU5OUt2P38oCOOmM5P5UrSfu84yCM5x171Fgo4K4A5wfypxVuAc5xyQcd+/vVWRKb2EDfMQcHnpnr/n/PSk3YT5OMemOnr/nmkVeCxbByc56Y/GmOH28YHHy+5/z/AFpgdd4ZmuJtMU2pX7RbOUwSATGPm257DGD+BrtlLXEAjJ2nJXPPy+4/z715v4PujHqc0RdiJozlSc8g9vwJ/Kuz1Sd10x1hkuAV2t+65bAPOPqARXy2Opezrtd9fvP0DLK3t8HBvdafcdBawyRzIiIvkFdzyE4JPoBVtokaDD8OM8/U/dx+GKjSef7NutoVaZV/dq5IBPuaXVlkkiSeMpGUViwAJBJHYdz1H41550czlJGfAs00ssrxjd0VQQT+fbp+FdFZFfKXzOcDGcng+n51jaXJLLZwStHseT5mRuNi/wCOMfnWzZlQ7DB4IOR6Utbk4l307Fq0illUidREQSEAH8P07Vu2IHlnDYCYyccnHYZ9qyZUuWktvszxpEGzIGGTt9vetW2hDBsB8YIPsMfzqo7nkYh3V2zQhAVGG35jy2W6mrDjggt94YU+tUriQxWuVUybV+VEHOB70sF5Hf2CXFo25dxAzxhhkGuhNLQ85wk1zdCXfHI4xIGbGQM+nfP5VwXxOgC+B9fZk+7Y3JQg8jKHFdpZRXa28j3McKTO5cKnRAccZ7nrXJfEhGuvBPiZLdlfFlPHgHnOzJH+fSpT96LZvTXK2k9D5UUkD5iOR64J+opjKS6gHkcjI701Jd6iTIcn/a55H60/CcLj5gxORyO1fVI8Tc9C8Iwi48TWoLOVVXLnPQbcf1Nen2iDyJIUBWQZwwBGAX6j/PYV5v4EXGoXkudzKiRA55JJycenavWNOUqsYVQN6naTyM9s14GZSvVt2Pqspj7PDc3d3J7KFLW2SFF2onykE5P0/X9asNcRQxgOApBx689Bj/GnvAuZHw25vmOfXp+XvUdrEs9srvEy7sZDcEEcEV5x0uSl70jTXbHDzliTgsBz0PWsHWZdTsnhktYhNEX5Tb8wFbEeFMi7idq/LuOeO1MuwsqZLEqDljnke9Iyoy5J3aujMk84SF5ZA0bAbUbsfY/XtUiq3krJF8y7gCAc98H8vSnahbJcw+VMVKMwbaOvHceh96S3iXT7Nlt1DxKS7A8H3P1zQzo5k4q25YtIUgV1gjCs53uAvc9z9azpLlYp2SV9kk5Plq564rUkyYFnhYTFwGABBBz3HrWbeWkbSrchI1lClQxHAosKk05Ny6nPateMWbc23P3V3ckc5/yK858QXP2jVDsICxLt/EjJ/pXd6zNGsbNHbEMkvlBWG0DsSPYBifwrzKScy3Es3O+R2c9Oc9OPyr18qp3m5vp+pxZ/W5KEaS6v8F/wbAzFdpOc4xj9P60xiAMADd0PFMGC3BGF64/pTW6F1GRjH/16+gsfGXuPVlVm9GPoelKxIUAA5bjB/wAKi4y2ckdRyP8AGnocqM8dDnOc5FMAYYbALbe2e/saTJQAjbk/e3Ujt8hx1zjHXimyZOOSO4yDx7e1MLq4+yma0vLe5VuI5hk7scHgn9TXqcEjzw74hht5Qg8Dg4P4YH8q8gm+ZXQgfMOmOo9vf/61epeHbtrjTIbhVGZo1fHUZNeJm1P4Z/I+q4drXjOl6P8AR/odBJcXDWzRWztFuDMsxA/dnjArVtmeSBWUN06Mu3pwT+lULGN47UCVC7KSVUYBIzx+Y5rX3BPlkGcDovcda8FnvVGrWSKlsha4lTr1GCeD9KsWjy/ao1jhXyW++7NggD0FRRhkUtIq5LYX0xj+dW7XzfMQFCcsMBeoHr/OkZzlozbhMfJLY2gnPr7VdtY3Uh3chcnoPUelYz2v2mMKJpICOUweh9TW1asqmONWHnAfKCeX45arW55NZJLRmlGzbDwATxwOn0qjY6cumWssUMp+z5Z/nPIJ6nP5flVwsEUMgLAHHX+f5VLcGT7OzxKrk44zwBnrn6fyrW116HApyj7q2ZEtyXshJnkxeYCO4x/T0rnvFNql1pGrW0S5a7t3jYYxyyFc/wBK1bTFs6xxJmKaZyCedvVmz9eag1FQ/mbWHBAO08EY5H48YqXJ2ub04qM7dP8AgnxLagfY4WwCxQZ45zj86sZwSTjdjPPbntRcI1pc3Vs7k/ZppYiCem1yp/lULs7HB4PBA79P/r19atdTxX7rsex+B0P2UMBtV2LszLyMZAx7d69HspB5SkjaMhRn+tcV4Ytxb6fbK4XKoS46EkdPxrt9LiIj2yjfzlgMjBPavl8VPnqto+0owVLDRi+w4XEsViZJCJJlQttHcjPAz1qSymkdUkIEZMYYxuPuucH9f6VNBa+YCSxMicbm45HH60kIkuWjUkCQDBUZBU+n/wBeuUTlFpkgdpVY7cMh2lce+fyqaZokhZ2RtiZIIPXiqlxpn2ucMkkkbxNvBBI4xyP0p0pku0jSRHh8t/mGcbwOn4Ggi0Xaz9fIDOHYeTGdijdgjqemPrSTR/aLNl6F1KMqtg4PH50qGVHlhkXaQAYmPOc54I9RUenTW1yZTC+WSQq5A70yrWV10BcaZpTLFEzrDGMKFJYiqKX6XsTPEkixIx+YjkHOGx9MGtpTufcMnjBQ8A1l3u0RSNFyjk7htx+n50mVSkm3da9zh/FlwGgllJbdB5mQDjb8nf8AMfnXmkZCR7QGI7M3Oa73xqxj067VQY3aMNuPQgsBz71wecjjI7jtk19DlMbU2zw+IXerCPZfr/wBWmzgYXGDjHFJksMiPjHGe3tSS9tzE9QfSghUPBAA5x2P+f6V6yPnpREAx90Y5zg9v8/4U5W2quQqjHGepH+f6U2PAfIwFJGD6fhSEKpIL44DHPPH+e9O5FgkbjC5+maYoYg7jjgbQBSlio+bgenT1qJju/iyP71MLiyMNhJ7nOSOv/1/eu28Go9zoUSxyBJIpHEbHgAhiB9RzXDMcruDfMBgEdK7r4fsHsWjG0lJiSG575ya8zM1+5+Z7+QzaxL9H+aPQrGPIhJZto+UEjJOMf4VYdfPRo1fzFbILDgn2z61Stlee0niYvCR8oZcZP8AtD3PNXordIrXZAfL2/eI7ZP696+Z9T6iWj31HhykGG+d0UAsBwG7jPep4HbeWc+WpzgjjB9x1+lU5VKokMcmzZxtxlic9avW1u4i3Nu34Jwf4TRYylZLUuRXCu0McWJBvxK3GRn1x36VpoqtLuLIyggKccgfX8Kw9GsprS3BuVUTSsWkkQAHnHJH6fjWzaQTQSyyXEw+zt9xCOY/c+9NHJXUU2ov/gmvJIqQMCCqheR0BHsKbYTrPaI8aPFEDtCvx6npSkM6E7kkYjIJGAc9AR2qDTZ2uFuXlAQRSNHgsGDle4/H+VaPc83lvBl8HywockOxJAxwCTg/zqpq+yMSF1Qx7eS5xzjA6dKsTSqFG4vuEnJ6FlHf/PpWXq12I79rCC2MlxLGZgC2AD0x/Pmqk7IKMHKZ8n/Em1Wz8da5BGNyPKt0i+0qLJj82YVzsRBLZGMk555HXmvQfjpp623jmO4RW+z3VopIHcozKR+RX8q4BY8scgZ9dvH0PvX0eFlzUYvyPMxMeSrJef8AwT3/AEeLbsIwqqm5/l6nHTPtwa6q2jJlSQEptweR0yB1HqMVzmnBY7TfkfKuSOvJ6V0ukiQvkGNtmBnPy8cf0r5mprJn2s7qFzTiAErhUZQ2FPoMcZP0xT2t0UlcZy/LjrvqtYzpNv8ALBZU5QnvwQR9QQfzFSpIzR7pE6nBB4ORxn+dQcMlJOxnX4u2uliBaOKIiSOXGQGAxtYenQ1fSfdboZHTzI/9Ye2R196llWR1dQDnaQSex9/Wsq8GowaUqWyI9yRtLbs7h/e59cdKLWNY2qpR0Rdju2giaS9kh8wBirrwpXORgH24/CotORZbMXUYQed83yZwSSefaqj6bHdCEXkClxEOUcr83ccdutaFtKWgaMIYMZQKQDj39xQtRzUVH3N+vYjuJpElEsh8uCIZkUAk/UH8KrFxPHNLFL50DsGjOOQuKtt80DxTEtLGAHwOCTx/kVlXYi07TJFTckMGWBH8PPT9aGiqaT0W5wHj8rJpEs0c7GHYWXByCDjH5YP51wKyfNyBk/h/nmvSPGdkiaXOqKBHHAwTByASAf6V5qmCNpPB4yM19BlT/dteZ4Of/wAWLW1h8nTACkD2wCKX5jkluO3Hp7VGCNgAJxgDjqaduDMGZuR1Ix14616yPn2AyxO0c8KMDrUikk4RmPHOB3zVfOT8vpnBbH4U4Elg3Iz3xjvzmmyRrsDjapBx1znv+tMYnA4wTkDK9qe55yTyOQAMn64pPMxuXOQFwBz/AJHNFykiJMhghBwDjGf/AK9dj4GKyabdbyyhpGG5SM9uAfzrjmYkBRznBXtkY/8ArV2vgVBNZumGdTM/A9cgD9Qa87M/4J7eRaYn5P8AQ9LhnUROq5JC/N2CAYP59afaXcdzC4tWUlBgkcjPpWZOZLixulQKJGLou1uq9C3v/wDqpLW0XTiYlJCOclRzk4r5myPq3BWd3qakciBpWcITnGQMZ9s+g/XFW7a7iaAGOZAjdJHbP/6qx7UJKZISskbKoDIATgEd/wA+nvWzpUUcVrCsilWA+UcMAO/bB+tDRjNJLUvWl1DBeW9m0hlnn3Sq3UKq8VrW2Hupigf5fk3Pna3viq9okMDxuADKRhWxyfYelaO55Pk9DjAJx9f/AK1NI86tJX0Rbt0KqckbeuMZ/T1p5toVjMSmJNxLsCM5zyfzNVIfNhsPlVRcou1QclQ2M9e4FW7YOYYZJ2WR/KG5sY7ZyO/rWq10OCaabdxnlNHJM+5iZpAHz0XoMAds/wA6gv4Q2ybB3Lu6H7wJHJP4frVySJLtIEkBZch1AGOR/F+dZN4WMKRDGGbDnr8g9PQ8Ciasi6V5SWup4l+0DB5kOjX6KMJcywn1+dAxH5p+teRRgjPzjrtxjGf88V7X8dIQ2gTjGVS7hnAPUFmKkZ9OT+deHhxgk55yfcV7eWyboW7N/wCf6nLmMOSrddUn+n6H0PaJmCGOEKGKKMY689T+Famn2iNE8NtK6LKUkYjrx1/PGPxrL01BvXzDygYKR/FgnA/z71q2zIqTyJKQxIZkP8PHA+v+NeDLc+xd+WyNyzgjhto1hjX99I0hQd27498fy960LQsIyjDnA5ByR74rJslM0TPcEkht4QdUHVelWrlmaWN4nMIiIPB4PB/MGhHl1I80mmySd1UlRJukYblwRk8dQPQ1Rga4toz9sKswYspUYAB4/wAioL8Wi3AvriNw6khTnvnOPx7VG7rqthIZWMkbMcdQwXPAP49/epNoUvdV9uun5F4ggeYmTkcJztB7/gaWwmmkBFwgT5iqNndx7n3rNeO8hhjEEgEnmDdv6BcVrRKWtwHwWA+YgZUnp92hCqRUY9xY2ZS6yRMoVsBepIxzz9P8KqaksTJOjhdjjJAHDDHJq6k6PGTJsXc3ynoeP6f41nXMSu6MwPnRqyqh4GCOv14psmmveu9DiPEMKLpU3lyeYkgBX/dOOPpjNeQ2sjNbwliAWX5sjrXr2qOJLad4iDaDyvLx1GfvZHp7/wCFePqptpXRyRscqTjsDwf5V7WUvSS9DzuIIXcH6/oWw3y+38Q/z9KSQlmG4DOQDnnHrUYIGMFuAeuRimDggckH0Ne0j5dk7M2dqnDnjp39aZnc5YHJztBBxTMg5L+wPtSgghjzn37UxXHHIUZ3fMf8/wAqaXXgBmC4yf8ACkbg7lJA4PUnH/1utRdCxGQ2cjHc/wCfSi1wWg4vtO5Rv3Htx9a7fwDE/wDZttMWP7yWR8rwT8xAHTjvz9K4TdtB2Nxnk54/z0r0bwpaNb+HLSJRhhGoOODzzx9N2a8vNHakl5n0GRJ+3b8v1R2yEWqBgcvsweMd/TsMn1qVIiJS4OWZt23qQfr6VnRTuoBtyJZAFj542jJya0zFIwVRIwwcuR3HpXzr0Ppmu5JBbO8pDGQMCDuz378d+P51tWwXcnCjH+elc3/aEh1cQwrtto4/3kgGWZs8Advan39zcwhTh2ibCoidRnAJz37UiXTlNpNnV2bATyTlmfbkBeufUj/PetSy2NbpJgosh3kN1BP9a463u3S7hhV5yykIFHR+OpPoK6+3b7PbA8IVGeBwF9B61UWefiqTjbzLwdnLJvH3Ms23gAnBA+tXADHAjcMq/eJONwHSqNqZWdpDnbuB44JGep/w+lWFMpRfMEexvvljyFB6fqa2izy5rWws8pilRo9pGSH55zjAH51n3ylYHUYPyEM2Tw2OtWLySWVY3gUA7mZ9x6LglTj67fwqlcTP5kTPnj7yoOM7ecn0yRipm09DWjB6M8j+N483wZM5Pzq0TZ9QZV55+teCJ8wYEkjsB2x/SvoD42bm8CX2GGVkgiLE8nMq4/EY96+e5MdSATjk88/WvYyq/sX6/ojDNre1iv7v6s+ibKRZGXYxV12lZG79DirrmUzxN5Y2LIJCoH3gfl/IdfxqhbFPIjTaERgFOemcfz5rURVMUSTEtiPy1K5+X8fUnFeLNWeh9jCXupnR222O4kRQPL6853ZyCP6/jU6CNYJWXc53Hcc5+Y5yPp0/Oshp3EBljUmVQrjk5b8Ae1PM2yUSNKxgZfMkGOS4PH4461NzglSb6iG2LXSzMsphmAOxsHGP61P+6S5QxIBGR1Tgj0BHpSPcB1RkYKknzfOu0sOcj696jkmjQ77hkCoOd3cdjnsc1JfvS3LJV5DyNqk4A6/h15FS2ss5hbcikqCQoJyT6YqrLdrFGNzfL98P/D/n/CrFtcb4iwcKduW+bv8A5700ZSi+XYPNEkUM7QtG6fMEPITd1xWRbS3cKSi6bc3msyd8A+9acpMseCWSReQfQ+/5VkX90Y7e1S4jMksrbGEQ+Vf9r8sfpQaUl0MXUTiGeAIP3Y8zaeOpzx7V5Fqm2DWL9NvyeYSMnkdOPrXqmuO2JXKqzIjA54G0jAH8vyry3WTu1u8cnarFTycHPQ5/EGvYyrSTPLz5XpJ+f6FcujEnPX+LHX+lNLcjHXHQmmqQqLt+VRzjd29qGYB92eT09a91HyckO42thsDONo7fh60m4plhnb0wp6U1WyuAeabvwvO0kY5zzQJjn+9kDOCTt3d6ReSQHGQd/wBRz7UxmbPAJye/Xr3oL4YknAH4fypiS7kV5xCVUfIQV57nvj2zXsmjRmG2Adhsjj+UbuRjqfwrxyNfMvLSFgMPOikY4HzDsfXFevqHl+cPsUEck9R/d+p4/KvHzV35Y+p9NkUfjl6GnGWhhBtEQyKFOCSNxx/iTVh7u4DLAkalQyk7m4OfT1waoSB1MQRR5ijOM/dHQmrkskMKIJlPOSXwDgD5sf4V4jSPoW9Vpc0LUqtwQzAfxhc/Mf8AGtGPBCyPHgH7oHftz6VzkUcf2r7X5vmMQAgHIUEc8+/FaccjIWLOWXduYFuFH1/PioZLjfZm7GiiTeF3S+WcDHAIPFWreQvOjJKwZHUDdznt+H/6qoWF0GiwGXcw4xwW+h/OrlpCsWwuFAbkAY56cHn/ADzSOSot7m4L4RQf6sbV688e2P51JJIvlb3RSCcFd2Bwf0xmqi+Y+QYh5ZA2Nnkk9fpVe+ubee5e0kuFQqFZowRwM9/Xt/WtOfQ89UlKWi9TRmk8qKURsoZxtUFeh6Dj0/wrHkuVLOXO3azR7VyTkHk+54H4VNIwMiKSXUEE7m6EdP6ms2TiJmDDeZWbIGcgkgZP41EpXOijSS3PNfjxdpF4Ut4sD/SL6MADknaGfj34FeEB2ZiMnpzn+nrXrHx8nCpodujA7pZ5TjjIChf/AGYivIkk4AXcVGctjqD/AJ6V9DlseWgn3v8A5Hk5m74hrtY+jLbBVV34AA3EDOSDgE1cN1JJ8se8Bj03Y+pzWVYDam7JLsTxnjkg/wBP51pF0aIFDja2xvlwR04/z614dVWZ9hQacUaiZeYTFljBG372AewOfX+lWHlbyQxwZNuADj8fbnFZ1vsa2lilXPmEKQcbW9QPSpVLcCHPQAkHOfbJ6HisWgaTY5ntr6NDGSfKkxgn7rY7enHboeabbKITIhAZnOQGXcOT6enFNjt0s/OnY7DIcucd88EUJGwi3TlA2cYC4OP6fSmO6SsnoXIld1CzJEY3XbjqD3xU0MaJJNIkQjkP3t3dR0I+n9KbaMGVmPVeuG+9x1/GpnkJmGMqqqCSwyOeMcc0k9TCTd2ilq9y8Sb4gyXjrtjzyGII7fnWa96JbYSsUmYsyARjoexHp2+taVykszoI2jZFUhcr82fY9iKxHiFldK/3DKuxiDt3t646GqKp8rjbqQ6uTLp8kYkU70JDjGFJ7V5V4jcr4lunKgKyqxyMYJySBXqWq5aylCYIHy7m6k4x/wDW/KvIdblLa7O+TkxpnJznjPTt1/nXrZYrzbPGzqVqKj5jFbaV54xwT1xSqF5KjK8HBOe1QsWVijZ6YzQ8rbmbO0k8mvdVz5XRljgoCT1Hbkn0qIgHJ24XHf8Az+FMLnaQvIOMUgL7eCBg85/+v2qkhAXAPXAzkAcdKcSSTgnPXqOKbkZLY6kDnAH+f/rUzI64OGoZKLOkq0niDTFBO3z8g5/2WIOfw/GvVbMqbdED7Qf4265PH5//AFq8o0V1TxFphbdhpCBx0HlsK9N0fJSIFdyuAxBx14x/j9K8XMleSPpsldqb9f8AI1xp/wDpyzNI7KFXIBCgjHGas31wluqvKhkfOBgZP0H4fWpkAC56lupI6+4/GqUqebIHcMWjYkBjxjjk+/GfavHs7nuqak1c0Q6rAoRtpK5AIOR3JBqSPZDFEjBnz8y7hk/989/rWbNO8MqGP94q/M25uAvr6H/9dSW9yLgPIAHc5VmUk5UnrntSauCjZX6GxYWyfanmO5sLtUM2VUY7en/66uCFptQhuGuUaIKGRR39OPTvWYz7Sy7iFfDAKcEnsPp2xUySTymOMofN8wByh6jPPT3/AEFZMqzetzrA0MskKyMg+YuBuzlh16egrPuWS51iOCAAujBnkYY2jPTPf/61LFdJ5jMJPnCgrngAD1/r60K0f2aSINvYqQ7j178/j2obOGEXB3LslxBLkxE5Q7enG4HnH5isrUnxaSumSC3y7vugk45/Q/jUdxI5tgI/lQuMndxzzz6DBpbsrHZ4LhYozyxzjr1pXuaQpqnZngnxvu2k8W2lopO+1slAOM/M7E/yAx9PpXnpKsOCR6Hv6V0HxHu/t3jnVpEyQpSEjOCdqAH9d1cuoIk6MSSMjP5V9ZhYclGK8j5fGT58RN+b/DQ+gvD95HcQWztnLqWwWxjIB4rZjkiIBCfu3ypJ9ccZ/wA/zrhfB10v9mwEghoWMRB6jkkH8iPwrpba9HmPGQAQSFwcEDnII+vevFxNJxmz6nBVlOktTYgnceYrrGFY9C2RjHH51PbTKCoDlWUANuycdsD1HH1rMjfaqopwSCM7QSB/XH9amWdF2qwZdnGc/l26VzSidqdzSjmjMmI5suGBdFXOPcDuOOal2tvLpuMeSQCO2OAM9O1ZWSksTAvgDO5Dg4PUn/D3q5HMjQvIshYvnOF5YdKhxSH6FqFIzJMUbcG+YjnAJ9frS212ofLAxuflxtJzjj/PtVC4Yz5Bwd67DyVLUxZJN6qrvG20Ahhjp0OaFEzlrozTW8dcrcYY4LeYBtUgn09h1rnY7vzxPbyOH2fvUkIwME9iOwq416EujE2ZFK7mGPkx7EdG9azJJYQyRQqRHGMkEevXP5c//XrWMDNzUfUbqFydpVyCMEN2yAMfnXkep5Ou3i9Ciqo4A/hB5/z2r0fUbllQo5O+RmZcLwF5A/QV5mZfP1G9nyRG8pxgdhgL+HQ16uXw5W2eFnM+aCiSguzAYIc8HJzil3EP13AHPHSmnKEjgHng/X9KTP8ACN2eoGMnt6166PnUOdsk8jI4J55puQygKT7d+P8AOKWMkgEHI6//AF6QEKTk5HuKYr+QyR2yh6E8gH3/APrVAxUjA3ZDd+/Xv/SrDE5PPyHrVeZFGc+wz7etCsDHac+Nc0xgRs+0YyO5KkV6nojTrEVuGRPLPyNnsRwCOnQH9a8mLiC6tpix3JPGSVXp83+Feo2pLYkOQE3K65+6Qevv0/WvLzCN2me7lErRlE0mVjGB5hJAweTkDPA9qvT33lLvkZlUtjgZ56D61Q+0ByBIclsneWABPP8AnHtUdxLvTyyc7DkZGAnfgV5bjd2Pbjo7s0kVREFj8xwzEKh6EntVkbY7GKIBo4yPlOeCAT0/lWLYXjRqWlcSHOMkD6dKsz3y+XvlAZwOo4C8cn+VZSibRb2N6zmWd1dG4xhRtxx+Par2myoZFmyA65TrgBQe3HtXNwuLnyWilYRBQw+XsMcD61d0/UAqSHLlgxjZtu3gdeOnJrBx7GrWh0dxOJAfNyrEEgEjAHv60kM0klqwRQGjyRt744/Af49aqi8VYGnPzSbOiggnnoPz/OpLK8aPJkc7pSGVepQenv8AWosR00RpIRtdTjOOQD6+g/A1m6xII4l807YyMuD/AHRkkn8qWe/cyKQrADOHHG31P9K4v4m6m1h4Q1eSJisrIIY3Bycu4Tr9M1pSp881FdTKpL2UXN9NTwO7uTe3dxdNlpbiV5mHqWYk1AMEjaeMDk8/XFND5QKSSq/IMjGaA7AjAAXOM9SBivrkraHxrd9T0TwtcCOe8iDZZtsyK3oPlJP6V2+myKzqzbjldpzzj6/nmvK7G7+z6xA5zh/3bnPBBGOfxxXolpd/J5ZyQR9/0OSOfTtXnY2lrfue7ltX3bdjbZkkQsZAJI2AIzwG7fTg/rU/mRthgGyVxhu/tWGrwFGEqhJJF4DdGYdPxqW3uWn8pUdlkiPzgj7xHY/pXnumz11U1N2SQOq7MyHbzx1XsR64z1qNZxDGY4mwNzAY7HHP/wCqsyORo4PMjYZDEhG9+o9RUqSM4ByGJ6qRn9O5/nUKn3NHUS2LttPcRoUkQySoCCWYANjofbrUM00xhmaZpG4JCE5298A+9LHKGX5VVcDHyjPf9e9AnKjC4Izg4J/n+VCiJ1Oo9Z8Qqz5UnqG5BJ65rPkkjSV7iZ2zkHJ5xxgfzH5068uWNu/kkGRegODg+hxWIt1Id0UiAryGlVvl6cnH+e1axWmhju9Q1q+XEjkjaikhffuM15zpLb7VXYsHfnJ4PJP/AOr610XjGdY9DuJFHzuirH7bmAx+OTWBChiRRljt7njg162BhaLZ89m0k5qJYEg+XAwpIwff/OKN6feOOvAI/wA5qMkR4+UMT6ZFIshfn07gf1rvSPGsSeYNwO5jhcnP60isBwAAwPb/AAqEHKrkndzknr/nildsOxHQcAEf4c9u9A0iT5GJbOCD27c019qZz0xk+p6/5/8A11EGYnnjbyWGB69ajYhR8hBHByep9/SixNtRmogtbkJgkDdjOPwr06wnV1z821m3MfbjH9P0ryy5AeORNwOV4GcDHTmu10l5bnSrWSNmAaFDnoQSnX8xXDjY6JnsZW05NHTSInlxxyJwr5A9fQ/yp7sg77kbpxkZ/wD1+v8ASs1pHncAKoR12uBxggdf1NOjeUAF8ow64H8/rXmOD3Pb5raM0YwjyrwA5bdx1J9fapRBGTLiMbpCcMep/CqqEY6MAOx/iPrnvx1/GrELq/MjfKfmAf07H9KylG5tCpYvQFreGNcg4GwHv+Pp+FWNmIS3AfaNpxk+vT+tUbKZjCTMuCG3BQT06DNXoyWTD8RMw+XHPIIxx2NYyjbQ2jPqatvelbeJVG5zhATjk/8A6qnSVigIOfm7n/H1/wAKx1DGSMtuAQYz268nHf6e1WGEke3C7yuR94BmPHPHGeh47+lZOA0lcuq/kmR33M+dx5/h5OB7e1eWfG3VQbbTdMHy+a7zPGechQAP1J/KvS7m4NuDKrM5AKqPXPr/AJ714F8SL1LvxZcJE+5LSJLTcowGK5LH/vpj+Vd2X0eaqn2PPzSryUGu5zjEHnaTjv8A5/GkO4PxtKEZOR09qGY+UQTgjvjJI9evYimlstg5I7+/4+te/Y+YOku13AuuAQOAeme3613mj3K3FlFcxlVilUNlvfnJ/Mg15/OWVWBzjI6+vpXU+FLvztIa3BCywOUKnjgncP51y4qN4noYKpy1LPqdGExHmTBjLK6B+dnHIP4jNPjdVkf5stLyGHHP/wCofrSNjO5V2oedw4x71DEpTKuuRnGwDOO/Hp7CvPaPajMvLMsg5k5Q7TuOSCe2fxqxEUWc7MsD8o3Eev8AI1TBVQJIyDuKknGM47H9KV2gkDrcHa/3huO1iOMfiKza0NFPUvG74VpbclVO3Kjn0J/z7UCVZFQLJsGRjtnBxjH5cU1MY3AOdxwVxwf89/rTrZoWcgPGyxMVABwF9s/nU+ZpdsguLdXVUX5Pn35HGcH0/wA9Kp3EixgeVFkMTxt9jz/n1q3NNtYl9xBO3Kn/ACKpTygnO8MTnO0ZGPX88ZrSETCdTocf40lCfYbVckST7yCccRjdn82BrNZxwVIGOCD61H4guTceJhGHylrbhgfRnPP6AflUTHEmMHI4A68V7OGilBHzONm51WTl1LFHxjGCB7dqaMKD8pIAxnPzdR0piszPtGW9iOtKCm1Qud2PX+VdGxx3uAYAnP4d8D2/+vSedhvlAHXH+f8APSkdQCdwIoVRtBY5z3z9OtJuwxHlG4jJAPr0P/1qhmlYkBc5xxg4zTnCq/IB5P1z/jio5CmQcJyenAU0BdDZHDkg4xjGDz9a6fwHcNJofku4LRyOhLnkAMcfjyK5Nn4PAJzt5P6H2rY8BTgyajakfvEmEiBvdRz9PlrnxSvA7cBLlqo7aCeQNKjqEAORJjAx16GpYgd25zu3+vc/X/IpsLxx4aQqSVDDJ5I6Ae1SAhYgI1G3O7g424rymrbHvqXMPiw7SRFcKucOTkNx/SlWVrv94kpSIAdRg8HBxn9Ko3UsltMuY3dW+Vs8qB3/AJ1o2+7ygXVQAMEnkgntUPQpMvaeqAkygBs8gnOfTnuf0q5HJIDEAq7WIDHPOPYVSDYww2tjALDoPerSJ5gKhiCxK4XgY47/AJf5FYTR0QlbQ0WZfLyE5TBB9faojcHapcgyPyR0+n61AAqoERdyR/KoJyQffH4frTZPLwGPIz/EOtZKOptzWQ68v44LA3F0xEVsplfPHyL8x/A4/WvnSa6NzLNdTctKzSkkd2OSPwzXrvxI1A23heaEf629ItlPfnk4/wCArj8fevHCwDgYGcADd2/CvZy6nyxcu54GbVeeagun6jmYxMVdSHTgqRSI4AzuPqB2Bz/nmosfKq/LwTwRz1pivhioAz0A9K9A8g6a4ZiWx19M49a1/CUwTVWhDYe5AkA5OGQEcfgw/KsGdsy7iQSOhz1p+nXYttYsZZD8vnbXI9G+XPX3BrKpHmi0b058k0z1fCyIQSNvcZxgnjBps7kREsfmXAJPUH/OKpeY7TgOzGMrhlHU98+x6/zqdW3M8A5cjJ3L74z+leZax7qaLCyFdrr8wZcHI68HH1OKikijuWdpUIcE/eH3jjt+GKdbo62yROWcAEBgcDOM5/KhGbYAA3zcAkdfx9M/55qfM0Ltqx+zRgsT1yzHJHHQ+tRQLKxP7mONuTlOeOuT/WnqxK70YlW5OO3+T39qmjIOQWyWzlR37Z+nb2qG7Gid1YrXAwv73cPmPXv16evris28uEXzjuzIqbgeNv8AnHP4Vfvc7H2HJXd82eFIH88CsLUZRHp0oIPIYE4G3pj8jnitYamFTTU8/gl+1atqlznAeRVGf9kFfyq0gdVXZtbJJznj1/SsfSZQ9tG4P7xmdyenVjzmtDzGXID8etezDRJI+Yqe9JvuXNzA7QwLYBFOJdTyRg8ccY/GqPmPwcY4wWzn8/WljlYNkBgQDkn1FXcz5S43LNu4wMgZ4Bpu0ocH5gCTz09M+tVnlkYE8LIT/COM96RHcEbtofHU/wAXvSuKzLBA2nA4HU55H/1qiVgoJYDcTz8uSR6VC0ny/P8AeHPHalaXcD0yMfj9P8aB2HNgJtBIIOOQTipfC8y2fiS8jOFWWFH+UYHBH+NU2JGHwNhxtJ7HvTtDV28TpkEkwuo4GOMH+RrOtZwZtQTVRHpqsFXLFl3YYevtVlJEVPLAJbuemPw/lVK2j8+VHDsq5BGDyecEGreUYgKgPXoM8DtnpXlSPfg7IbEXLHey++0ZB7Z56/59KtRH5gu8sBxj15/z+dVcjzQeMcZGCeT7+nWrkduEBIxubg4OMGolaxrF66FqzOY1YKGPIXA+6Pxq6h8oRncHI+782cHA/wAKrg+UwREUjqXXoCP/ANX060okSN0X+MgOMnI9+e5rnkdES3CwbD52ksSylPx/T+lR3E2zBRQQxG3/AGv84/zmmSODJgYjG3nJwee/6fyqO4xEUDABc5Ynsvcj2x/k1KWpUpaanmXxWvHOo2Wn+crJbwmVwDkF5D6fQDA964Ft3AOBleCDg571d1vUG1DWtSvnbetxITGWHIQcIc+yjFZQUsQVPfPy/wAPpXvUo+zgony9abq1HPuSF9yKRtXA59xmmxqM5ABGBxnknrSiVwiq5RhzgMAQOaYNu9jtKjrkDj8T2+tXczsdFM4WbOGyc+nB7/T6VXeUyrtAOeuO/B9P/r0kpIZiwOAc5zwfeolJCs6x4J+6S2D+Pr+FBb8j1nTrxb2wgv1YL5kIkz6jv/X8qtRhUmcjaFVSAQexwSf1rkfA18raa1jKSFtHKct/yzf5h/49uFdarDKjt5ZBbHfpXmVIOLaPYoT54pj4pAdyuMd07g44Bx6809JkZ3hQOXC8jHB6dD2PT9KZk7GlyV43EYzknjP481OUCkLjIJK8MSScdazaOnmLEZbYsTHO4bsjpg/4ccZ9KaFlywJBcDJxwCvTPtz1/CmwtIzo6r8pVc5XGfUfyOatXRRVJQnzASw2jOeecf571m1qXHYy5maZQin5XUAZ4PUZH161k+I5VOmyZYbTxuHHRhkfiAfetWd2F0hj5jDKGUjP6/n1/pWH4xBXRLuSMnzFjaRTgccE1rTWqOerJKLPOtK50+LJG4KMAjgj/OKvMQe5POSeCRWdprBLGFSDuA6Y6d6uK5QDcDu7MB09a9hLQ+cJc7nycgnnn0wKB8rfIVAIx/ve1RpMrbjwew54xmkMsjHlju4O7HvTsDJyw3KApx2z1z+FNc55IBB+bn3qESYOQMHPTrj6UinsoJUHr6n6UrButSSXOfcHIH9OtNY5VgzYOBtI6Z9+fcU1m+8ASFI5PpUT5cEfMQ3XHGKq3cdxxcjjPTBAOeD6VLo0nl+JrBlyceaCM9fkJAqsWLAEOQR0UjH+eeaXSWI8R6eVDffbgDIxsI49e/61FX4WVSb50eqWkWY0jJHCFiTzwD19v8BU0ZKRv5m5yASoXrjrtH+fWo7curu4Y5KkgMPu4znPtwKmWGTCqjYQjJ3dfbHpnr/+uvJZ78LWI4LtFtVuWG0NySeuM4/+tWxY8QpldjNnIPb0z3rOjtxPAyTKqq2C+MfXFasHlsMZ42jB3VnNGkLPYsQxmSIl2x15I4J+g+lMMBt5nk5ZnYDdnOPb+dPCq0hw4+XIwDu2+3X2xTmjjwwU/ITkgHpwf61i9WdCVkQXhRyHZxtyG2j0H/6v5Vy/xA1gab4fvZYmKTXAW2i77d2d3/joat28LJIGGCqcnjH+e1eW/FTUzLqVtpyyHyoIxLIN3AkYf0UD866MPS5pI48XV5Kb1ONM2CBwCgwB1B6n+VN3ZUA4DD/x31NVxhiOQOe/OP8AGmLknr06jpmvVPDv0LDyDhl4PXk5xTA4J5xtJyW/vYqDIG4FSDj1oGSW6AHn6fSpuJn/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urticaria pigmentosa lesions in an adult&nbsp;patient with cutaneous mastocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Soter AN. J Invest Derm 1991; 96(3):S32. Copyright &copy; 1991 Blackwell Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41746=[""].join("\n");
var outline_f40_49_41746=null;
var title_f40_49_41747="Betaine: Drug information";
var content_f40_49_41747=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Betaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/26/7588?source=see_link\">",
"    see \"Betaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23459?source=see_link\">",
"    see \"Betaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cystadane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cystadane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Homocystinuria, Treatment Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of homocystinuria: Oral: 6 g/day administered in divided doses of 3 g twice daily. Dosages of up to 20 g/day have been necessary to control homocysteine levels in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage in all patients can be gradually increased until plasma total homocysteine is undetectable or present only in small amounts",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23459?source=see_link\">",
"      see \"Betaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of homocystinuria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &lt;3 years:",
"     </i>",
"     Initial dose: 100 mg/kg/day administered in 2 divided doses; increase weekly by 50 mg/kg increments, as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;3 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage in all patients can be gradually increased until plasma total homocysteine is undetectable or present only in small amounts. One study in six patients with CBS deficiency, ranging from 6-17 years of age, showed minimal benefit from exceeding a twice daily dosing schedule and a 150 mg/kg/day dosage.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral, as anhydrous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cystadane&reg;: 1 g/scoop (180 g) [1 scoop = 1.7 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11239625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cystadane&reg; may be obtained by contacting Accredo Health Group Inc at 1-888-454-8860.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F140582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Measure prescribed amount with provided measuring scoop and dissolve in 120-180 mL of water, juice, milk, or formula, or mix with food for immediate ingestion.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of homocystinuria (eg, deficiencies or defects in cystathionine beta-synthase [CBS], 5,10-methylene tetrahydrofolate reductase [MTHFR], and cobalamin cofactor metabolism [CBL])",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Betaine may be confused with Betadine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cystadane&reg; may be confused with cysteamine, cysteine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined: Gastrointestinal: Diarrhea, dysgeusia, GI distress, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Alopecia, anorexia, agitation, cerebral edema (associated with hypermethioninemia), dental disorders, depression, hives, glossitis, irritability, personality disorder, sleep disturbances, skin odor abnormalities, urinary incontinence, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2989268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cystathionine beta-synthase (CBS) deficiency: Use caution in patients with CBS deficiency; treatment with betaine may cause large increases of plasma methionine concentrations which may cause cerebral edema.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with betaine. It is not known whether betaine can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Betaine should be given to a pregnant woman only if needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3342809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3342810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Betaine is found naturally in human breast milk. The influence from betaine therapy is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3342811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be mixed with water, juice, milk, formula, or with food. Betaine is a metabolite of choline and is present in small amounts in foods such as beets, spinach, cereals, and seafood.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Betaine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $7.13",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2989272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Total plasma homocysteine levels to determine therapeutic response. In patients with elevated plasma methionine (eg, CBS deficiency), monitor plasma methionine (maintain &lt;1000 micromol/L).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cystadan (AU, IL);",
"     </li>",
"     <li>",
"      Cystadane (CZ, DK, EE, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3343058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine. Homocystinuria is an inborn error of metabolism in which elevated plasma homocysteine levels can lead to mental retardation, ocular abnormalities, osteoporosis, premature atherosclerosis and thromboembolic disease. Remethylation is one of the two divergent pathways in the metabolism of homocysteine. The second pathway involves transulfuration of homocysteine to produce cysteine.  A number of enzymes and cofactors are also involved in these pathways.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burns SP, Iles RA, Ryalls M, et al &ldquo;Methylgenesis From Betaine in Cystathionine-Beta-Synthase Deficiency,&rdquo;",
"      <i>",
"       Biochem Soc Trans",
"      </i>",
"      , 1993, 21:455S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/49/41747/abstract-text/7510653/pubmed\" id=\"7510653\" target=\"_blank\">",
"        7510653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Devlin AM, Hajipour L, Gholkar A, &ldquo;Cerebral Edema Associated With Betaine Treatment in Classical Homocystinuria,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001,144(4):545-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/49/41747/abstract-text/15069409/pubmed\" id=\"15069409\" target=\"_blank\">",
"        15069409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kishi T, Kawamura I, Harada Y, et al, &ldquo;Effect of Betaine on S-Adenosylmethionine Levels in the Cerebrospinal Fluid in a Patient With Methylenetetrahydrofolate Reductase Deficiency and Peripheral Neuropathy,&rdquo;",
"      <i>",
"       J Inherit Metab Dis",
"      </i>",
"      , 1994, 17:560-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/49/41747/abstract-text/7837762/pubmed\" id=\"7837762\" target=\"_blank\">",
"        7837762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawson-Yuen A and Levy, HL, &ldquo;The Use of Betaine in the Treatment of Elevated Homocysteine,&rdquo;",
"      <i>",
"       Mol Genet Metab",
"      </i>",
"      , 2006, 88(3):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/49/41747/abstract-text/16545978/pubmed\" id=\"16545978\" target=\"_blank\">",
"        16545978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matthews A, Johnson TN, Rostami-Hodjegan A, et al, &ldquo;An Indirect Response Model of Homocysteine Suppression by Betaine: Optimising the Dosage Regimen of Betaine in Homocystinuria,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2002, 54(2):140-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/49/41747/abstract-text/12207633/pubmed\" id=\"12207633\" target=\"_blank\">",
"        12207633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smolin LA, Benevenga NJ, and Berlow S, &ldquo;The Use of Betaine for the Treatment of Homocystinuria,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1981, 99:467-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/49/41747/abstract-text/7264811/pubmed\" id=\"7264811\" target=\"_blank\">",
"        7264811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8598 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41747=[""].join("\n");
var outline_f40_49_41747=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140590\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140591\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140600\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140592\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140596\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140593\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140580\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140570\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11239625\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140582\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140581\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140604\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140598\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140584\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2989268\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298857\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218393\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140577\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140587\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3342809\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3342810\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3342811\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323018\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2989272\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038539\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3343058\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8598|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/26/7588?source=related_link\">",
"      Betaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23459?source=related_link\">",
"      Betaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_49_41748="Fluorometholone: Drug information";
var content_f40_49_41748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorometholone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/55/25460?source=see_link\">",
"    see \"Fluorometholone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/47/23283?source=see_link\">",
"    see \"Fluorometholone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flarex&reg;;",
"     </li>",
"     <li>",
"      FML Forte&reg;;",
"     </li>",
"     <li>",
"      FML&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flarex&reg;;",
"     </li>",
"     <li>",
"      FML Forte&reg;;",
"     </li>",
"     <li>",
"      FML&reg;;",
"     </li>",
"     <li>",
"      PMS-Fluorometholone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F172559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F172525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Ocular inflammation:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment (FML&reg;): Apply small amount (~",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch ribbon) to conjunctival sac 1-3 times daily; may increase application to every 4 hours during the initial 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flarex&reg;: Instill 1-2 drops into conjunctival sac 4 times daily; may increase application to 2 drops every 2 hours during initial 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FML&reg;, FML&reg; Forte: Instill 1 drop into conjunctival sac 2-4 times daily; may instill 1 drop every 4 hours during initial 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Re-evaluate therapy if improvement is not seen within 2 days; use care not to discontinue prematurely; in chronic conditions, gradually decrease dosing frequency prior to discontinuing treatment.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F172542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/47/23283?source=see_link\">",
"      see \"Fluorometholone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years and Adolescents (FML&reg;, FML&reg; Forte): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F172526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FML&reg;: 0.1% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic, as acetate [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flarex&reg;: 0.1% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic, as base [drops]: 0.1% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FML Forte&reg;: 0.25% (5 mL, 10 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FML&reg;: 0.1% (5 mL, 10 mL, 15 mL [DSC]) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Suspension (as base)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4844876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Wash hands prior to use. Do not touch tip of container to eye. Contact lenses should be removed before instillation; do not reinsert contact lenses within 15 minutes of fluorometholone eye drops. Shake suspension well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F172512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of steroid-responsive inflammatory conditions of the eye",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3197884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flarex [U.S., Canada, and multiple international markets] may be confused with Fluarix brand name for influenza virus vaccine (inactivated) [U.S. and multiple international markets] and Fluorex brand name for fluoride [France]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F172557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, burning, cataract formation, delayed wound healing, glaucoma, glaucoma with optic nerve damage, intraocular pressure increased, irritation, secondary ocular infection (bacterial, fungal, viral), stinging, visual acuity and field defects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, systemic hypercorticoidism (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Effects reported with other corticosteroids: Anterior uveitis, bleb formation increased, conjunctival hyperemia, conjunctivitis, corneal ulcers, keratitis, loss of accommodation, mydriasis, perforation of the globe, ptosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F172515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorometholone or any component of the formulation; viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis, vaccinia, and varicella); mycobacterial or fungal infections of the eye; untreated eye infections which may be masked/enhanced by a steroid",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F172500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Use following cataract surgery may delay healing or increase the incidence of bleb formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corneal perforation: Perforation may occur with topical steroids in diseases which cause thinning of the cornea or sclera.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Exacerbation of viral infections: May exacerbate severity of viral infections. Use caution in patients with history of herpes simplex. Re-evaluate after 2 days if symptoms have not improved. Use is contraindicated in most viral diseases of the cornea and conjunctiva.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in presence of glaucoma. Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP); damage to the optic nerve; and defects in visual acuity and fields of vision. Monitor IOP in any patient receiving treatment for &ge;10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: May mask infection or enhance existing infection. The possibility of persistent corneal fungal infection should be considered after prolonged use; obtain cultures when appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be adsorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Initial prescription and renewal of medication &gt;20 mL should be made by healthcare provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate). Patients should be re-evaluated if symptoms fail to improve after 2 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F172517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies following use of ophthalmic fluorometholone. The extent of systemic absorption following topical application of the ophthalmic drops is not known.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F172529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14877584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. The extent of systemic absorption following topical application of the ophthalmic drops is not known.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F172516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (FML Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (3.5 g): $60.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Flarex Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (5 mL): $57.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Fluor-Op Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (10 mL): $22.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Fluorometholone Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (10 mL): $16.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (FML Forte Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (5 mL): $38.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (FML Liquifilm Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (5 mL): $47.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F172509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure in patients with glaucoma or when used for &ge;10 days; presence of secondary infections (including the development of fungal infections and exacerbation of viral infections)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F172518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aflarex (CN, CO, PE, VE);",
"     </li>",
"     <li>",
"      Efflumidex (BG, CZ, DE, HN, HR, HU);",
"     </li>",
"     <li>",
"      F.M.L. (UY);",
"     </li>",
"     <li>",
"      Flarex (AE, AR, AT, AU, BF, BG, BH, BJ, CI, CL, CY, CZ, EG, ET, GH, GM, GN, HK, HN, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PH, PL, PY, QA, RU, SA, SC, SD, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Florom (PK);",
"     </li>",
"     <li>",
"      Flosef (IN);",
"     </li>",
"     <li>",
"      Flu-Base (JP);",
"     </li>",
"     <li>",
"      Fluaton (IT);",
"     </li>",
"     <li>",
"      Flucon (AU, BE, CH, CZ, FR, GR, HK, HN, HU, LU, NZ, PT, TW);",
"     </li>",
"     <li>",
"      Flulon (PH);",
"     </li>",
"     <li>",
"      Flumelon (KP);",
"     </li>",
"     <li>",
"      Flumetholon (HK, JP, KP, TW);",
"     </li>",
"     <li>",
"      Flumetholone (KP);",
"     </li>",
"     <li>",
"      Flumetol NF (DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Flumetol NF Ofteno (MX);",
"     </li>",
"     <li>",
"      Flumex (CO, EC);",
"     </li>",
"     <li>",
"      Flumexo (BR);",
"     </li>",
"     <li>",
"      Fluoftal (CO);",
"     </li>",
"     <li>",
"      Fluoropos (KP);",
"     </li>",
"     <li>",
"      Flurolon (DK, NO);",
"     </li>",
"     <li>",
"      FML (AE, AR, BE, BH, CL, CR, CY, EG, ES, GB, GR, HK, IE, IL, IQ, IR, JO, KW, LB, LY, MY, OM, PE, PH, QA, SA, SG, SY, TH, TW, YE, ZA);",
"     </li>",
"     <li>",
"      FML Damla (TR);",
"     </li>",
"     <li>",
"      FML Liquifilm (AU, CH, FI, LU, NL, NZ);",
"     </li>",
"     <li>",
"      Fuluson (KP);",
"     </li>",
"     <li>",
"      Isopto Flucon (ES);",
"     </li>",
"     <li>",
"      Ocuflam (ID);",
"     </li>",
"     <li>",
"      Ocumetholone (KP);",
"     </li>",
"     <li>",
"      Okilon (JP);",
"     </li>",
"     <li>",
"      Ursnon (JP);",
"     </li>",
"     <li>",
"      Vitoron (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F172499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids inhibit the inflammatory response including edema, capillary dilation, leukocyte migration, and scar formation. Fluorometholone penetrates cells readily to induce the production of lipocortins. These proteins modulate the activity of prostaglandins and leukotrienes.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F172514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Primarily into aqueous humor",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8463 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41748=[""].join("\n");
var outline_f40_49_41748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172523\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172524\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172559\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172525\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172542\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172526\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896228\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896229\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172496\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4844876\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172512\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3197884\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172557\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172515\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172500\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299353\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172505\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172507\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172517\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172529\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14877584\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172516\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172509\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172518\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172499\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172514\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8463\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8463|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/55/25460?source=related_link\">",
"      Fluorometholone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/47/23283?source=related_link\">",
"      Fluorometholone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_49_41749="Honeycomb cysts in IPF CT";
var content_f40_49_41749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82237%7EPULM%2F75204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82237%7EPULM%2F75204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Honeycomb cysts in IPF/UIP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Idiopathic pulmonary fibrosis/usual interstitial pneumonia with bilateral, small subpleural honeycomb cysts which are separated by normal parenchyma. The anterior segmental bronchus of the left upper lobe is slightly dilated, consistent with mild traction bronchiectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marked honeycombing in IPF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Usual interstitial pneumonia pattern with marked honeycombing and traction bronchiectasis in both lower lobes along with an absence of ground glass changes. The peripheral regions of the lower lobes and middle lobe are typically involved, initially sparing the central parts of the lower lobes.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41749=[""].join("\n");
var outline_f40_49_41749=null;
var title_f40_49_41750="Schematic representation of endochondral bone formation";
var content_f40_49_41750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 644px\">",
"   <div class=\"ttl\">",
"    Schematic representation of endochondral bone formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 624px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial phase of long bone development occurs through mesenchymal condensation to form a cartilage model. Following chondrocytes hypertrophy, the cartilaginous template is calcified by osteoblasts and then partially resorbed by osteoclasts, resulting in the formation of the primary and the secondary ossification centers. Through additional cycles of remodeling, the cartilage of the primary and secondary ossification centers is converted to the trabecular bone of the metaphysis and epiphysis, respectively. Longitudinal bone growth occurs at the growth plates and results from the elongation of the cartilaginous template. In adult bones, the growth plate is fully resorbed, so that one marrow cavity extends the full length of the bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baron R. Chapter 1: Anatomy and ultrastructure of bone - Histogenesis, growth and remodeling. In: Diseases of bone and mineral metabolism, Singer F (Ed). Copyright &copy; 2008 WWW.ENDOTEXT.ORG website, Version of 09/26/2012, published by MDTEXT.COM, Inc, South Dartmouth, MA.",
"     <a href=\"file://www.endotext.org/parathyroid/parathyroid1/parathyroidframe1.htm\" style=\"font-style: italic;\" target=\"_blank\">",
"      file://www.endotext.org/parathyroid/parathyroid1/parathyroidframe1.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41750=[""].join("\n");
var outline_f40_49_41750=null;
var title_f40_49_41751="Continuous venovenous hemodiafiltration: Technical considerations";
var content_f40_49_41751=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Continuous venovenous hemodiafiltration: Technical considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41751/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41751/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41751/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41751/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41751/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41751/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/49/41751/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuous renal replacement therapies (CRRT) comprise a spectrum of treatments that include both convection-based (hemofiltration) and diffusion-based (hemodialysis) solute removal techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with intermittent therapy, the major advantage of continuous therapy is the slower rate of solute or fluid removal per unit of time. Thus, CRRT is generally better tolerated than conventional intermittent therapy, since many of the complications of intermittent hemodialysis are related to the rapid rate of solute and fluid loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRRT techniques initially utilized arteriovenous extracorporeal circuits in which blood flow was driven by the gradient between the mean arterial pressure and venous pressure. Continuous venovenous hemodialysis (CVVHD) was developed in the mid-1980s as an alternative to continuous arteriovenous hemofiltration (CAVH) and continuous arteriovenous hemodialysis (CAVHD).",
"   </p>",
"   <p>",
"    The use of a pump-driven venovenous circuit in CVVHD permits blood flows that are both higher and more constant than provided by an arteriovenous circuit. In addition, since there is no need for a large bore arterial catheter, the associated risks of arterial thrombosis and arterial bleeding are eliminated.",
"   </p>",
"   <p>",
"    Continuous venovenous hemodiafiltration (CVVHDF) combines the convective solute removal of continuous hemofiltration (CVVH) with the diffusive solute removal of continuous hemodialysis (CVVHD).",
"   </p>",
"   <p>",
"    The technical aspects of performing CVVHDF will be reviewed here. General discussions of CRRT, the technical aspects of the different renal replacement modalities, and the indications for the treatment of acute renal failure are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .) and \"(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20935?source=see_link\">",
"     \"Continuous venovenous hemodialysis: Technical considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The geometry of the extracorporeal circuit in CVVHDF combines features of both CVVH and CVVHD. Angioaccess in CVVHDF is generally achieved using a standard double-lumen hemodialysis catheter. A blood pump drives blood flow through the extracorporeal circuit, with rates usually maintained between 100 and 300",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    As",
"    with CVVH, a large ultrafiltrate volume is generated across a membrane with high hydraulic permeability. Replacement fluid is infused into the extracorporeal circuit, either prior to (predilution) (",
"    <a class=\"graphic graphic_figure graphicRef76626 \" href=\"mobipreview.htm?43/12/44239\">",
"     figure 1",
"    </a>",
"    ) or after (post-dilution) (",
"    <a class=\"graphic graphic_figure graphicRef64868 \" href=\"mobipreview.htm?30/27/31167\">",
"     figure 2",
"    </a>",
"    ) the hemodiafilter, replacing the volume of ultrafiltrate that is in excess of the desired net negative fluid removal. In addition, as in CVVHD, dialysate is perfused through the hemodiafilter, countercurrent to the direction of blood flow.",
"   </p>",
"   <p>",
"    Since the sieving coefficients of most low molecular weight solutes are close to unity and since equilibration of these solutes between blood and dialysate is nearly complete under the standard operating parameters, clearance of low molecular weight solutes, such as urea, approximates the total effluent outflow rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SELECTION OF VENOVENOUS TREATMENT MODALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages and disadvantages of the different renal replacement therapies in the patient with acute renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If CRRT is the optimal choice, we prefer the pump-driven venovenous circuit rather than an arteriovenous circuit. This is because the venovenous circuit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Permits blood flows that are both higher and more constant than provided by an arteriovenous circuit.",
"     </li>",
"     <li>",
"      Eliminates the need for a large bore arterial catheter that is associated with the associated risks of arterial thrombosis and arterial bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, the selection of a particular venovenous modality of CRRT is based more upon local factors and preferences than on evidence of specific benefits associated with CVVH, CVVHD or CVVHDF. Although convective modalities of therapy (hemofiltration) provide enhanced clearance of middle molecular weight solutes as compared to diffusive modalities of therapy (hemodialysis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], clinical benefit assessed based upon either survival or recovery of renal function has",
"    <strong>",
"     not",
"    </strong>",
"    been demonstrated with any particular technique.",
"   </p>",
"   <p>",
"    It has been suggested that augmented removal of pro-inflammatory cytokines by hemofiltration may be of benefit, particularly in patients with concomitant sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, the rates of cytokine removal with hemofiltration are low relative to production and endogenous clearance, resulting in minimal change in plasma cytokine concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In addition, it appears that a substantial component of cytokine removal is attributable to membrane adsorption rather than to convective removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, a common reason for the use of hemodiafiltration was the desire to achieve a higher dose of therapy than could be realized with either CVVH or CVVHD using available equipment. As an example, using the Gambro Prisma machine (previously the most widely utilized equipment for CRRT in the United States, although now supplanted by newer models), the maximal dialysate flow rate that could be provided was 2500",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    and the achievable ultrafiltration rate during CVVH was constrained by the maximal blood flow rate of 180",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and the need to avoid excessive filtration fraction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20935?source=see_link\">",
"     \"Continuous venovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .) These limitations are not present in newer CRRT equipment.",
"   </p>",
"   <p>",
"    Thus, to provide higher doses of therapy, a combination of convection and diffusion (eg, CVVHDF) may be required. In addition, some sites adopted CVVHDF as a means to maximize the dose of therapy while minimizing usage of more expensive custom-prepared solutions prior to the availability of FDA-approved and commercially marketed replacement fluids. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Dialysate and replacement fluids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Previous systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial descriptions of CVVHDF utilized individual components rather than an integrated system. Commonly, a conventional, variable-speed roller blood-pump was used to maintain blood flow and dialysate, and replacement fluid and effluent flow were controlled by infusion pumps. Since the difference between the sum of dialysate and replacement fluid inflow and effluent outflow is net ultrafiltration, small errors in the delivered flow rates resulted in substantial errors in net ultrafiltration.",
"   </p>",
"   <p>",
"    Intravenous infusion pumps are also not designed to operate against pressure gradients, resulting in an increased chance of error. Delivery of dialysate and replacement fluid against a pressure gradient resulted in decreased flow rates as compared to the nominal settings whereas the positive pressure in the ultrafiltrate compartment augmented flow across the outflow pump [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/10\">",
"     10",
"    </a>",
"    ]. At flow rates of 3 liters per hour and zero ultrafiltration, a 2 percent error by each pump (40",
"    <span class=\"nowrap\">",
"     mL/hour)",
"    </span>",
"    would result in excess ultrafiltration of almost 3 liters per day.",
"   </p>",
"   <p>",
"    Errors are greatest with linear peristaltic pumps. Although piston-type volumetric pumps and roller pumps are more accurate, they may be associated with rapid pressure changes in the dialysate compartment and an increased risk of fiber rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Current integrated systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result, although individually assembled component systems were the standard of care through the mid 1990s, an increasing number of \"integrated\" CRRT machines have subsequently become available and represent the",
"    <strong>",
"     current",
"    </strong>",
"    standard of care. While each model has slightly different features, their basic components are similar: pumps for control of blood flow and fluids; pressure monitors on blood and fluid lines; an air detector with integrated blood-pump shut-off and return line clamp on the blood return line; and fluid balancing systems to provide precise ultrafiltration control.",
"   </p>",
"   <p>",
"    Four integrated CRRT systems are currently marketed in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aquarius, Baxter Healthcare, Deerfield, IL",
"     </li>",
"     <li>",
"      Diapact, B. Braun, Bethlehem, PA",
"     </li>",
"     <li>",
"      PrismaFlex, Gambro, Lakewood, CO",
"     </li>",
"     <li>",
"      System One, NxStage Medical, Lawrence, MA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To perform CVVHDF, a system must have a minimum of three fluid management pumps to regulate dialysate inflow, replacement fluid infusion, and effluent (spent dialysate plus ultrafiltrate) outflow. Only two of these systems, the Accura, and PrismaFlex, are capable of performing hemodiafiltration without the addition of an external infusion pump. The Diapact and System One are designed to provide CVVH and CVVHD, but lack the additional integrated pump required to control both dialysate and replacement fluids that is needed for CVVHDF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VASCULAR ACCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issues for angioaccess for CVVHDF are the same as for other venovenous modalities of CRRT. Angioaccess is generally established using conventional double-lumen dialysis catheters in the internal jugular, subclavian, or femoral veins. As with other catheters, prolonged cannulation of the femoral vein is associated with an increased risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of triple lumen dialysis catheters, containing an additional lumen for infusion of parenteral nutrition, medications or other fluids may be of value. This is particularly true if citrate anticoagulation is employed, necessitating systemic infusion of calcium.",
"   </p>",
"   <p>",
"    The avoidance of subclavian venous catheters to prevent venous stenosis and preserve the upper extremities for future arteriovenous fistulas is not a significant issue in most patients requiring CVVHD. While the mortality of such patients is high, the majority of surviving patients recover renal function and do not require long-term maintenance dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEMODIAFILTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the artificial kidney device used for CVVHDF is frequently referred to as a \"hemofilter\" or \"hemodialyzer\", the term \"hemodiafilter\" is more accurate in describing the use of a membrane for both diffusive and convective solute transport. Because CVVHDF uses a pump driven system, many of the issues regarding hemodiafilter design that are important for arteriovenous forms of CRRT are not relevant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Essentially any hemodialyzer or hemofilter that provides both a high ultrafiltration coefficient and sufficient diffusive solute clearance may be utilized in patients undergoing CVVHDF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In general, synthetic, biocompatible membranes are preferred over cellulosic membranes, due in part to possible (although unproven) benefits related to less complement activation. Certain polyamide membranes, such as the Gambro FH66, although highly effective for convective solute transport, have poor diffusive solute flux, and are therefore not suitable for CVVHDF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these considerations, we recommend the use of polysulfone (eg, Fresenius F8 or F80), AN69 (eg, Gambro Multiflow 100), or polyarylethersulfone (eg, Gambro HF 1000) membranes or other high-flux synthetic membranes. However, in patients being treated concomitantly with angiotensin converting enzyme inhibitors, we suggest that AN69 membranes be avoided because of an increased risk of anaphylactoid reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIALYSATE AND REPLACEMENT FLUIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The composition of the dialysis fluid and replacement fluids should approximate normal plasma composition. The issues regarding the composition of these fluids are the same as for other modalities of CRRT and are reviewed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=see_link&amp;anchor=H8#H8\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\", section on 'dialysate'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Options for dialysate include the use of blended mixtures of fluids, custom preparation of fluids by individual hospital pharmacies, batch-preparation of custom solutions by regional pharmacies or use of commercial CRRT dialysis solutions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20935?source=see_link\">",
"     \"Continuous venovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .) While the same solutions can be used as replacement fluid, commercial CRRT dialysis solutions are not labeled for intravenous administration and their use as replacement fluid constitutes off-label use.",
"   </p>",
"   <p>",
"    Custom preparation of fluids for CVVHDF has been associated with significant rates of compounding errors, including errors associated with patient deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Quality controls employed during batch-preparation of custom fluids by commercial pharmacies reduce the risk of these errors and provide enhanced patient safety.",
"   </p>",
"   <p>",
"    None of the solutions marketed as dialysate for CRRT are FDA approved for use as replacement fluid, although many are manufactured to the standards of intravenous fluids and have been safely used for this purpose, off-label, in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/13\">",
"     13",
"    </a>",
"    ]. However, nearly identical commercial fluids are available as replacement solutions for CVVH and CVVHDF. These replacement fluids may also be used as dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other CRRT modalities, clotting of the extracorporeal system is the most common technical problem during CVVHDF, and anticoagulation is generally required to maintain system patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is the most commonly utilized anticoagulant. A single optimal regimen for heparin administration during CRRT has not been identified and heparin administration regimens need to balance the therapeutic benefit of preventing clotting in the extracorporeal circuit with the risk of systemic bleeding. Typically, a bolus dose of between 50 to 2000 units of heparin is administered into the inflow (\"arterial\") limb of the extracorporeal circuit followed by a continuous infusion of between 300 to 500 units per hour. Therapy may be monitored by following the partial thromboplastin time in the venous limb; the heparin dose should be titrated to maintain a value of 1.5 to 2.0 times control. Larger doses of heparin may be required in patients with recurrent system clotting. Its discontinuation may be necessary in the setting of clinical bleeding or if severe thrombocytopenia develops. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Citrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional citrate anticoagulation has been widely used as an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in all modalities of CRRT, including CVVHDF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/15-20\">",
"     15-20",
"    </a>",
"    ]. During citrate anticoagulation, sodium citrate is infused into the inflow (\"arterial\") limb of the extracorporeal circuit, chelating calcium and thereby inhibiting clotting. Intravenous calcium must be infused systemically to maintain a normal ionized serum calcium concentration. The use of citrate anticoagulation may require modification of the dialysate composition.",
"   </p>",
"   <p>",
"    Since the citrate provides an alkali load, buffers (eg, bicarbonate, lactate) may need to be reduced in concentration or deleted from the dialysate and replacement fluids. The dialysate and replacement fluids should also be calcium free, to prevent reversal of the citrate effect in the extracorporeal circuit. If a hypertonic citrate solution is utilized, the sodium concentration in the dialysate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replacement fluids will need to be reduced to prevent the development of hypernatremia.",
"   </p>",
"   <p>",
"    The selection of anticoagulation method is generally dictated by local practice. Each method has its inherent risks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      -induced thrombocytopenia with heparin anticoagulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolic alkalosis and hypocalcemia from citrate toxicity with citrate anticoagulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have suggested more prolonged filter patency using citrate anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. However, this benefit needs to be balanced against the increased costs associated with citrate anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=see_link&amp;anchor=H7#H7\">",
"     \"Hemodialysis anticoagulation\", section on 'Regional citrate anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OPERATIONAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solute removal during CVVHDF occurs by both diffusion and convection. The proportion of solute removal by each mechanism is determined by the relative rates of dialysate flow and ultrafiltration. During CVVHDF, blood flow is usually several-fold greater than dialysate flow and solute equilibration between blood and dialysate is dependent upon the dialysate flow rate. For low molecular weight solutes, such as urea, there is near complete equilibration at low dialysate flow rates, with decreasing equilibration as dialysate flow increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the commonly utilized range for dialysate flows (500 to 2500",
"    <span class=\"nowrap\">",
"     mL/hour),",
"    </span>",
"    the relationship between dialysate flow and diffusive clearance is nearly linear. However, for higher molecular weight species (eg, beta2-microglobulin), equilibration is limited, and clearance plateaus or increases non-linearly with increasing dialysate flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/3\">",
"     3",
"    </a>",
"    ]. By comparison, the impact of blood flow upon solute clearance is small, but with increased dependence as dialysate flow increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When replacement fluid is administered post-filter (",
"    <a class=\"graphic graphic_figure graphicRef64868 \" href=\"mobipreview.htm?30/27/31167\">",
"     figure 2",
"    </a>",
"    ), convective solute clearance is proportional to the ultrafiltration rate. The clearance can therefore be estimated as the product of the membrane sieving coefficient(s) and the ultrafiltration rate.",
"   </p>",
"   <p>",
"    However, when replacement fluid is administered prefilter (",
"    <a class=\"graphic graphic_figure graphicRef76626 \" href=\"mobipreview.htm?43/12/44239\">",
"     figure 1",
"    </a>",
"    ), the concentration of solutes is diluted, thereby diminishing the effective clearance at any given ultrafiltration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The predicted reduction in effective clearance is a function of plasma flow (QP) and the rate of prefilter infusion of replacement fluids (QPF) and can be expressed as",
"    <span class=\"nowrap\">",
"     QP/(QP+QPF)",
"    </span>",
"    where QP is equal to blood flow (QB) x (1-hematocrit).",
"   </p>",
"   <p>",
"    This has an important impact in comparing clearances of low molecular weight solutes during CVVH, CVVHD and CVVHDF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When replacement fluid is only administered post-filter (at any fixed effluent flow rate), the relationship of small solute clearance between modalities is CVVH &gt; CVVHDF &gt; CVVHD.",
"     </li>",
"     <li>",
"      In contrast, if the replacement fluid is infused prefilter (again at a fixed effluent flow rate), clearances of small solutes during CVVHDF will exceed those provided by CVVH (",
"      <a class=\"graphic graphic_figure graphicRef77486 \" href=\"mobipreview.htm?34/53/35678\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While there are theoretical considerations that have an impact on the use of prefilter as opposed to postfilter replacement fluids, clinical data are limited. Although postfilter infusion of replacement fluids has no impact upon solute concentration within the hemodiafilter, high ultrafiltration rates will result in hemoconcentration, which may impair flow though filter fibers and increase the risk of clotting the extracorporeal circuit. To minimize the rheologic effects of hemoconcentration, the filtration fraction within the hemodiafilter (defined as the ultrafiltration rate divided by the hemodiafilter plasma inflow rate) should not exceed 30 percent. This will constrain the maximal attainable ultrafiltration rate; particularly if blood flow is limited.",
"   </p>",
"   <p>",
"    Infusion of replacement fluids prefilter minimizes hemoconcentration, eliminating the constraint on the maximal attainable ultrafiltration rate. However, infusion of fluids prefilter dilutes solutes within the hemodiafilter, reducing clearance at any given effluent flow rate as compared to the postfilter infusion at the same effluent flow rate. The reduction in clearance can be compensated for by increasing the total effluent flow rate. In a study comparing prefilter to postfilter administration of replacement fluids during CVVH, postfilter administration was associated with reduced filter life without any net beneficial effect solute control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DOSE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascertainment of the optimal dose of therapy in CVVHDF and other modalities of CRRT has been the subject of multiple studies. A single center study of 435 patients comparing three doses of continuous venovenous hemofiltration (CVVH) with postfilter infusion of replacement fluids found an improved survival at effluent flow rates of 35 and 45",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour (57 and 58 percent, respectively) as compared to an effluent flow rate of 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour (41 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/21\">",
"     21",
"    </a>",
"    ]. A subsequent smaller study of patients treated with CVVH did not confirm a survival benefit with increased effluent flow rate; however, this study was severely underpowered and reported better overall survival than most other CRRT studies, suggesting that the study population had a lesser acuity of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increase in solute clearance through the addition of dialysate flow to a fixed dose of hemofiltration may be associated with a better survival than that observed with CVVH alone. In a comparison cohort study, 206 patients were randomly assigned to CVVH or CVVHDF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/23\">",
"     23",
"    </a>",
"    ]. The addition of 1 to 1.5",
"    <span class=\"nowrap\">",
"     L/hour",
"    </span>",
"    of dialysate (18&plusmn;5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) to an ultrafiltration rate of 1 to 2.5",
"    <span class=\"nowrap\">",
"     L/hour",
"    </span>",
"    (24&plusmn;6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour), with prefilter infusion of replacement fluid, was associated with a significant improvement in both 28 day (39 versus 59 percent) and 90-day survival (34 versus 59 percent).",
"   </p>",
"   <p>",
"    In contrast, there was no difference in survival or recovery of renal function in two studies that directly compared lower and higher doses of CVVHDF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center study, 200 patients were randomized to CVVHDF with total effluent flow rates (the sum of dialysate and ultrafiltration rates) of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour or 35",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, with replacement fluid administered prefilter. Survival to ICU discharge or day 30 was 56 percent with the lower dose of CVVHDF, compared to 49 percent with the higher dose of therapy.",
"     </li>",
"     <li>",
"      In a large, multicenter randomized controlled trial, 1508 patients were randomly assigned to CVVHDF with total effluent flow rates of 25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour or 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour. Replacement fluids were administered post-filter. Survival to 90 days was 44.7 percent in both treatment arms (OR 1.00, 95% CI 0.81-1.23), with no differences in survival at ICU discharge or hospital discharge, and no difference in recovery of kidney function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A full discussion of the",
"    <span class=\"nowrap\">",
"     VA/NIH",
"    </span>",
"    Acute Renal Failure Trial Network (ATN) Study is presented separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41751/abstract/26\">",
"     26",
"    </a>",
"    ]; this study also demonstrated no improvement in survival with more intensive doses of renal replacement therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, these studies found that total effluent flow rates above (",
"    <a class=\"graphic graphic_figure graphicRef77486 \" href=\"mobipreview.htm?34/53/35678\">",
"     figure 3",
"    </a>",
"    ) 20 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour do not provide significant clinical benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The continuous renal replacement therapies (CRRT) comprise a spectrum of treatments that include both convection-based (hemofiltration) and diffusion-based (hemodialysis) solute removal techniques. Continuous venovenous hemodiafiltration (CVVHDF) combines the convective solute removal of continuous hemofiltration (CVVH) with the diffusive solute removal of continuous hemodialysis (CVVHD). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"       \"Continuous renal replacement therapies: Overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The selection of a particular modality of CRRT is based more upon local factors and preferences than on evidence of specific benefits associated with CVVH, CVVHD, or CVVHDF. Clinical benefit assessed based upon either survival or recovery of renal function has",
"      <strong>",
"       not",
"      </strong>",
"      been demonstrated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Selection of venovenous treatment modality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To perform CVVHDF, a system must have a minimum of three fluid management pumps to regulate dialysate inflow, replacement fluid infusion, and effluent (spent dialysate plus ultrafiltrate) outflow. A number of \"integrated\" CRRT machines represent the current standard of care. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Essentially any hemodialyzer or hemofilter that provides both a high ultrafiltration coefficient and sufficient diffusive solute clearance may be utilized. Synthetic, biocompatible membranes are preferred over cellulosic membranes. We recommend the use of polysulfone (eg, Fresenius F8 or F80), AN69 (eg, Gambro Multiflow 100) or polyarylethersulfone (eg, Gambro HF 1000) membranes. However, in patients being treated concomitantly with angiotensin converting enzyme inhibitors, AN69 membranes should be avoided because of an increased incidence of anaphylactoid reactions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hemodiafilter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The composition of the dialysis fluid and replacement fluids are the same as for other modalities of CRRT and are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=see_link\">",
"       \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticoagulation is generally required to maintain system patency.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      is the most commonly utilized anticoagulant. Regional citrate anticoagulation has been widely used as an alternative to heparin in all modalities of CRRT, including CVVHDF. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Solute removal during CVVHDF occurs by both diffusion and convection. The proportion of solute removal by each mechanism is determined by the relative rates of dialysate flow and ultrafiltration. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Operational characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend delivered total effluent flow rates of 20 to 25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour during CVVHDF (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose of therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/1\">",
"      Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/2\">",
"      Mehta RL. Continuous renal replacement therapy in the critically ill patient. Kidney Int 2005; 67:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/3\">",
"      Brunet S, Leblanc M, Geadah D, et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/4\">",
"      Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant 2003; 18:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/5\">",
"      Hoffmann JN, Hartl WH, Deppisch R, et al. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 1995; 48:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/6\">",
"      Kellum JA, Johnson JP, Kramer D, et al. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med 1998; 26:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/7\">",
"      Sanchez-Izquierdo JA, Perez Vela JL, Lozano Quintana MJ, et al. Cytokines clearance during venovenous hemofiltration in the trauma patient. Am J Kidney Dis 1997; 30:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/8\">",
"      Sieberth HG, Kierdorf HP. Is cytokine removal by continuous hemofiltration feasible? Kidney Int Suppl 1999; :S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/9\">",
"      De Vriese AS, Colardyn FA, Philipp&eacute; JJ, et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/10\">",
"      Roberts M, Winney RJ. Errors in fluid balance with pump control of continuous hemodialysis. Int J Artif Organs 1992; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/11\">",
"      Ifediora OC, Teehan BP, Sigler MH. Solute clearance in continuous venovenous hemodialysis. A comparison of cuprophane, polyacrylonitrile, and polysulfone membranes. ASAIO J 1992; 38:M697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/12\">",
"      Relton S, Greenberg A, Palevsky PM. Dialysate and blood flow dependence of diffusive solute clearance during CVVHD. ASAIO J 1992; 38:M691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/13\">",
"      Johnston RV, Boiteau P, Charlebois K, et al. Responding to tragic error: lessons from Foothills Medical Centre. CMAJ 2004; 170:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/14\">",
"      Culley CM, Bernardo JF, Gross PR, et al. Implementing a standardized safety procedure for continuous renal replacement therapy solutions. Am J Health Syst Pharm 2006; 63:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/15\">",
"      Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/16\">",
"      Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/17\">",
"      Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000; 35:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/18\">",
"      Tolwani AJ, Campbell RC, Schenk MB, et al. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/19\">",
"      Tobe SW, Aujla P, Walele AA, et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003; 18:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/20\">",
"      Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/21\">",
"      Uchino S, Fealy N, Baldwin I, et al. Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract 2003; 94:c94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/22\">",
"      Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/23\">",
"      Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 2002; 30:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/24\">",
"      Tolwani AJ, Campbell RC, Stofan BS, et al. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 2008; 19:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/25\">",
"      RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41751/abstract/26\">",
"      VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1934 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41751=[""].join("\n");
var outline_f40_49_41751=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SELECTION OF VENOVENOUS TREATMENT MODALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Previous systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Current integrated systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VASCULAR ACCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEMODIAFILTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIALYSATE AND REPLACEMENT FLUIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OPERATIONAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DOSE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1934|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/12/44239\" title=\"figure 1\">",
"      Schematic CVVHDF pre-filter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/27/31167\" title=\"figure 2\">",
"      Schematic CVVHDF post-filter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/53/35678\" title=\"figure 3\">",
"      Clearance CVVH and CVVHDF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=related_link\">",
"      Continuous arteriovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20935?source=related_link\">",
"      Continuous venovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_49_41752="Intrapartum management and outcome of shoulder dystocia";
var content_f40_49_41752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrapartum management and outcome of shoulder dystocia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41752/contributors\">",
"     John F Rodis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41752/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41752/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/49/41752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder dystocia is best defined as the need for additional obstetric maneuvers to effect delivery of the fetal shoulders at the time of vaginal delivery. It occurs in 0.2 to 3 percent of all births and represents an obstetric emergency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Few shoulder dystocias can be anticipated and prevented, as most occur in the absence of risk factors. Therefore, the obstetrician must be prepared to recognize a shoulder dystocia immediately and proceed through an orderly sequence of steps to affect delivery in a timely manner. The goal of management is to prevent fetal asphyxia and permanent Erb's palsy, while avoiding physical injury (eg, bone fractures, maternal trauma), but the latter are acceptable if needed to prevent permanent injury in the child.",
"   </p>",
"   <p>",
"    Intrapartum diagnosis and management of shoulder dystocia will be reviewed here. Risk factors for shoulder dystocia and management of pregnancies at risk are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal biacromial diameter (the distance between the outermost parts of the fetal shoulders) normally enters the pelvis at an oblique angle with the posterior shoulder ahead of the anterior one, rotating to the anterior-posterior position at the pelvic outlet with external rotation of the fetal head. The anterior shoulder can then slide under the symphysis pubis for delivery (",
"    <a class=\"graphic graphic_figure graphicRef52812 \" href=\"mobipreview.htm?25/17/25881\">",
"     figure 1",
"    </a>",
"    ). If the fetal shoulders remain in an anterior-posterior position during descent or descend simultaneously rather than sequentially into the pelvic inlet, then the anterior shoulder can become impacted behind the symphysis pubis; the posterior shoulder may be obstructed by the sacral promontory. If descent of the fetal head continues while the anterior or posterior shoulder remains impacted, then stretching of the nerves in the brachial plexus may occur and may result in nerve injury.",
"   </p>",
"   <p>",
"    Injuries diagnosed at birth may have resulted from prenatal insults, trauma related to labor and the impacted shoulder itself, or from the provider's attempt to deliver the infant. Acidemia may result from compression of the umbilical cord, from compression of the vessels in the fetal neck by a tight nuchal cord, or a combination of factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder dystocia is a subjective clinical diagnosis. It should be suspected when the fetal head retracts into the perineum (ie, turtle sign) after expulsion due to reverse traction from the shoulders being impacted at the pelvic inlet. The diagnosis is made when the routine practice of gentle, downward traction of the fetal head fails to accomplish delivery of the anterior shoulder.",
"   </p>",
"   <p>",
"    A more objective definition, such as one based upon time to delivery, would be more useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. One group attempted to devise objective criteria for diagnosis of shoulder by first determining the mean interval from delivery of the head to expulsion of the body in 210 patients who did not undergo any ancillary obstetrical maneuvers (eg, McRoberts position, delivery of the posterior arm, suprapubic pressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/5\">",
"     5",
"    </a>",
"    ]. The upper limit of normal for head-to-body delivery time was considered to be two standard deviations above this mean value (24 seconds) or 60 seconds. A subsequent prospective series by the same group found that deliveries complicated by a head-to-body expulsion time greater than 60 seconds or use of ancillary maneuvers to effect delivery described a subpopulation of infants who had higher birth weight, lower one-minute Apgar scores, and a greater prevalence of birth injury than infants who did not meet these criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of interest, only 24 of the 99 cases of objectively defined shoulder dystocia were reported as shoulder dystocia by the clinician, even though ancillary maneuvers were used to effect delivery in 46 cases. This discrepancy illustrates the difficulty in collecting and analyzing data for a condition that is subjectively determined. Further research is needed to determine an objective, clinically relevant definition of shoulder dystocia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of management is to safely effect delivery of the infant before asphyxia and cortical injury occur from umbilical cord compression and impeded inspiration, and without causing peripheral neurologic injury or other trauma. Most interventions are intended to disimpact the anterior shoulder from behind the symphysis pubis by rotating the fetal trunk or delivering the posterior arm and shoulder. In general, the operator has up to five minutes to deliver a previously well-oxygenated term infant before an increased risk of asphyxial injury occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The mean umbilical artery pH at term is 7.27; in two studies umbilical artery pH was estimated to fall 0.01 and 0.04 pH units per minute, respectively, in the interval between delivery of the fetal head and trunk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. However, in practice, the correlation between the head-to-body delivery interval and pH, pCO2, or base deficit is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35702?source=see_link\">",
"     \"Umbilical cord blood acid-base analysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1253?source=see_link\">",
"     \"Fetal acid-base physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The occurrence of shoulder dystocia cannot be accurately predicted on the basis of antenatal risk factors or labor abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    .) Therefore, the clinician should be prepared for possible shoulder dystocia in all vaginal deliveries, be cognizant of the various procedures that have been shown to be effective for delivering the impacted shoulders, and have a step-wise plan of action, which allows expeditious execution of diagnosis and treatment.",
"   </p>",
"   <p>",
"    The following sequence describes a series of steps starting with simple procedures and progressing to those that are more complicated. The initial approach may vary depending upon the clinical situation, clinician preference, accessibility of assistants, and availability of anesthesia. There are no randomized trials comparing results from use of the various maneuvers. The general consensus is that no maneuver is clearly superior for resolving the dystocia and preventing injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Initial steps",
"    </span>",
"    &nbsp;&mdash;&nbsp;When shoulder dystocia is suspected, the gravida and labor room personnel should be given instructions in a clear and calm manner.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nursing, anesthesia, obstetric, and pediatric staff should be called to the room, if not already available, to provide assistance as needed.",
"     </li>",
"     <li>",
"      The mother should be told",
"      <strong>",
"       not",
"      </strong>",
"      to push while preparations are made and maneuvers are undertaken to reposition the fetus.",
"     </li>",
"     <li>",
"      Excessive neck rotation, head and neck traction, and fundal pressure",
"      <strong>",
"       should be avoided",
"      </strong>",
"      because this combination of maneuvers can stretch and injure the brachial plexus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/3,10-12\">",
"       3,10-12",
"      </a>",
"      ]. These actions may further impact the shoulders and cause uterine rupture or other injury.",
"     </li>",
"     <li>",
"      The patient should be positioned with her buttocks flush with the edge of the bed to provide optimal access for executing maneuvers to affect delivery.",
"     </li>",
"     <li>",
"      Performing a generous episiotomy may be useful to facilitate delivery of the posterior shoulder and other internal procedures, but does not by itself help to release the anterior shoulder and increases perineal trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A distended bladder, if present, should be drained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some providers find it useful for a nurse to verbally note the passage of time in 60 second increments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68133738\">",
"    <span class=\"h3\">",
"     Traction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since further descent of the fetal shoulder is prevented by the maternal pelvic bones, maneuvers to release the impacted shoulder are needed to resolve the dystocia; increasing traction is counterproductive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/15\">",
"     15",
"    </a>",
"    ]. A study using force-sensing devices on 29 randomly selected vaginal births found that clinician-applied peak forces are about 47 Newtons (N) for routine deliveries, 69 N for difficult deliveries, and 100 N for shoulder dystocia deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/16\">",
"     16",
"    </a>",
"    ]. In one case, fracture of the clavicle occurred at peak force of about 100 N, and appeared to be related to applying a high peak force quickly rather than gradually and for applying it for a prolonged period of time (over 30 seconds). However, measuring traction forces during shoulder dystocia is not practical. Clinicians should think about whether they are applying greater than normal force to deliver the shoulders, and if they perceive this is the case, then this perception should prompt utilization of maneuvers to resolve the dystocia. After releasing the shoulder, normal traction will allow delivery of the infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single maneuver is clearly more effective or safer for the fetus than another; the initial choice and order of progression is at the provider's discretion. We and others suggest beginning with the least invasive maneuvers (suprapubic pressure and McRoberts) and, if unsuccessful, moving on to more invasive options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/2\">",
"     2",
"    </a>",
"    ]. As more maneuvers are attempted, the likelihood of success increases, but the risk of fetal injury also increases, which may reflect increasingly severe dystocia rather than use of increasingly morbid maneuvers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/17\">",
"     17",
"    </a>",
"    ]. Some experts suggest beginning with delivery of the posterior arm because of its high success rate, even though it is a more invasive maneuver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2531262\">",
"    <span class=\"h3\">",
"     Suprapubic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assistant applies pressure suprapubically with the palm or fist, directing the pressure on the anterior shoulder both downward (to below the pubic bone) and laterally (toward the baby's face or sternum) in conjunction with the McRoberts maneuver (",
"    <a class=\"graphic graphic_figure graphicRef74910 \" href=\"mobipreview.htm?33/9/33936\">",
"     figure 2",
"    </a>",
"    ). Suprapubic pressure is supposed to adduct the shoulders or bring them into an oblique plane, since the oblique diameter is the widest diameter of the maternal pelvis. It is most useful in mild cases and those caused by an impacted anterior shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     McRoberts",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the McRoberts maneuver as the initial approach for releasing the impacted shoulder because it is less invasive than other maneuvers and often successful. The McRoberts maneuver requires two assistants, each of whom grasps a maternal leg and sharply flexes the thigh back against the abdomen (",
"    <a class=\"graphic graphic_figure graphicRef74910 \" href=\"mobipreview.htm?33/9/33936\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/19\">",
"     19",
"    </a>",
"    ]. This procedure relieves shoulder dystocia via marked cephalad rotation of the symphysis pubis and subsequent flattening the sacrum, thus removing the sacral promontory as an obstruction site (",
"    <a class=\"graphic graphic_figure graphicRef58081 \" href=\"mobipreview.htm?10/4/10307\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In addition, by bringing the pelvic inlet into the plane perpendicular to the maximum expulsive force, pushing efficiency improves significantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/21\">",
"     21",
"    </a>",
"    ]. McRoberts maneuver does not change the actual dimensions of the maternal pelvis.",
"   </p>",
"   <p>",
"    McRoberts position alone has successfully alleviated shoulder dystocia in as many as 42 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/22\">",
"     22",
"    </a>",
"    ]. There is no advantage to performing the maneuver before diagnosis of shoulder dystocia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In rare cases, excessive force or prolonged placement of the patient's legs in a hyperflexed position has led to maternal complications such as symphyseal separation, sacroiliac joint dislocation, and transient lateral femoral cutaneous neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28001966\">",
"    <span class=\"h3\">",
"     Delivery of the posterior arm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery of the posterior arm almost always relieves impaction of the anterior shoulder and resolves the dystocia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. It is an appropriate second maneuver if the less technically demanding and often successful McRoberts maneuver and suprapubic pressure fail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maneuver, which is best performed under adequate anesthesia, requires introducing a hand into the vagina to locate the posterior shoulder and arm. If the fetal abdomen faces the maternal right, the operator's left hand should be used; if the fetal abdomen faces the maternal left, the right hand is used. The posterior arm should be identified and followed to the elbow. If the elbow is flexed, the operator can grasp the forearm and hand and pull out the arm. If it is extended, pressure is applied in the antecubital fossa. This flexes the elbow across the fetal chest and allows the forearm or hand to be grasped. The arm is then pulled out of the vagina, which brings the posterior shoulder into the pelvis (",
"    <a class=\"graphic graphic_figure graphicRef66929 \" href=\"mobipreview.htm?37/62/38882\">",
"     figure 4",
"    </a>",
"    ) and reduces the shoulder diameter by 2 to 3 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/18\">",
"     18",
"    </a>",
"    ]. If the anterior shoulder cannot be delivered at this point, the fetus can be rotated and the procedure repeated for the anterior (now posterior) arm.",
"   </p>",
"   <p>",
"    The greatest risk with delivery of the posterior arm is fracture of the humerus, which has been reported in 0 to 20 percent of cases; the risk is highest when used after other maneuvers have failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. To minimize this risk, it is important to apply pressure at the antecubital fossa to flex the fetal forearm and then sweep it out over the infant&rsquo;s chest, rather than grasping and pulling directly on the fetal arm or mid-humeral shaft.",
"   </p>",
"   <p>",
"    A similar procedure is followed if the arm is trapped behind the fetus. In this case, manipulation of the forearm so that it can be swept ventrally and out the vagina may involve deliberate or inadvertent fracture of the humerus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1055812455\">",
"    <span class=\"h4\">",
"     Posterior axilla modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;If it is not possible to reach the elbow or forearm, it may be possible to deliver the posterior shoulder before delivering the arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. After an assistant gently flexes the fetal head toward the anterior shoulder, the obstetrician places",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    right middle finger into the fetus&rsquo; posterior axilla from the left side of the pelvis and the left middle finger into the posterior axilla from the right side of the pelvis. The two middle fingers in the axilla are then used to pull the posterior shoulder downward along the curve of the sacrum. Once the shoulder has been brought down sufficiently, the posterior arm can be grasped and delivered. These maneuvers are associated with an increased risk of fracture, but not brachial plexus injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rubin maneuver causes adduction of the fetal shoulder so that the shoulders are displaced from the anteroposterior diameter of the inlet, thereby allowing the posterior arm to enter the pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/34\">",
"     34",
"    </a>",
"    ]. Under adequate anesthesia, the clinician places one hand in the vagina and on the back surface of the posterior fetal shoulder, and then rotates it anteriorly (towards the fetal face). If the fetal spine is on the maternal left, the operator's right hand is used; the left hand is used if the fetal spine is on the maternal right (",
"    <a class=\"graphic graphic_figure graphicRef62024 \" href=\"mobipreview.htm?25/52/26435\">",
"     figure 5",
"    </a>",
"    ). Alternatively, the Rubin maneuver can be attempted by placing a hand on the back surface of the anterior fetal shoulder, if it is more accessible.",
"   </p>",
"   <p>",
"    Use of a laboratory birthing simulator showed that the Rubin maneuver required less traction force and resulted in less brachial plexus extension than the McRoberts maneuver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/35\">",
"     35",
"    </a>",
"    ]. However, it is more invasive than the McRoberts procedure and less easily performed in unanesthetized patients.",
"   </p>",
"   <p>",
"    Another approach is to combine the Rubin maneuver on the back of the posterior shoulder with external abdominal pressure on the front of the anterior shoulder in the opposite direction or with the McRoberts maneuver. Alternatively, the Rubin and Woods (see below) procedures can be combined so that one shoulder is being pushed from the back and the other shoulder is being pushed from the front in the same clockwise or counterclockwise direction. This increases the rotational force on the shoulders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Woods screw",
"    </span>",
"    &nbsp;&mdash;&nbsp;Woods likened shoulder dystocia to the \"crossed thread\" of a bolt into a nut. Although a bolt cannot be forced into a nut, it goes through easily when turned repeatedly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/36\">",
"     36",
"    </a>",
"    ]. The Woods screw maneuver rotates the fetus by exerting pressure on the anterior, clavicular surface of the posterior shoulder to turn the fetus until the anterior shoulder emerges from behind the maternal symphysis (",
"    <a class=\"graphic graphic_figure graphicRef71838 \" href=\"mobipreview.htm?27/0/27651\">",
"     figure 6",
"    </a>",
"    ). If the fetal spine is on the maternal left, the operator uses the left hand to push on the clavicle of the posterior arm and rotate the baby 180 degrees in a counterclockwise direction. The fetal head and neck should not be twisted. As discussed above, the Woods and Rubin maneuvers can be combined so that one shoulder is being pushed from the front and the other shoulder is being pushed from the back in the same clockwise or counterclockwise direction. &nbsp;This increases the rotational force on the shoulders.",
"   </p>",
"   <p>",
"    If counterclockwise rotation is unsuccessful, clockwise rotation may release the shoulder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gaskin all-fours",
"    </span>",
"    &nbsp;&mdash;&nbsp;This maneuver, first introduced by Ina May Gaskin, CPM, places the mother on her hands and knees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/37\">",
"     37",
"    </a>",
"    ], but not in the knee-chest position. An alternative is a racing start or &lsquo;sprinter&rsquo; position. The infant is delivered from this position by gentle downward traction on the posterior shoulder (the shoulder against the maternal sacrum) or upward traction on the anterior shoulder (the shoulder against the maternal symphysis). This may be a good choice for the initial management of the mother in a birthing bed with only local or pudendal anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clavicular fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clavicle can be intentionally fractured to shorten the biacromial diameter. This is done by pulling the anterior clavicle outward. However, intentional clavicular fracture can be difficult to perform and can lead to injury of underlying vascular and pulmonary structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Zavanelli",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure, also known as the Gunn-Zavanelli-O'Leary maneuver, requires replacement of the fetal head in the pelvis, followed by cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/38\">",
"     38",
"    </a>",
"    ]. The following steps are taken:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prepare for abdominal delivery.",
"     </li>",
"     <li>",
"      Administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      (0.25 mg subcutaneously) or another uterine relaxant (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      50 to 500 mcg intravenously in aliquots of 50 to 100 mcg).",
"     </li>",
"     <li>",
"      Place a fetal scalp electrode.",
"     </li>",
"     <li>",
"      Rotate the head back to an occiput anterior position (reversal of restitution).",
"     </li>",
"     <li>",
"      Flex the head from its extended position and push it as far cephalad as possible using firm pressure with the palm of one hand. The other hand may be used to depress the perineum.",
"     </li>",
"     <li>",
"      Insert a catheter into the bladder and proceed with cesarean delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over 100 such procedures have been reported, mostly in single case reports, with a high rate of success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1294345\">",
"    <span class=\"h3\">",
"     Abdominal rescue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal rescue has been described in case reports where classical maneuvers and cephalic replacement (Zavanelli maneuver) were unsuccessful. A low transverse hysterotomy is performed to allow transabdominal manual rotation of the anterior shoulder to the oblique diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The fetus is then delivered vaginally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Symphysiotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splitting the symphysis pubis is effective in opening the maternal pelvis and relieving the obstruction, but has high maternal morbidity and is rarely used except in remote areas where operating rooms are unavailable. The skin over the symphysis pubis and fibrocartilaginous area is infiltrated with local anesthetic. The urethra is displaced laterally using the index and middle fingers placed against the posterior aspect of the symphysis and an incision made through the cartilaginous portion of the symphysis. We recommend avoiding symphysiotomy unless all other maneuvers have failed and cesarean delivery is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clear and complete documentation in the medical record is critically important after deliveries complicated by shoulder dystocia (",
"    <a class=\"graphic graphic_figure graphicRef54369 graphicRef70280 \" href=\"mobipreview.htm?7/38/7779\">",
"     figure 7A-B",
"    </a>",
"    ). We suggest including the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The results of screening for gestational diabetes and the type of test used.",
"     </li>",
"     <li>",
"      The recommendations given to diabetic gravida regarding diet and glycemic control and information provided about complications of poor glycemic control, such as macrosomia. Documentation of blood sugars and patient compliance with treatment recommendations should also be described. If insulin was required for glycemic control, this should be noted.",
"     </li>",
"     <li>",
"      The best estimated fetal weight (clinical or ultrasound) should be noted on the labor admission physical examination. Although the error in estimated fetal weight at term may be large, documentation confirms that the weight was assessed in consideration of delivery.",
"     </li>",
"     <li>",
"      An instrumental delivery should have a description of the indication, fetal station, position of the head, instrument used, and time required to effect delivery.",
"     </li>",
"     <li>",
"      When and how the diagnosis of dystocia was made and the position of the head.",
"     </li>",
"     <li>",
"      Each of the steps taken to resolve the dystocia, the order in which they were taken, and the results, should be described. The elapsed time should be recorded as accurately as possible. All significant personnel involved, including nurses, anesthesiologists, pediatricians, and other obstetric staff should write their own notes.",
"     </li>",
"     <li>",
"      Umbilical cord gases (arterial and venous) should be obtained at birth in all shoulder dystocia cases, even if the infant does not appear to be depressed.",
"     </li>",
"     <li>",
"      The time the pediatrician and anesthesiologist were called to the delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the provider should discuss the events that occurred at delivery with the mother, including an explanation of the problem, the steps taken to correct it, and possible sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series including over 2000 cases of shoulder dystocia, approximately 5 percent were complicated by neonatal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/2\">",
"     2",
"    </a>",
"    ]. Brachial plexus injury and clavicular fracture were by far the most common injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder dystocia may result in numerous injuries to the infant, such as fractured clavicle or humerus, brachial plexus injury, hypoxic brain injury, and death. In series including over 100 cases of shoulder dystocia, reported neonatal outcomes included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient brachial plexus palsy (3.0 to 16.8 percent)",
"     </li>",
"     <li>",
"      Clavicular fracture (1.7 to 9.5 percent)",
"     </li>",
"     <li>",
"      Humerus fracture (0.1 to 4.2 percent)",
"     </li>",
"     <li>",
"      Permanent brachial plexus palsy (0.5 to 1.6 percent)",
"     </li>",
"     <li>",
"      Hypoxic-ischemic encephalopathy (0.3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/2\">",
"       2",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Death (0 to 0.35 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both arms may be injured, such as fracture of the left arm and brachial plexus palsy of the right arm. Clavicular and humeral fractures generally have a benign course, with complete recovery and no neurological or orthopedic sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/42\">",
"     42",
"    </a>",
"    ]. The majority of brachial plexus palsies resolve with conservative therapy, resulting in a 1.6 percent rate of permanent brachial plexus injury associated with shoulder dystocia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. These neurological disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=see_link\">",
"     \"Brachial plexus syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although shoulder dystocia is a major risk factor for brachial plexus injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/45\">",
"     45",
"    </a>",
"    ], many cases of fractured clavicle or brachial plexus injury are not due to shoulder dystocia or excessive force by the provider. In fact, several series reported antecedent shoulder dystocia in no more than one-half of the cases of brachial plexus injury in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. A prenatal insult was documented in a significant number of affected infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/47,48\">",
"     47,48",
"    </a>",
"    ] and these injuries have been reported following cesarean deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/49\">",
"     49",
"    </a>",
"    ]. The forces of labor, fetal position, and maternal pushing may be sufficient to cause excessive traction on the brachial plexus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/50,51\">",
"     50,51",
"    </a>",
"    ] and fetal bones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, a study that attempted to determine intrapartum risk factors for permanent brachial plexus injury reported difficulty in predicting which cases of shoulder dystocia would have this outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/53\">",
"     53",
"    </a>",
"    ]. There were no significant differences in maternal weight, body mass index, height, race, gestational age, average number of maneuvers, head-to-body delivery interval, operative delivery rate, prolonged second stage rate, precipitous second stage rate, or sex between cases of shoulder dystocia with and without brachial plexus injury.",
"   </p>",
"   <p>",
"    Damage to the brachial plexus may be accompanied by damage to the sympathetic pathway, resulting in Horner's syndrome. In one report, a history of delivery with shoulder dystocia, forceps, vacuum extraction, fetal rotation, or postterm delivery was elicited in 16 of 31 patients with congenital Horner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=see_link\">",
"     \"Horner's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most brachial plexus injuries result from stretching or compression of the nerve; nerve root avulsion is uncommon. There is a strong association between the presence of a pseudomeningocele (traumatic meningocele) and nerve root avulsion; however, avulsion does not always result in pseudomeningocele and pseudomeningocele can occur without nerve root avulsion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Maternal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential maternal complications include hemorrhage (11 percent) and fourth degree lacerations (3.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/22\">",
"     22",
"    </a>",
"    ]. Uterine atony can be treated with uterine massage and uterotonic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    , prostaglandin F2alpha analogs). Lower genital tract lacerations should be repaired. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44071?source=see_link\">",
"     \"Evaluation and management of lower genital tract trauma in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1570126\">",
"    <span class=\"h1\">",
"     REDUCING THE RISK OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Joint Commission (formerly JCAHO) recommends that obstetrical departments consider periodically conducting clinical drills to help staff prepare for shoulder dystocia, conduct debriefings to evaluate team performance, and identify areas for improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41752/abstract/60\">",
"     60",
"    </a>",
"    ]. Such drills appear to improve recognition and management of shoulder dystocia, and there is some evidence of improvement in neonatal outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=see_link&amp;anchor=H8#H8\">",
"     \"Reducing adverse obstetrical outcomes through safety sciences\", section on 'Shoulder dystocia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36953874\">",
"    <span class=\"h1\">",
"     GUIDELINES FROM NATIONAL ORGANIZATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.rcog.org.uk/womens-health/clinical-guidance/shoulder-dystocia-green-top-42\">",
"       Royal College of Obstetricians and Gynaecologists",
"      </a>",
"      . Shoulder Dystocia. Green-top 42. March 2012.",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.acog.org/\">",
"       American College of Obstetricians and Gynecologists",
"      </a>",
"      . Practice bulletin no. 40. Shoulder Dystocia. November 2002.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/2/19490?source=see_link\">",
"       \"Patient information: Shoulder dystocia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shoulder dystocia is defined as failure of the shoulders to spontaneously traverse the pelvis after delivery of the fetal head. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The occurrence of shoulder dystocia cannot be accurately predicted on the basis of antenatal risk factors or labor abnormalities. Therefore, the clinician should be prepared for possible shoulder dystocia in all vaginal deliveries and be cognizant of the various procedures that have been shown to be effective for delivering the impacted shoulders. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized trials comparing results from use of the various maneuvers to manage shoulder dystocia. The general consensus is that no maneuver is clearly superior for resolving the dystocia and preventing injury. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial steps in management include having the patient stop pushing, ensuring proper patient position, assembling necessary personnel, and draining a distended bladder. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial steps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the McRoberts maneuver with suprapubic pressure as the initial approach for releasing the impacted shoulder, given that it is less invasive than other maneuvers (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'McRoberts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the McRoberts maneuver is unsuccessful and the patient has good regional anesthesia, we suggest delivery of the posterior arm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28001966\">",
"       'Delivery of the posterior arm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the McRoberts maneuver is unsuccessful and the patient does not have good regional anesthesia, we suggest the Gaskin all-fours maneuver (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Gaskin all-fours'",
"      </a>",
"      above.) A rotational maneuver (Woods, Rubin) is a reasonable alternative.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/1\">",
"      ACOG Committee on Practice Bulletins-Gynecology, The American College of Obstetrician and Gynecologists. ACOG practice bulletin clinical management guidelines for obstetrician-gynecologists. Number 40, November 2002. Obstet Gynecol 2002; 100:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/2\">",
"      Hoffman MK, Bailit JL, Branch DW, et al. A comparison of obstetric maneuvers for the acute management of shoulder dystocia. Obstet Gynecol 2011; 117:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/3\">",
"      Gherman RB, Chauhan S, Ouzounian JG, et al. Shoulder dystocia: the unpreventable obstetric emergency with empiric management guidelines. Am J Obstet Gynecol 2006; 195:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/4\">",
"      Beall MH, Spong C, McKay J, Ross MG. Objective definition of shoulder dystocia: a prospective evaluation. Am J Obstet Gynecol 1998; 179:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/5\">",
"      Spong CY, Beall M, Rodrigues D, Ross MG. An objective definition of shoulder dystocia: prolonged head-to-body delivery intervals and/or the use of ancillary obstetric maneuvers. Obstet Gynecol 1995; 86:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/6\">",
"      Allen RH, Rosenbaum TC, Ghidini A, et al. Correlating head-to-body delivery intervals with neonatal depression in vaginal births that result in permanent brachial plexus injury. Am J Obstet Gynecol 2002; 187:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/7\">",
"      Leung TY, Stuart O, Sahota DS, et al. Head-to-body delivery interval and risk of fetal acidosis and hypoxic ischaemic encephalopathy in shoulder dystocia: a retrospective review. BJOG 2011; 118:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/8\">",
"      Lerner H, Durlacher K, Smith S, Hamilton E. Relationship between head-to-body delivery interval in shoulder dystocia and neonatal depression. Obstet Gynecol 2011; 118:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/9\">",
"      Wood C, Ng KH, Hounslow D, Benning H. Time--an important variable in normal delivery. J Obstet Gynaecol Br Commonw 1973; 80:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/10\">",
"      Benjamin K. Part 1. Injuries to the brachial plexus: mechanisms of injury and identification of risk factors. Adv Neonatal Care 2005; 5:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/11\">",
"      Gross SJ, Shime J, Farine D. Shoulder dystocia: predictors and outcome. A five-year review. Am J Obstet Gynecol 1987; 156:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/12\">",
"      Phelan, JP Ouzounian, JG, Gherman, GB, et al. Shoulder dystocia and permanent Erb palsy: the role of fundal pressure. Am J Obstet Gynecol 1997; 176:S138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/13\">",
"      Gurewitsch ED, Donithan M, Stallings SP, et al. Episiotomy versus fetal manipulation in managing severe shoulder dystocia: a comparison of outcomes. Am J Obstet Gynecol 2004; 191:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/14\">",
"      Paris AE, Greenberg JA, Ecker JL, McElrath TF. Is an episiotomy necessary with a shoulder dystocia? Am J Obstet Gynecol 2011; 205:217.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/15\">",
"      Crofts JF, Fox R, Ellis D, et al. Observations from 450 shoulder dystocia simulations: lessons for skills training. Obstet Gynecol 2008; 112:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/16\">",
"      Allen R, Sorab J, Gonik B. Risk factors for shoulder dystocia: an engineering study of clinician-applied forces. Obstet Gynecol 1991; 77:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/17\">",
"      Chauhan SP, Christian B, Gherman RB, et al. Shoulder dystocia without versus with brachial plexus injury: a case-control study. J Matern Fetal Neonatal Med 2007; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/18\">",
"      Poggi SH, Spong CY, Allen RH. Prioritizing posterior arm delivery during severe shoulder dystocia. Obstet Gynecol 2003; 101:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/19\">",
"      Gonik B, Stringer CA, Held B. An alternate maneuver for management of shoulder dystocia. Am J Obstet Gynecol 1983; 145:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/20\">",
"      Gherman RB, Tramont J, Muffley P, Goodwin TM. Analysis of McRoberts' maneuver by x-ray pelvimetry. Obstet Gynecol 2000; 95:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/21\">",
"      Buhimschi CS, Buhimschi IA, Malinow A, Weiner CP. Use of McRoberts' position during delivery and increase in pushing efficiency. Lancet 2001; 358:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/22\">",
"      Gherman RB, Goodwin TM, Souter I, et al. The McRoberts' maneuver for the alleviation of shoulder dystocia: how successful is it? Am J Obstet Gynecol 1997; 176:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/23\">",
"      Beall MH, Spong CY, Ross MG. A randomized controlled trial of prophylactic maneuvers to reduce head-to-body delivery time in patients at risk for shoulder dystocia. Obstet Gynecol 2003; 102:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/24\">",
"      Poggi SH, Allen RH, Patel CR, et al. Randomized trial of McRoberts versus lithotomy positioning to decrease the force that is applied to the fetus during delivery. Am J Obstet Gynecol 2004; 191:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/25\">",
"      Heath T, Gherman RB. Symphyseal separation, sacroiliac joint dislocation and transient lateral femoral cutaneous neuropathy associated with McRoberts' maneuver. A case report. J Reprod Med 1999; 44:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/26\">",
"      SCHWARTZ BC, DIXON DM. Shoulder dystocia. Obstet Gynecol 1958; 11:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/27\">",
"      Leung TY, Stuart O, Suen SS, et al. Comparison of perinatal outcomes of shoulder dystocia alleviated by different type and sequence of manoeuvres: a retrospective review. BJOG 2011; 118:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/28\">",
"      McFarland MB, Langer O, Piper JM, Berkus MD. Perinatal outcome and the type and number of maneuvers in shoulder dystocia. Int J Gynaecol Obstet 1996; 55:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/29\">",
"      Gherman RB, Ouzounian JG, Goodwin TM. Obstetric maneuvers for shoulder dystocia and associated fetal morbidity. Am J Obstet Gynecol 1998; 178:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/30\">",
"      Baskett TF, Allen AC. Perinatal implications of shoulder dystocia. Obstet Gynecol 1995; 86:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/31\">",
"      Menticoglou SM. A modified technique to deliver the posterior arm in severe shoulder dystocia. Obstet Gynecol 2006; 108:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/32\">",
"      Schramm M. Impacted shoulders--a personal experience. Aust N Z J Obstet Gynaecol 1983; 23:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/33\">",
"      HOLMAN MS. A new manoeuvre for delivery of an impacted shoulder, based on a mechanical analysis. S Afr Med J 1963; 37:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/34\">",
"      RUBIN A. MANAGEMENT OF SHOULDER DYSTOCIA. JAMA 1964; 189:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/35\">",
"      Gurewitsch ED, Kim EJ, Yang JH, et al. Comparing McRoberts' and Rubin's maneuvers for initial management of shoulder dystocia: an objective evaluation. Am J Obstet Gynecol 2005; 192:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/36\">",
"      Woods, C. A principle of physics as applicable to shoulder dystocia. Am J Obstet Gynecol 1943; 145:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/37\">",
"      Bruner JP, Drummond SB, Meenan AL, Gaskin IM. All-fours maneuver for reducing shoulder dystocia during labor. J Reprod Med 1998; 43:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/38\">",
"      Sandberg EC. The Zavanelli maneuver: a potentially revolutionary method for the resolution of shoulder dystocia. Am J Obstet Gynecol 1985; 152:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/39\">",
"      Sandberg EC. The Zavanelli maneuver: 12 years of recorded experience. Obstet Gynecol 1999; 93:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/40\">",
"      O'Leary JA, Cuva A. Abdominal rescue after failed cephalic replacement. Obstet Gynecol 1992; 80:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/41\">",
"      O'Shaughnessy MJ. Hysterotomy facilitation of the vaginal delivery of the posterior arm in a case of severe shoulder dystocia. Obstet Gynecol 1998; 92:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/42\">",
"      Hsu TY, Hung FC, Lu YJ, et al. Neonatal clavicular fracture: clinical analysis of incidence, predisposing factors, diagnosis, and outcome. Am J Perinatol 2002; 19:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/43\">",
"      Benjamin K. Part 2. Distinguishing physical characteristics and management of brachial plexus injuries. Adv Neonatal Care 2005; 5:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/44\">",
"      Gherman RB, Ouzounian JG, Goodwin TM. Brachial plexus palsy: an in utero injury? Am J Obstet Gynecol 1999; 180:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/45\">",
"      Foad SL, Mehlman CT, Ying J. The epidemiology of neonatal brachial plexus palsy in the United States. J Bone Joint Surg Am 2008; 90:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/46\">",
"      Chauhan SP, Rose CH, Gherman RB, et al. Brachial plexus injury: a 23-year experience from a tertiary center. Am J Obstet Gynecol 2005; 192:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/47\">",
"      Paradiso G, Gra&ntilde;ana N, Maza E. Prenatal brachial plexus paralysis. Neurology 1997; 49:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/48\">",
"      Dunn DW, Engle WA. Brachial plexus palsy: intrauterine onset. Pediatr Neurol 1985; 1:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/49\">",
"      Torki M, Barton L, Miller DA, Ouzounian JG. Severe brachial plexus palsy in women without shoulder dystocia. Obstet Gynecol 2012; 120:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/50\">",
"      Gonik B, Walker A, Grimm M. Mathematic modeling of forces associated with shoulder dystocia: a comparison of endogenous and exogenous sources. Am J Obstet Gynecol 2000; 182:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/51\">",
"      Jennett RJ, Tarby TJ, Krauss RL. Erb's palsy contrasted with Klumpke's and total palsy: different mechanisms are involved. Am J Obstet Gynecol 2002; 186:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/52\">",
"      Turnpenny PD, Nimmo A. Fractured clavicle of the newborn in a population with a high prevalence of grand-multiparity: analysis of 78 consecutive cases. Br J Obstet Gynaecol 1993; 100:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/53\">",
"      Poggi SH, Stallings SP, Ghidini A, et al. Intrapartum risk factors for permanent brachial plexus injury. Am J Obstet Gynecol 2003; 189:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/54\">",
"      Jeffery AR, Ellis FJ, Repka MX, Buncic JR. Pediatric Horner syndrome. J AAPOS 1998; 2:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/55\">",
"      Huang YG, Chen L, Gu YD, Yu GR. Histopathological basis of Horner's syndrome in obstetric brachial plexus palsy differs from that in adult brachial plexus injury. Muscle Nerve 2008; 37:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/56\">",
"      Al-Qattan MM, Clarke HM, Curtis CG. The prognostic value of concurrent Horner's syndrome in total obstetric brachial plexus injury. J Hand Surg Br 2000; 25:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/57\">",
"      Hashimoto T, Mitomo M, Hirabuki N, et al. Nerve root avulsion of birth palsy: comparison of myelography with CT myelography and somatosensory evoked potential. Radiology 1991; 178:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/58\">",
"      Medina LS, Yaylali I, Zurakowski D, et al. Diagnostic performance of MRI and MR myelography in infants with a brachial plexus birth injury. Pediatr Radiol 2006; 36:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41752/abstract/59\">",
"      Trojaborg W. Clinical, electrophysiological, and myelographic studies of 9 patients with cervical spinal root avulsions: discrepancies between EMG and X-ray findings. Muscle Nerve 1994; 17:913.",
"     </a>",
"    </li>",
"    <li>",
"     Joint Commission on Accreditation of Healthcare Organizations. www.jcaho.org/. (Accessed on March 10, 2005).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5397 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41752=[""].join("\n");
var outline_f40_49_41752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Initial steps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68133738\">",
"      - Traction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Maneuvers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2531262\">",
"      - Suprapubic pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - McRoberts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28001966\">",
"      - Delivery of the posterior arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1055812455\">",
"      Posterior axilla modification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rubin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Woods screw",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gaskin all-fours",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clavicular fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Zavanelli",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1294345\">",
"      - Abdominal rescue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Symphysiotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Documentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Maternal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1570126\">",
"      REDUCING THE RISK OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36953874\">",
"      GUIDELINES FROM NATIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5397|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/17/25881\" title=\"figure 1\">",
"      Cardinal movements labor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/9/33936\" title=\"figure 2\">",
"      McRoberts maneuver and suprapubic pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/4/10307\" title=\"figure 3\">",
"      McRoberts position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/62/38882\" title=\"figure 4\">",
"      Delivery of posterior arm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/52/26435\" title=\"figure 5\">",
"      Rubin manuever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/0/27651\" title=\"figure 6\">",
"      Woods corkscrew maneuver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/63/16383\" title=\"figure 7A\">",
"      Shoulder dystocia documentation form A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/14/31983\" title=\"figure 7B\">",
"      Shoulder dystocia documentation form B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2906?source=related_link\">",
"      Brachial plexus syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44071?source=related_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1253?source=related_link\">",
"      Fetal acid-base physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32262?source=related_link\">",
"      Horner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/2/19490?source=related_link\">",
"      Patient information: Shoulder dystocia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=related_link\">",
"      Reducing adverse obstetrical outcomes through safety sciences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/1/16408?source=related_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35702?source=related_link\">",
"      Umbilical cord blood acid-base analysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_49_41753="Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas";
var content_f40_49_41753=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     Sunil G Sheth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     Tara S Kent, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41753/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/49/41753/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5512616\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal papillary mucinous neoplasms of the pancreas (IPMNs) are potentially malignant intraductal epithelial neoplasms that are grossly visible (&gt;1 cm) and are composed of mucin-producing columnar cells. The lesions show papillary proliferation, cyst formation, and varying degrees of cellular atypia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IPMNs may involve the main pancreatic duct, the branch ducts, or both. Whereas patients with branch duct lesions are at lower risk for developing malignancy (approximately 20 percent at 10 years), patients with IPMN involving the main duct are at high risk (approximately 70 percent). As a result, these lesions need to be accurately diagnosed and characterized so that appropriate treatment can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H8191002#H8191002\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H5506456#H5506456\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Pancreatic malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the diagnosis and treatment of IPMNs. The pathophysiology and clinical manifestations of IPMNs and an overview of pancreatic cystic neoplasms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=see_link\">",
"     \"Pancreatic cystic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511878\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of intraductal papillary mucinous neoplasm of the pancreas (IPMN) includes chronic obstructive pancreatitis, mucinous cystic tumors of the pancreas, and, rarely, pancreatic ductal adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=see_link\">",
"     \"Classification of pancreatic cysts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Traditional abdominal ultrasound and computed tomography (CT) scanning often cannot distinguish IPMN from these entities. As a result, additional testing with endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasound (EUS), or pancreatoscopy is frequently required. None of these imaging modalities is conclusive, and each has advantages and disadvantages.",
"   </p>",
"   <p>",
"    We suggest either a pancreatic protocol CT scan or an MRCP as the initial radiologic test to evaluate patients with suspected IPMN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H5507120#H5507120\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Clinical presentation'",
"    </a>",
"    .) Endoscopic ultrasound is then used in cases of diagnostic uncertainty. We suggest that ERCP be reserved for centers in which these other tests are unavailable or in which the quality of these other imaging tests has not been standardized. We also suggest ERCP and pancreatoscopy for distinguishing benign from malignant tumors when the necessary expertise and equipment are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511885\">",
"    <span class=\"h2\">",
"     Endoscopic evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511892\">",
"    <span class=\"h3\">",
"     Endoscopic retrograde cholangiopancreatography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical ERCP findings of IPMN include a diffusely or segmentally dilated pancreatic duct without stricturing. The side branches may also be dilated. Filing defects may be seen due to mucus or mural nodules. The papilla is patulous and resembles a \"fish-mouth\", frequently with mucus extruding from the orifice (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66926 \" href=\"mobipreview.htm?6/40/6784\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52643 \" href=\"mobipreview.htm?18/34/18976\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. An advantage of ERCP is the ability to obtain cytology by aspiration of the duct contents or brushings. In addition, therapeutic maneuvers can be performed to help clear the tenacious mucin from the pancreatic duct.",
"   </p>",
"   <p>",
"    Cytologic examination may reveal mucin and floating epithelial cells with varying degrees of atypia. Pancreatic secretions can be tested for molecular markers such as K-ras, P53, and telomerase activity. These markers can be helpful for detecting malignant IPMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, they cannot be relied upon to discriminate among the various cystic lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=see_link&amp;anchor=H8#H8\">",
"     \"Pancreatic cystic neoplasms\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because it is less invasive, MRCP is often performed instead of ERCP. (See",
"    <a class=\"local\" href=\"#H5511927\">",
"     'CT scan and magnetic resonance imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511899\">",
"    <span class=\"h3\">",
"     Endoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUS findings of main duct (MD)-IPMN include segmental or diffuse dilation of the main pancreatic duct and intraductal (mural) nodules. In branch duct (BD)-IPMN, there are often multiple small cysts (5 to 20 mm). EUS can help distinguish between BD-IPMN and other cysts if communication with the main pancreatic duct (present in BD-IPMN) can be demonstrated. Certain EUS features suggest malignancy, although their sensitivity and specificity have not been well established. These findings include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/4,9-11\">",
"     4,9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A main pancreatic duct &ge;7 mm in MD-IPMN",
"     </li>",
"     <li>",
"      Cystic lesion &gt;30 mm with an irregular, thick septum in BD-IPMN",
"     </li>",
"     <li>",
"      Mural nodules &gt;10 mm for both MD- and BD-IPMN",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fine-needle aspiration of cyst fluid and mural nodules can also be performed for cytologic evaluation and assessment of tumor markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/10\">",
"     10",
"    </a>",
"    ]. However, 50 to 60 percent of fluid samples are nondiagnostic or acellular, and the absence of atypical or malignant cells does",
"    <strong>",
"     not",
"    </strong>",
"    exclude the presence of malignant IPMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=see_link&amp;anchor=H8#H8\">",
"     \"Pancreatic cystic neoplasms\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3561?source=see_link\">",
"     \"Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies are variable regarding the ability of tumor markers in the cyst fluid to differentiate malignant from benign IPMN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, a carcinoembryonic antigen (CEA) level &gt;200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      had a sensitivity and specificity for malignant IPMN of 90 and 71 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study found that neither CEA nor cancer antigen 19-9 were useful for distinguishing malignant from benign IPMN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study with 40 patients, mean mucin-2 (MUC2) and MUC4 cyst fluid concentrations were elevated in patients with high-grade dysplasia or carcinoma compared with patients with low-grade or moderate dysplasia (10 versus 4.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and 20.6 versus 4.5",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EUS may also be useful for distinguishing IPMN from chronic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29591?source=see_link\">",
"     \"Endoscopic ultrasound in chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511906\">",
"    <span class=\"h3\">",
"     Pancreatoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patulous pancreatic orifice can be cannulated easily with a pancreatoscope during ERCP permitting direct visualization of the pancreatic duct (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62216 \" href=\"mobipreview.htm?39/16/40206\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81337 \" href=\"mobipreview.htm?7/16/7439\">",
"     picture 2",
"    </a>",
"    ). Pancreatoscopy can help determine the extent of IPMN, especially if skip lesions are present, which may aid preoperative staging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/16\">",
"     16",
"    </a>",
"    ]. Features suggesting malignancy include spotty or linear red markings, \"fish egg-like\" lesions, villous proliferations (",
"    <a class=\"graphic graphic_picture graphicRef71357 \" href=\"mobipreview.htm?32/45/33502\">",
"     picture 3",
"    </a>",
"    ), and vegetative type lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of pancreatoscopy was illustrated in a study of 60 patients with IPMN in which 57 (95 percent) were correctly identified as IPMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/18\">",
"     18",
"    </a>",
"    ]. In another report of patients with IPMN, the presence of fish egg-like, villous, and prominent mucosal protrusions had a sensitivity of 68 percent and a specificity of 87 percent for malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/19\">",
"     19",
"    </a>",
"    ]. The sensitivity was lower for side branch IPMN compared with lesions of the main pancreatic duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511913\">",
"    <span class=\"h3\">",
"     Intraductal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal ultrasonography using high frequency ultrasound catheter probes can be helpful for determining tumor extent in MD-IPMN (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79828 \" href=\"mobipreview.htm?33/38/34401\">",
"     image 3",
"    </a>",
"    ). However, intraductal ultrasonography has a limited ability to detect lesions more than a few millimeters away from the main pancreatic duct due to poor penetration of the high frequency waves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33353?source=see_link\">",
"     \"Intraductal ultrasound of the pancreaticobiliary ductal system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511920\">",
"    <span class=\"h2\">",
"     Radiographic evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511927\">",
"    <span class=\"h3\">",
"     CT scan and magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonendoscopic imaging, such as CT scan using a protocol to maximize pancreatic visualization and MRCP, can be used to diagnose and characterize IPMN (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51921 \" href=\"mobipreview.htm?2/19/2354\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66204 \" href=\"mobipreview.htm?10/12/10432\">",
"     image 5",
"    </a>",
"    ). The studies can assess the tumor, its relationship to surrounding structures, whether there is lymph node involvement, and if there is metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both CT and MRCP are capable of detecting mural nodules. A CT scan finding of &gt;3 mm mural nodules within a cyst or the duct is highly suggestive of malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/24\">",
"     24",
"    </a>",
"    ]. MRCP is more sensitive than ERCP for differentiating mural nodules from mucin globs since mucin has the same signal intensity as pancreatic fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/21,24-27\">",
"     21,24-27",
"    </a>",
"    ]. MRCP also consistently demonstrates the internal architecture of the main duct and the extent of IPMN better than ERCP. However, MRCP is inferior to ERCP in demonstrating peripheral ductal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/28\">",
"     28",
"    </a>",
"    ] and in the ability to obtain tissue or perform therapeutic interventions. MRCP appears to be superior to CT scan for determining whether side branch lesions communicate with the main pancreatic duct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511934\">",
"    <span class=\"h3\">",
"     Positron emission tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) scanning has been used for detecting malignancy in IPMN and in selecting patients for surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. A study of 162 patients with main duct or branch duct IPMN examined the ability of PET scanning to detect malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/32\">",
"     32",
"    </a>",
"    ]. The study compared PET scanning with either histology (81 patients) or the results of surveillance (62 patients; median follow-up 21 months).",
"    <span class=\"nowrap\">",
"     Follow-up/histologic",
"    </span>",
"    data were not available for 19 patients. The sensitivity and specificity for PET scanning were 83 and 100 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5511941\">",
"    <span class=\"h2\">",
"     Serum tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of serum levels of carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) may aid in the differentiation of invasive from noninvasive IPMN. In a study of 142 patients undergoing surgical resection for IPMN, patients with invasive IPMN had higher CA19-9 and CEA levels compared with patients with noninvasive IPMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/34\">",
"     34",
"    </a>",
"    ]. Eighty percent of patients with invasive IPMN had one or both markers elevated, compared with 18 percent of patients with noninvasive IPMN. Using a cutoff of 37",
"    <span class=\"nowrap\">",
"     units/mL,",
"    </span>",
"    CA19-9 was 74 percent sensitive and 86 percent specific for invasive IPMN. The sensitivity and specificity for CEA at a cutoff of 5",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    were 40 and 92 percent, respectively. Taken together (ie, CA19-9",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CEA positive), the tests had a sensitivity of 80 percent and a specificity of 82 percent.",
"   </p>",
"   <p>",
"    Mucin-5AC (MUC5AC) serum levels may help differentiate high-risk IPMN from low-risk IPMN. A study found elevated MUC5AC levels in patients with high-grade dysplasia or carcinoma compared with patients with lesser degrees of dysplasia (20 versus 2",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5510671\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5510679\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the only treatment option in patients with intraductal papillary mucinous neoplasm of the pancreas (IPMN) with high-grade dysplasia or invasive cancer. Preoperative staging using a combination of endoscopic retrograde cholangiopancreatography (ERCP), pancreatoscopy, endoscopic ultrasound (EUS), and intraductal ultrasonography may be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/19,26,35,36\">",
"     19,26,35,36",
"    </a>",
"    ]. Invasive cancer in IPMN is staged using the tumor-node-metastasis (TNM) system (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"mobipreview.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link&amp;anchor=H18017084#H18017084\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'Staging system and the staging workup'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical series have described a variety of operations for IPMN, including total pancreatectomy (",
"    <a class=\"graphic graphic_figure graphicRef68307 \" href=\"mobipreview.htm?29/29/30175\">",
"     figure 1",
"    </a>",
"    ), pancreaticoduodenectomy (",
"    <a class=\"graphic graphic_figure graphicRef82519 \" href=\"mobipreview.htm?16/57/17303\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60689 \" href=\"mobipreview.htm?5/43/5810\">",
"     figure 3",
"    </a>",
"    ), distal pancreatectomy (",
"    <a class=\"graphic graphic_figure graphicRef64624 \" href=\"mobipreview.htm?33/19/34101\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74555 \" href=\"mobipreview.htm?31/22/32100\">",
"     figure 5",
"    </a>",
"    ), and segmental resection of the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. The choice of surgery will be determined by the location of the tumor and the extent of involvement of the gland. It is not clearly established that multifocality corresponds to a higher risk of invasive cancer, and in most cases with more than one lesion, the dominant or concerning lesion is resected, and the other(s) may be observed with follow-up imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/43\">",
"     43",
"    </a>",
"    ]. However, some data suggest that patients with multiple (&ge;4) pancreatic cysts may have high-grade dysplasia or invasive carcinoma, even in the absence of worrisome CT findings (cysts &ge;3 cm, pain pancreatic ductal dilation &ge;6 mm, or mural nodularity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/44\">",
"     44",
"    </a>",
"    ]. In a study of 43 patients with &ge;4 cysts and no solid pancreatic mass who underwent surgical resection, 18 (42 percent) had IPMN with either high-grade dysplasia or invasive carcinoma. Importantly, seven patients (16 percent) lacked worrisome CT findings but were found to have high-grade dysplasia or invasive carcinoma. However, the results of this study should be viewed in light of the fact that it was a retrospective series and that the indications for surgery were not discussed. Therefore, the study is at risk for bias with regard to which patients underwent surgery. Surgical resection of the entire pancreas may be appropriate for patients with multiple symptomatic lesions or with cysts that have concerning radiologic or endoscopic features, though the risk of malignancy needs to be carefully weighed against the issues that arise in apancreatic patients. Additional long-term studies of outcomes in patients with multiple asymptomatic cysts are needed before recommending total pancreatectomy in this setting.",
"   </p>",
"   <p>",
"    The most common operation is pancreaticoduodenectomy (70 percent) because most tumors are in the head of the pancreas. Examination of frozen sections of the resection margins during surgery can determine tumor extent and the need for further surgical resection, bearing in mind that given the \"field defect\" nature of IPMN, a negative surgical margin does not preclude the presence of neoplasia in the remnant pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/41,45\">",
"     41,45",
"    </a>",
"    ]. Intraoperative pancreatoscopy may also be helpful in determining tumor extent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43721?source=see_link\">",
"     \"Pancreaticoduodenectomy (Whipple procedure): Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2569?source=see_link\">",
"     \"Distal pancreatectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resection of the tumor can be attempted in patients with no imaging or endoscopic evidence of local vascular invasion or distant metastases. The management of patients with local invasion or metastatic disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2006, a group of experts proposed criteria for pancreatic resection in IPMN (the Sendai Consensus Guidelines) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/43\">",
"     43",
"    </a>",
"    ]. These guidelines were subsequently updated in 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/46\">",
"     46",
"    </a>",
"    ]. According to the 2012 guidelines, resection of main duct (MD)-IPMN is recommended for all patients who are good surgical candidates with reasonable life expectancy if the duct is &ge;10 mm in diameter. If the duct is 5 to 9 mm in diameter, additional evaluation (EUS with fine-needle aspiration) is recommended prior to surgery. Surgery is then indicated if there is evidence of thickened walls, intraductal mucin, or mural nodules on EUS, or if cytology is suspicious or positive for malignancy. If there is no evidence of thickened walls, intraductal mucin, or mural nodules in a patient with MD-IPMN, the results of the EUS are considered to be inconclusive.",
"   </p>",
"   <p>",
"    For patients with branch duct (BD)-IPMN, resection is indicated without further evaluation if there is obstructive jaundice in a patient with a cystic lesion in the head of the pancreas, if there is an enhancing solid component within the cyst, or if there is associated main pancreatic duct dilation of &ge;10 mm. Further evaluation is indicated if worrisome features are present. Worrisome features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyst size &ge;30 mm",
"     </li>",
"     <li>",
"      Thickened or enhancing cyst walls on imaging",
"     </li>",
"     <li>",
"      Associated pancreatitis",
"     </li>",
"     <li>",
"      Main pancreatic duct size of 5 to 9 mm in diameter",
"     </li>",
"     <li>",
"      Presence of a non-enhancing mural nodule",
"     </li>",
"     <li>",
"      An abrupt change in the caliber of the pancreatic duct with distal pancreatic atrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with BD-IPMN, surgery is indicated if there is evidence of thickened walls, intraductal mucin, or mural nodules on EUS, or if cytology is suspicious or positive for malignancy. The criteria for proceeding with surgery are the same for patients with single and multiple cysts.",
"   </p>",
"   <p>",
"    For patients who do not meet criteria for surgery, follow-up depends upon the certainty of the",
"    <span class=\"nowrap\">",
"     EUS/cytology",
"    </span>",
"    findings and the size of the cyst. If the EUS findings or cytology are inconclusive, or if a branch duct cyst is &gt;3 cm, surgery should be strongly considered for young, fit patients. For all other patients, close surveillance with alternating MRI and EUS is suggested every three to six months. If the cyst is 2 to 3 cm in size, the guidelines recommend EUS in three to six months. If the cyst is stable, the surveillance interval can be lengthened (eg, to annually), alternating magnetic resonance imaging (MRI with EUS). Again, surgery should be considered in young, fit patients. For cysts that are 1 to 2 cm in size, CT or MRI is recommended every two years, with lengthening of the interval if there is no change in the cyst. Finally, if the cyst is &lt;1 cm in size, a repeat CT or MRI in two to three years is suggested. In all cases, surgery should be considered if the cyst rapidly increases in size.",
"   </p>",
"   <p>",
"    There appears to be an increased risk of malignancy if the CEA level in the pancreatic juice of &gt;30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (based upon CEA values measured in the pancreatic juice of patients undergoing ERCP prior to surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/11,47\">",
"     11,47",
"    </a>",
"    ]. However, CEA levels are not currently used to decide which patients should undergo resection (though they can be used to differentiate patients with mucinous neoplasms from those with other lesions). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=see_link&amp;anchor=H11#H11\">",
"     \"Pancreatic cystic neoplasms\", section on 'Tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The consensus criteria have not been extensively validated prospectively, but data are emerging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. The data suggest that the 2006 guidelines have high sensitivity for malignancy (close to 100 percent) but low specificity (around 25 to 30 percent).",
"   </p>",
"   <p>",
"    The generally high sensitivity of the guidelines suggests that it is reasonable to follow patients who do not meet criteria for resection. On the other hand, the low specificity, combined with the fact that the majority of patients with BD-IPMN have a prolonged clinical course without the development of cancer, means that if the guidelines are followed, a large number of patients will undergo surgery (most often pancreaticoduodenectomy) for benign lesions.",
"   </p>",
"   <p>",
"    Given that there is significant morbidity and mortality associated with pancreaticoduodenectomy, we believe that clinicians and patients should carefully weigh the risk of developing a malignancy with the risks associated with surgery. In general, we suggest surgery for patients who are good surgical candidates and who meet the revised consensus criteria. We also suggest surgery in cases where the diagnosis is in doubt. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H5506456#H5506456\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Pancreatic malignancy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5510701\">",
"     'Following patients who do not undergo surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5510686\">",
"    <span class=\"h2\">",
"     Role of adjuvant therapy for invasive cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with invasive ductal adenocarcinoma of the pancreas, postresection adjuvant therapy improves survival, even in patients with positive margins or involved lymph nodes. There is controversy as to the best adjuvant strategy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of adjuvant therapy for patients with invasive carcinoma associated with IPMN has been addressed in a retrospective report. In a series of 70 patients treated at Johns Hopkins hospital between 1999 and 2004, 40 received adjuvant chemoradiotherapy (mostly external beam radiotherapy with concomitant infusional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    , followed by fluorouracil chemotherapy alone), while 30 had resection only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/53\">",
"     53",
"    </a>",
"    ]. Invasive carcinoma was present at the resection margin in 16 percent of cases, and 50 percent had involved lymph nodes. Despite the fact that patients receiving adjuvant therapy were more likely to have adverse prognostic features (nodal metastases, perineural invasion, and stage II or III rather than stage I disease) (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"mobipreview.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    ), the two-year survival rate after surgery with chemotherapy was similar to that seen in those who did not receive chemoradiotherapy (56 versus 59 percent). In multivariate analysis, after adjusting for major confounders, adjuvant chemoradiotherapy was associated with a significant 57 percent reduction in mortality after pancreaticoduodenectomy.",
"   </p>",
"   <p>",
"    Extrapolating from the experience with invasive ductal pancreatic adenocarcinoma, it appears reasonable to offer postresection adjuvant therapy to patients with IPMN and an invasive component. However, the identification of the specific subgroups that benefit from postoperative therapy and the optimal treatment strategy (chemoradiotherapy versus chemotherapy alone) is undefined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5510693\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND SURVEILLANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5510701\">",
"    <span class=\"h2\">",
"     Following patients who do not undergo surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intraductal papillary mucinous neoplasm of the pancreas (IPMN) who do not have indications for surgery are still at risk for developing pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H5506456#H5506456\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Pancreatic malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 60 patients with branch duct (BD)-IPMN who did not undergo surgery, pancreatic ductal adenocarcinoma subsequently developed in five (8 percent) and the risk of developing cancer was approximately 1",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/54\">",
"     54",
"    </a>",
"    ]. In a second study that included 170 patients who underwent surveillance, 97 patients (57 percent) ultimately had surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/55\">",
"     55",
"    </a>",
"    ]. The indications for surgery were endoscopic or radiographic changes in the cyst (55 percent), concern that the cyst may be premalignant (eg, main duct IPMN or BD-IPMN that met resection criteria; 29 percent), and suspicious cytology (11 percent). Invasive lesions were present in 18 patients (19 percent of the patients who underwent resection and 11 percent of the patients overall), 11 of which were tubular carcinomas (11 percent of those undergoing resection, 6 percent of the patients overall).",
"   </p>",
"   <p>",
"    Due to the cancer risk, surveillance is recommended in patients who do not undergo surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/43\">",
"     43",
"    </a>",
"    ]. Computed tomography (CT) using a pancreatic protocol or magnetic resonance cholangiopancreatography (MRCP) are typically used to follow patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/56\">",
"     56",
"    </a>",
"    ]. The following surveillance schedule has been suggested in international consensus guidelines based upon limited data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lesions &lt;10 mm: Evaluation every 12 months",
"     </li>",
"     <li>",
"      Lesions between 10 and 20 mm: Evaluation every 6 to 12 months",
"     </li>",
"     <li>",
"      Lesions &gt;20 mm: Evaluation every 3 to 6 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines recommend resection if the patient develops symptoms attributable to the cyst, if the cyst increases in size to &gt;30 mm, if intramural nodules develop, or if there is dilation of the main pancreatic duct (&gt;6 mm). However, our practice is to consider surgery for cysts that are increasing in size and are greater than 2 cm. If there are no changes in the cyst after two years, the interval of follow-up can be lengthened (we suggest no longer than every two to three years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5510708\">",
"    <span class=\"h2\">",
"     Follow-up after surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall prognosis following surgery in patients with early stage IPMN containing a cancer is favorable, with up to 60 to 80 percent three-year survival, with patients with BD-IPMN faring better than those with main duct (MD)-IPMN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/57\">",
"     57",
"    </a>",
"    ]. Prognosis is less favorable when an invasive component is identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only one-fifth of patients with invasive cancer and positive margins at the time of resection are alive at three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/42,58,59\">",
"       42,58,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with lymph node metastases have a less favorable outcome than do those with negative nodes. In a series of 104 patients with invasive IPMN (58 percent node-negative), five-year disease-specific survival rates for those with positive and negative nodes were 29 and 80 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/60\">",
"       60",
"      </a>",
"      ]. The total lymph node count also influenced prognosis; patients with a lower lymph node ratio (calculated by dividing the total number of nodes harboring metastases by the total number of examined nodes) had better outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the prognosis of invasive IPMN is better than that of pancreatic ductal adenocarcinoma (five-year survival 31 to 62 versus 9 to 20 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/61-66\">",
"     61-66",
"    </a>",
"    ]. This is largely attributable to lower rates of advanced T stage, nodal metastases, high-grade differentiation, positive resection margins, and perineural as well as vascular invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/65,67\">",
"     65,67",
"    </a>",
"    ]. However, when any of these features is present in the resected specimen, survival outcomes are similar to those of pancreatic ductal adenocarcinoma. This was illustrated in a report from the SEER (Surveillance, Epidemiology and End Results) database, which compared outcomes of 729 patients with resected invasive IPMN and 8082 patients with resected pancreatic ductal adenocarcinoma. Five-year survival rates for node-negative invasive IPMN and ductal cancer were 35 and 17 percent, respectively, whereas the corresponding values for node-positive disease were 9 and 7 percent.",
"   </p>",
"   <p>",
"    Following surgery, patients are at risk for recurrence of IPMN. In patients with noninvasive IPMN, the risk of developing a recurrence in the remaining pancreas is at least 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/39,42,68\">",
"     39,42,68",
"    </a>",
"    ]. In such patients, yearly follow-up with CT or MRCP has been suggested, with an increase in the surveillance interval if no changes are detected after several years. For patients with invasive IPMN, studies suggest the risk of recurrence is 25 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/69-71\">",
"     69-71",
"    </a>",
"    ], and it has been suggested that these patients undergo surveillance every six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients found to have a recurrence will generally require surgery, even for noninvasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/42,71,72\">",
"     42,71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5510715\">",
"    <span class=\"h2\">",
"     Surveillance for extrapancreatic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IPMN appear to be at risk for extrapancreatic malignancies, particularly gastric and colon cancer. However, the magnitude of risk for extrapancreatic malignancies and the benefit of surveillance strategies remain uncertain. A reasonable approach is to perform an upper endoscopy and colonoscopy in patients with established IPMN, with subsequent surveillance guided by the initial findings and individual patient factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H5506766#H5506766\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Extrapancreatic malignancies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=see_link&amp;anchor=H5#H5\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5513707\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraductal papillary mucinous neoplasm of the pancreas (IPMN) is a cystic neoplasm of the pancreas with malignant potential. It may involve the main pancreatic duct, the branch ducts, or both. Patients with IPMN involving the main duct are at increased risk of cancer compared with patients who have side branch IPMN. (See",
"      <a class=\"local\" href=\"#H5512616\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest either a pancreatic protocol CT scan or an MRCP as an initial radiologic test to evaluate patients with suspected IPMN. Endoscopic ultrasound is then used in cases of diagnostic uncertainty. We suggest that ERCP be reserved for centers in which these other tests are unavailable or in which the quality of these other imaging tests has not been standardized. We also suggest ERCP and pancreatoscopy for distinguishing benign from malignant tumors when the necessary expertise and equipment are available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=see_link\">",
"       \"Pancreatic cystic neoplasms\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5511878\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend surgical resection for patients with main duct IPMN if there is no imaging or endoscopic evidence of local invasion or metastases (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5510679\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Decisions regarding treatment of branch duct (BD)-IPMN should take into account the natural history of the disease and the risks associated with surgery. Consensus criteria suggest resection of BD-IPMN if one or more of the following are present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptoms attributable to the cyst (eg, pancreatitis)",
"     </li>",
"     <li>",
"      Dilation of the main pancreatic duct (&ge;10 mm)",
"     </li>",
"     <li>",
"      Cyst size &ge;30 mm",
"     </li>",
"     <li>",
"      Presence of intramural nodules",
"     </li>",
"     <li>",
"      Cyst fluid cytology suspicious or positive for malignancy",
"     </li>",
"     <li>",
"      However, other data suggest an increased risk of malignancy if the pancreatic duct is dilated to &ge;6 mm. We suggest surgery for patients who meet the consensus criteria for resection, if the main pancreatic duct is dilated to &ge;7 mm, or if the diagnosis of IPMN is in doubt, provided the patients are good surgical candidates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Conservative management with periodic imaging is a reasonable alternative in patients who are not surgical candidates or who choose not to undergo surgery. (See",
"      <a class=\"local\" href=\"#H5510679\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5510701\">",
"       'Following patients who do not undergo surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of patients with local invasion or metastatic disease is discussed elsewhere. (See",
"      <a class=\"local\" href=\"#H5510679\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"       \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"       \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest postresection adjuvant therapy for patients with invasive IPMN (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, it is not clear whether all patients benefit from postoperative therapy, and the optimal treatment strategy (chemoradiotherapy versus chemotherapy alone) is undefined. In general, the approach is similar to adjuvant therapy for patients with noncystic pancreatic adenocarcinoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"       \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5510686\">",
"       'Role of adjuvant therapy for invasive cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We perform surveillance in patients who do not undergo surgical resection. Computed tomography (CT) using a pancreatic protocol or magnetic resonance cholangiopancreatography (MRCP) are typically used to follow patients. The frequency of surveillance will depend upon the size of the lesion. (See",
"      <a class=\"local\" href=\"#H5510701\">",
"       'Following patients who do not undergo surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also perform surveillance in patients who have undergone surgical resection. In patients with benign IPMNs, yearly follow-up with CT or MRCP is reasonable, with a lengthening of the surveillance interval if no changes are detected after several years. For patients with invasive IPMN, we suggest surveillance every six months. (See",
"      <a class=\"local\" href=\"#H5510708\">",
"       'Follow-up after surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with IPMN appear to be at increased risk for extrapancreatic malignancies, particularly gastric and colon cancer. We suggest that patients with IPMN undergo an upper endoscopy and colonoscopy at the time of diagnosis, as well as routine cancer screening (eg, mammography, prostate specific antigen) with subsequent surveillance guided by the initial findings and individual patient factors. There are no data to suggest changing the interval of cancer screening beyond that used for patients at average risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41753/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=see_link&amp;anchor=H5506766#H5506766\">",
"       \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Extrapancreatic malignancies'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5510715\">",
"       'Surveillance for extrapancreatic malignancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/1\">",
"      Longnecker DS, Adsay NV, Fernandez-del Castillo C, et al. Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas 2005; 31:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/2\">",
"      Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004; 28:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/3\">",
"      Nickl NJ, Lawson JM, Cotton PB. Mucinous pancreatic tumors: ERCP findings. Gastrointest Endosc 1991; 37:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/4\">",
"      Cellier C, Cuillerier E, Palazzo L, et al. Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series. Gastrointest Endosc 1998; 47:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/5\">",
"      Raijman I, Kortan P, Walden D, et al. Mucinous ductal ectasia: cholangiopancreatographic and endoscopic findings. Endoscopy 1994; 26:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/6\">",
"      Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994; 425:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/7\">",
"      Kaino M, Kondoh S, Okita S, et al. Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors. Pancreas 1999; 18:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/8\">",
"      Inoue H, Tsuchida A, Kawasaki Y, et al. Preoperative diagnosis of intraductal papillary-mucinous tumors of the pancreas with attention to telomerase activity. Cancer 2001; 91:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/9\">",
"      Sugiyama M, Atomi Y, Saito M. Intraductal papillary tumors of the pancreas: evaluation with endoscopic ultrasonography. Gastrointest Endosc 1998; 48:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/10\">",
"      Pais SA, Attasaranya S, Leblanc JK, et al. Role of endoscopic ultrasound in the diagnosis of intraductal papillary mucinous neoplasms: correlation with surgical histopathology. Clin Gastroenterol Hepatol 2007; 5:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/11\">",
"      Tanno S, Nakano Y, Nishikawa T, et al. Natural history of branch duct intraductal papillary-mucinous neoplasms of the pancreas without mural nodules: long-term follow-up results. Gut 2008; 57:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/12\">",
"      Gr&uuml;tzmann R, Niedergethmann M, Pilarsky C, et al. Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist 2010; 15:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/13\">",
"      Maire F, Voitot H, Aubert A, et al. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy. Am J Gastroenterol 2008; 103:2871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/14\">",
"      Maker AV, Katabi N, Gonen M, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol 2011; 18:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/15\">",
"      Aithal GP, Chen RY, Cunningham JT, et al. Accuracy of EUS for detection of intraductal papillary mucinous tumor of the pancreas. Gastrointest Endosc 2002; 56:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/16\">",
"      Yamaguchi T, Hara T, Tsuyuguchi T, et al. Peroral pancreatoscopy in the diagnosis of mucin-producing tumors of the pancreas. Gastrointest Endosc 2000; 52:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/17\">",
"      Kaneko T, Nakao A, Nomoto S, et al. Intraoperative pancreatoscopy with the ultrathin pancreatoscope for mucin-producing tumors of the pancreas. Arch Surg 1998; 133:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/18\">",
"      Yamao K, Ohashi K, Nakamura T, et al. Efficacy of peroral pancreatoscopy in the diagnosis of pancreatic diseases. Gastrointest Endosc 2003; 57:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/19\">",
"      Hara T, Yamaguchi T, Ishihara T, et al. Diagnosis and patient management of intraductal papillary-mucinous tumor of the pancreas by using peroral pancreatoscopy and intraductal ultrasonography. Gastroenterology 2002; 122:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/20\">",
"      Furukawa T, Tsukamoto Y, Naitoh Y, et al. Differential diagnosis between benign and malignant localized stenosis of the main pancreatic duct by intraductal ultrasound of the pancreas. Am J Gastroenterol 1994; 89:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/21\">",
"      Irie H, Honda H, Aibe H, et al. MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas. AJR Am J Roentgenol 2000; 174:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/22\">",
"      Sahani DV, Kadavigere R, Blake M, et al. Intraductal papillary mucinous neoplasm of pancreas: multi-detector row CT with 2D curved reformations--correlation with MRCP. Radiology 2006; 238:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/23\">",
"      Carbognin G, Zamboni G, Pinali L, et al. Branch duct IPMTs: value of cross-sectional imaging in the assessment of biological behavior and follow-up. Abdom Imaging 2006; 31:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/24\">",
"      Sugiyama M, Atomi Y, Kuroda A. Two types of mucin-producing cystic tumors of the pancreas: diagnosis and treatment. Surgery 1997; 122:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/25\">",
"      Koito K, Namieno T, Ichimura T, et al. Mucin-producing pancreatic tumors: comparison of MR cholangiopancreatography with endoscopic retrograde cholangiopancreatography. Radiology 1998; 208:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/26\">",
"      Izuishi K, Nakagohri T, Konishi M, et al. Spatial assessment by magnetic resonance cholangiopancreatography for preoperative imaging in partial pancreatic head resection. Am J Surg 2001; 182:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/27\">",
"      Albert J, Schilling D, Breer H, et al. Mucinous cystadenomas and intraductal papillary mucinous tumors of the pancreas in magnetic resonance cholangiopancreatography. Endoscopy 2000; 32:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/28\">",
"      Itai Y, Ohhashi K, Nagai H, et al. \"Ductectatic\" mucinous cystadenoma and cystadenocarcinoma of the pancreas. Radiology 1986; 161:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/29\">",
"      Waters JA, Schmidt CM, Pinchot JW, et al. CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg 2008; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/30\">",
"      Sperti C, Pasquali C, Chierichetti F, et al. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 2001; 234:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/31\">",
"      Baiocchi GL, Portolani N, Bertagna F, et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results. J Exp Clin Cancer Res 2008; 27:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/32\">",
"      Pedrazzoli S, Sperti C, Pasquali C, et al. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2011; 254:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/33\">",
"      Saito M, Ishihara T, Tada M, et al. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2013; 11:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/34\">",
"      Fritz S, Hackert T, Hinz U, et al. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 2011; 98:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/35\">",
"      Wakabayashi T, Kawaura Y, Morimoto H, et al. Clinical management of intraductal papillary mucinous tumors of the pancreas based on imaging findings. Pancreas 2001; 22:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/36\">",
"      Myung SJ, Kim MH, Lee SK. Pancreatoscopy and magnetic resonance pancreatography may decrease the margin-positive cases and recurrence rate in surgical therapy of mucinous ductal ectasia. Gastrointest Endosc 1998; 48:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/37\">",
"      Bassi C, Procacci C, Zamboni G, et al. Intraductal papillary mucinous tumors of the pancreas. Verona University Pancreatic Team. Int J Pancreatol 2000; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/38\">",
"      Traverso LW, Peralta EA, Ryan JA Jr, Kozarek RA. Intraductal neoplasms of the pancreas. Am J Surg 1998; 175:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/39\">",
"      Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004; 239:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/40\">",
"      Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 2001; 234:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/41\">",
"      Gigot JF, Deprez P, Sempoux C, et al. Surgical management of intraductal papillary mucinous tumors of the pancreas: the role of routine frozen section of the surgical margin, intraoperative endoscopic staged biopsies of the Wirsung duct, and pancreaticogastric anastomosis. Arch Surg 2001; 136:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/42\">",
"      Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002; 123:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/43\">",
"      Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/44\">",
"      Raman SP, Kawamoto S, Blackford A, et al. Histopathologic findings of multifocal pancreatic intraductal papillary mucinous neoplasms on CT. AJR Am J Roentgenol 2013; 200:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/45\">",
"      Paye F, Sauvanet A, Terris B, et al. Intraductal papillary mucinous tumors of the pancreas: pancreatic resections guided by preoperative morphological assessment and intraoperative frozen section examination. Surgery 2000; 127:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/46\">",
"      Tanaka M, Fern&aacute;ndez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/47\">",
"      Hirono S, Tani M, Kawai M, et al. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2012; 255:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/48\">",
"      Pelaez-Luna M, Chari ST, Smyrk TC, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007; 102:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/49\">",
"      Tang RS, Weinberg B, Dawson DW, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2008; 6:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/50\">",
"      Nagai K, Doi R, Ito T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2009; 16:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/51\">",
"      Woo SM, Ryu JK, Lee SH, et al. Branch duct intraductal papillary mucinous neoplasms in a retrospective series of 190 patients. Br J Surg 2009; 96:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/52\">",
"      Fritz S, Klauss M, Bergmann F, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 2012; 256:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/53\">",
"      Swartz MJ, Hsu CC, Pawlik TM, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys 2010; 76:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/54\">",
"      Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 2008; 57:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/55\">",
"      Lafemina J, Katabi N, Klimstra D, et al. Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. Ann Surg Oncol 2013; 20:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/56\">",
"      Fasanella KE, McGrath K. Cystic lesions and intraductal neoplasms of the pancreas. Best Pract Res Clin Gastroenterol 2009; 23:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/57\">",
"      Kobari M, Egawa S, Shibuya K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999; 134:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/58\">",
"      Rivera JA, Fern&aacute;ndez-del Castillo C, Pins M, et al. Pancreatic mucinous ductal ectasia and intraductal papillary neoplasms. A single malignant clinicopathologic entity. Ann Surg 1997; 225:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/59\">",
"      Loftus EV Jr, Olivares-Pakzad BA, Batts KP, et al. Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic. Gastroenterology 1996; 110:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/60\">",
"      Partelli S, Fernandez-Del Castillo C, Bassi C, et al. Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg 2010; 251:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/61\">",
"      Murakami Y, Uemura K, Sudo T, et al. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol 2009; 100:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/62\">",
"      Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002; 51:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/63\">",
"      Shimada K, Sakamoto Y, Sano T, et al. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas 2006; 32:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/64\">",
"      Woo SM, Ryu JK, Lee SH, et al. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma. Pancreas 2008; 36:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/65\">",
"      Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 2010; 251:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/66\">",
"      Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, et al. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg 2011; 213:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/67\">",
"      Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer 2010; 116:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/68\">",
"      Salvia R, Fern&aacute;ndez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004; 239:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/69\">",
"      Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000; 24:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/70\">",
"      Sho M, Nakajima Y, Kanehiro H, et al. Pattern of recurrence after resection for intraductal papillary mucinous tumors of the pancreas. World J Surg 1998; 22:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/71\">",
"      Niedergethmann M, Gr&uuml;tzmann R, Hildenbrand R, et al. Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg 2008; 32:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/72\">",
"      Raut CP, Cleary KR, Staerkel GA, et al. Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol 2006; 13:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41753/abstract/73\">",
"      Benarroch-Gampel J, Riall TS. Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg 2010; 2:363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16137 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41753=[""].join("\n");
var outline_f40_49_41753=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5513707\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5512616\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5511878\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5511885\">",
"      Endoscopic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5511892\">",
"      - Endoscopic retrograde cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5511899\">",
"      - Endoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5511906\">",
"      - Pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5511913\">",
"      - Intraductal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5511920\">",
"      Radiographic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5511927\">",
"      - CT scan and magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5511934\">",
"      - Positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5511941\">",
"      Serum tumor markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5510671\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5510679\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5510686\">",
"      Role of adjuvant therapy for invasive cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5510693\">",
"      PROGNOSIS AND SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5510701\">",
"      Following patients who do not undergo surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5510708\">",
"      Follow-up after surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5510715\">",
"      Surveillance for extrapancreatic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5513707\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/16137\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16137|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/40/6784\" title=\"diagnostic image 1\">",
"      IPMN ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/16/40206\" title=\"diagnostic image 2\">",
"      Ultrathin pancreatoscope ERCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/38/34401\" title=\"diagnostic image 3\">",
"      IPMN IDUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/19/2354\" title=\"diagnostic image 4\">",
"      CT IPMN parenchymal atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/12/10432\" title=\"diagnostic image 5\">",
"      MRCP mixed type IPMN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16137|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/29/30175\" title=\"figure 1\">",
"      Total pancreatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/57/17303\" title=\"figure 2\">",
"      Conventional pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/43/5810\" title=\"figure 3\">",
"      Pylorus-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/19/34101\" title=\"figure 4\">",
"      Spleen preserving distal pancreatectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/22/32100\" title=\"figure 5\">",
"      Distal pancreatectomy with splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16137|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/34/18976\" title=\"picture 1\">",
"      Papilla extruding mucus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/16/7439\" title=\"picture 2\">",
"      Ultrathin pancreatoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/45/33502\" title=\"picture 3\">",
"      Pancreatic tumor pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/16137|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/32/43532\" title=\"table 1\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/20/15686?source=related_link\">",
"      Classification of pancreatic cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/32/2569?source=related_link\">",
"      Distal pancreatectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29591?source=related_link\">",
"      Endoscopic ultrasound in chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3561?source=related_link\">",
"      Endoscopic ultrasound-guided fine-needle aspiration biopsy in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33353?source=related_link\">",
"      Intraductal ultrasound of the pancreaticobiliary ductal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=related_link\">",
"      Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3368?source=related_link\">",
"      Pancreatic cystic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43721?source=related_link\">",
"      Pancreaticoduodenectomy (Whipple procedure): Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33288?source=related_link\">",
"      Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_49_41754="Screening for breast cancer";
var content_f40_49_41754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41754/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41754/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41754/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/49/41754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/49/41754/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/49/41754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is more scientific evidence supporting screening for breast cancer, the most common non-skin cancer and second deadliest cancer in women, than for any other cancer. The relevant issues include determining who should be screened (risk stratification, age to begin screening, age to stop) and what method should be used for screening.",
"   </p>",
"   <p>",
"    There is a strong consensus, because of consistent findings from multiple randomized trials, that routine screening mammography should be offered to women ages 50 to 69. Consensus is not as strong for routine screening among women ages 40 to 49 or women over age 70, for screening with clinical breast examination or breast self-examination or for how frequently to screen.",
"   </p>",
"   <p>",
"    Discoveries of genetic mutations that increase the risk of breast cancer and the development of breast cancer risk prediction models have stimulated efforts to develop screening strategies stratified according to risk level. In tandem with mammography, breast magnetic resonance imaging (MRI) has been studied as a screening method for high-risk women.",
"   </p>",
"   <p>",
"    The evidence for screening for breast cancer in women and recommendations for breast cancer screening are discussed here. Performance characteristics of mammography, patient risk stratification, management options for women with a genetic predisposition to breast cancer, and surveillance in women with a personal history of breast cancer are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1980s, breast cancer rates rose steeply by 3.7 percent per year over the baseline incidence. This was most likely the result of increasing use of screening mammography. After increasing from 1994 to 1999, breast cancer incidence rates decreased from 1999 to 2007 by 1.8 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Annually, it is estimated that approximately 226,870 American women will be diagnosed with invasive breast cancer, and 39,510 women die from the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/2\">",
"     2",
"    </a>",
"    ]. Worldwide in 2008, there were 1,383,500 estimated new cases of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/3\">",
"     3",
"    </a>",
"    ]. Worldwide, breast cancer accounts for 23 percent of the total cancer cases, 14 percent of cancer deaths, and is the leading cause of cancer death in women.",
"   </p>",
"   <p>",
"    The majority of breast cancers in the US are diagnosed as a result of an abnormal screening study, although a significant number are also first brought to attention by a patient or clinician breast examination. US breast cancer incidence peaked in 1998 and decreased 3.5 percent per year from 2001 to 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/4\">",
"     4",
"    </a>",
"    ]. There has been an even greater decline among women aged 50 to 69 years.",
"   </p>",
"   <p>",
"    The increase in breast cancer incidence through the 1990's was seen mostly in early stage and in situ cancers, and was attributed to increased detection of early stage disease because of screening. However, environmental factors and increased lifetime estrogen exposure likely also contributed to the higher incidence. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A sharp decline in breast cancer incidence starting in 2003 may relate, in part, to reduction in postmenopausal hormone therapy since publication of the Women's Health Initiative report in 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Findings that the decline leveled off somewhat in 2004, and that it was primarily in estrogen receptor positive tumors in women over age 50, support a role for decreased use of hormone therapy in the declining incidence of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breast cancer mortality rates were remarkably stable during the latter half of the 20th century, at about 30 to 32 per 100,000, making breast cancer second only to lung cancer in cancer mortality among women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/10\">",
"     10",
"    </a>",
"    ]. However, in 1990, the mortality rate began declining; the 2007 age-adjusted mortality rate was 22.84 per 100,000, the lowest level since 1969 when national statistics began and a mortality reduction of greater than 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of this decline was in white women.",
"   </p>",
"   <p>",
"    Breast cancer incidence is lower in African American than white women (114.6 versus 121.9 per 100,000 in 2007) but breast cancer mortality is higher in blacks (32.4 versus 22.4 per 100,000 in 2007) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/11\">",
"     11",
"    </a>",
"    ]. The excess in incidence among whites may be due to greater use of mammography and hormonal replacement. Greater breast cancer mortality among black women may be due to having their breast cancer diagnosed at a later stage due to lower use of mammography. A study of over one million women who had at least one mammogram between 1996 and 2002 found that African American women were more likely to have inadequate mammographic screening than white women (RR 1.2, 95% CI 1.2-1.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/12\">",
"     12",
"    </a>",
"    ]. This discrepancy was even more striking among women diagnosed with breast cancer (RR 1.6, 1.5-1.8). African American women were more likely to have large, advanced-stage, high-grade, and lymph node positive breast tumors. Differences in size, stage, and lymph-node positivity (though not grade) were no longer significant when African-American and white women with the same screening history were compared.",
"   </p>",
"   <p>",
"    Differences in the incidence of breast cancer, available medical resources, and health priorities in different populations and geographic areas may influence policies regarding population screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. In 2010, the utilization of mammogram screening within two years for women aged 50 to 74 years in the United States was 72.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/17\">",
"     17",
"    </a>",
"    ]. Rates were lower for lower socioeconomic groups and for the uninsured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major risk factors for breast cancer in women are age, genetic predisposition and estrogen exposure (",
"    <a class=\"graphic graphic_table graphicRef64508 \" href=\"mobipreview.htm?15/52/16205\">",
"     table 1",
"    </a>",
"    ). Breast density is also a significant risk factor, particularly in women aged 40 to 49 years (",
"    <a class=\"graphic graphic_table graphicRef83694 \" href=\"mobipreview.htm?25/6/25709\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/18\">",
"     18",
"    </a>",
"    ]. A detailed discussion of the risk factors for breast cancer is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combined effects of several different risk factors can be calculated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age/Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age and gender are among the strongest risk factors for breast cancer. Breast cancer occurs 100 times more frequently in women than in men. In the US, there are an estimated 207,090 invasive breast cancers diagnosed annually among women versus 1970 in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=see_link\">",
"     \"Breast cancer in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing age is the primary risk factor for breast cancer in most women. Approximately 85 percent of breast cancers occur after women reach 50 years of age. Even in older age groups, many women must be screened in order to identify a single cancer (",
"    <a class=\"graphic graphic_table graphicRef63099 \" href=\"mobipreview.htm?30/17/31004\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;On average, a positive family history of breast cancer confers a modest increased risk (RR 2.6). However, having multiple first-degree relatives with premenopausal breast cancer confers a lifetime risk of breast cancer as high as 50 percent. Much of this risk is associated with a genetic defect in BRCA1 or BRCA2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Estrogen exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from age and genetics, most other risk factors for breast cancer are likely related to increased exposure to estrogen (",
"    <a class=\"graphic graphic_table graphicRef64508 \" href=\"mobipreview.htm?15/52/16205\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/22\">",
"     22",
"    </a>",
"    ]. Risk factors for breast cancer that are related to estrogen exposure include a breast biopsy showing atypical hyperplasia (RR 3.7), increased breast density (RR 1.8 to 6.0), and increased bone density (RR 2.7 to 3.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormone therapy with estrogen plus progestin, as studied in the Women's Health Initiative (WHI) over a 5.2 year period, was associated with increased breast cancer, compared to placebo (HR 1.24, 95% CI 1.02-1.50) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/24\">",
"     24",
"    </a>",
"    ] and increased breast cancer mortality (HR 1.96, 95% CI 1.00-4.04) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/25\">",
"     25",
"    </a>",
"    ]. The increased risk for breast cancer and breast cancer deaths continued for a total mean follow-up of 11 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/25\">",
"     25",
"    </a>",
"    ]. On the other hand, the Women's Health Initiative Estrogen-Alone trial demonstrated that unopposed conjugated estrogen in women with prior hysterectomy, compared to placebo, did not increase the incidence of breast cancer (HR 0.80, 0.62-1.04) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the use of estrogen alone did increase the frequency of abnormal mammograms requiring short-term follow-up (9.2 percent compared to 5.5 percent for the placebo group).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Breast cancer risk prediction tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several breast cancer risk prediction tools have been developed that combine major risk factors. The purpose of the models is to stratify women into risk categories that can be used to determine optimal screening strategies and indications for possible prophylactic therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most widely used tool to calculate breast cancer risk is the Breast Cancer Risk Assessment Tool (BCRAT), sometimes called the Gail Model after Dr. Mitchell Gail, its developer at the National Cancer Institute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The Gail Model tool that takes account race and ethnicity is available online at",
"    <a class=\"external\" href=\"file://www.cancer.gov/bcrisktool/\">",
"     www.cancer.gov/bcrisktool/",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Cancer risk assessment tools can be helpful in clarifying a patient's risk group. However, their accuracy for predicting whether an individual woman will develop cancer is modest, partly because not all important risks have been identified and partly because accurate stratification requires strong risk factors and most risk factors for breast cancer are relatively small.",
"   </p>",
"   <p>",
"    The strategy of incorporating genetic profiling, to evaluate combinations of genes contributing to cancer risk and thereby determine screening parameters (age to initiate screening, screening frequency, and type of screening) remains theoretical at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/29\">",
"     29",
"    </a>",
"    ]. Several breast cancer susceptibility loci have been found. In isolation they confer far lower risk than BRCA mutations, but in combination they could identify subgroups of women at moderate to high risk. As more such alleles are identified, the precision of risk estimates will improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of imaging modalities have been developed for identifying lesions that are suspicious for breast cancer. Mammography remains the mainstay of screening for breast cancer. Ultrasonography is commonly used for diagnostic follow-up of an abnormality seen on screening mammography, to clarify features of a potential lesion. The role of magnetic resonance imaging (MRI) for breast cancer screening is emerging; currently MRI screening, in combination with mammography is targeted to high risk patients. Newer tests, such as tomography, are under evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging studies cannot establish a diagnosis of cancer. Rather, they identify patients with abnormal findings who must then be further evaluated, either with follow-up imaging or biopsy. The diagnosis of cancer is dependent on obtaining a tissue sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Features of mammography, including test performance characteristics, and interpretation of mammogram reports, are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Film mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Film mammography can clearly detect asymptomatic early stage breast cancer. US surveillance data from over 1.5 million mammograms performed between 1996 and 2001 found that breast biopsy was performed within one year of screening in 1.6 percent of the mammograms, and breast cancer was diagnosed within one year for 0.53 percent of the mammograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/31\">",
"     31",
"    </a>",
"    ]. Seventy-eight percent of the invasive breast cancers identified were lymph node negative.",
"   </p>",
"   <p>",
"    The clinically important question, however, is whether screening with mammography decreases breast cancer mortality. Nine randomized controlled trials, including more than 650,000 women, have been conducted and reported mortality data. All used mammography with or without clinical breast examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/32\">",
"     32",
"    </a>",
"    ]. Historically, results of all trials showed a protective effect occurring relatively quickly among women ages 50 and older. A meta-analysis found a significant 34 percent reduction in breast cancer mortality by seven years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As more time passed, studies found decreased mortality in women screened in their 40s. A systematic review of screening mammography including eight studies of fair quality or better concluded that, with at least 11 years of follow-up, the pooled relative risk for breast cancer mortality was 0.85 (95% CI 0.75-0.96) for women 39 to 49 years of age, 0.86 (0.75-0.99) for women 50 to 59 years of age, and 0.68 (0.54-0.87) for women 60 to 69 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/34\">",
"     34",
"    </a>",
"    ]. Other analyses have also concluded that screening with mammography decreases breast cancer mortality in women ages 40 to 69 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. However, one review raised concern that breast cancer mortality outcomes in trials that did not blind assessment of the cause of death may have produced biased results in favor of screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strong evidence for an effective screening test is demonstrated by randomized trials that demonstrate a decrease in all-cause, as well as disease-specific, mortality. All-cause mortality is rarely documented because the required sample size for such a study is so large. Breast cancer screening was associated with reduced all-cause mortality in an analysis of four randomized trials in Sweden. The four trials followed 247,010 women for a median of 15.8 years; age-adjusted relative risk for total mortality was 0.98 (95% CI 0.96-1.00) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of screening in the era of increasingly more successful therapy for breast cancer has been considered. Available data from most randomized trials of screening predate currently accepted treatment protocols for breast cancer such as the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    or aromatase inhibitors for adjuvant treatment. Thus, it is uncertain how much of the 30 percent reduction in breast cancer mortality since 1990 is due to screening and how much to treatment advances. It is also unclear whether the results of careful randomized controlled trials are replicated in the community setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of more recent randomized trials, these questions have been evaluated by modeling and observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using seven different statistical models, estimates of the proportion of total reduction in overall US breast cancer mortality attributable to mammogram screening ranged from 28 to 65 percent (median 46 percent), with adjuvant treatment accounting for the rest [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/42\">",
"       42",
"      </a>",
"      ]. These results suggest that breast cancer mortality in the US has dropped about ten percent because of screening, a more modest reduction than that found in randomized trials.",
"     </li>",
"     <li>",
"      Investigators conducted a cohort study in Norway, taking advantage of staggered mammography introduction (in conjunction with multidisciplinary breast cancer management teams) for women aged 50 to 69 living in different regions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/43\">",
"       43",
"      </a>",
"      ]. Breast cancer mortality was compared in four groups:",
"      <br/>",
"      <br/>",
"      (a) current screening group (1996 to 2005);",
"      <br/>",
"      <br/>",
"      (b) historical data from group a before screening began (1986 to 1996);",
"      <br/>",
"      <br/>",
"      (c) current nonscreening group (1996 to 2005);",
"      <br/>",
"      <br/>",
"      (d) historical data from group c before screening began (1986 to 1996).",
"      <br/>",
"      <br/>",
"      Per 100,000 person-years, there were 7.2 fewer deaths in group a than group b, and 4.8 fewer deaths in group c than group d. Therefore, the combination of screening plus introduction of multidisciplinary management teams led to 2.4 fewer deaths per 100,000 person years, for a relative reduction in breast cancer mortality of 10 percent in the screening group. Additionally, breast cancer mortality rates among women not eligible for screening were examined over the same time periods. There was an 8 percent relative reduction in breast-cancer mortality for women over 70, suggesting that mammogram alone may have accounted for only 2 percent of the relative mortality reduction, with most of the reduction due to optimized patient care.",
"     </li>",
"     <li>",
"      A case-control study of women in the Netherlands found that women aged 49 to 75 years who died of breast cancer were less likely to have had a mammogram compared to controls matched for age and invitation for mammography (OR 0.51, 95% CI 0.40-0.66) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/44\">",
"       44",
"      </a>",
"      ]. An earlier case control study in six community health plans in the United States did not show a statistical difference in screening rates (clinical breast exam and mammography) for women who died of breast cancer compared with control patients matched for age and breast cancer risk, although there was a trend towards screening benefit among higher risk women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/45\">",
"       45",
"      </a>",
"      ]. However, the authors pointed out that study limitations make it difficult to draw firm conclusions from this report.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Full-field digital mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full-field digital mammography is similar to traditional film-screen mammography except that the image is captured by an electronic detector and stored on a computer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/46\">",
"     46",
"    </a>",
"    ]. Several studies have found little difference in cancer detection rates between digital and film mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. The largest study, DMIST, found that while the overall diagnostic accuracy of film and digital mammography was similar, digital mammography was more accurate for premenopausal and perimenopausal women, and for women with dense breasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, film mammography remains an acceptable screening modality for all women. Digital mammography may detect more breast cancers than film mammography in women younger than 50 years old, but is also associated with an increased rate of false-positive findings in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Computer-aided detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computer-aided detection (CAD) refers to computer-based technology designed to recognize mammographic patterns and help radiologists identify suspicious areas. CAD reading of digitalized mammograms places marks in areas of concern, often calcifications, for special attention in review by the radiologist; on average, four marks are placed per mammogram.",
"   </p>",
"   <p>",
"    CAD slightly increases sensitivity for breast cancer but also increases recall rate. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Frequency of mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the optimal frequency for performing mammography. Randomized trials evaluating the effectiveness of mammogram screening have used varying time intervals, without apparent effect on study results. An observational study comparing mammogram screening annually or every two years for predominantly Caucasian women aged 50 to 69 years in Vermont, US (annual) and Norway (biennial) found no significant difference in breast cancer detection rate or prognostic stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/55\">",
"     55",
"    </a>",
"    ]. In a large cohort study, the recall rate and rate of biopsy recommendation for false positives was greater for women who had annual, compared to biennial, mammogram screening, associated with a small and non-statistically significant increased rate of late-stage breast cancer in women who had biennial screening (",
"    <a class=\"graphic graphic_table graphicRef51375 \" href=\"mobipreview.htm?6/29/6620\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/56\">",
"     56",
"    </a>",
"    ]. A modeling study of different screening schedules for mammography estimated that biennial screening maintained an average of 81 percent of the benefits of annual screening (",
"    <a class=\"graphic graphic_table graphicRef69681 \" href=\"mobipreview.htm?35/61/36828\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breast cancers on average grow more slowly in older women than younger women. Longer intervals between screenings may be reasonable for women over 50, with biennial screening in younger women at higher risk. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'Frequency'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H112701155\">",
"     'Targeted screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) for detecting breast cancer requires injection of intravenous contrast material and costs more than mammography in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/58\">",
"     58",
"    </a>",
"    ]. The technique of breast MRI and indications for MRI in the evaluation of known breast abnormalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening breast MRI has been found to be more sensitive but less specific than mammography for the detection of invasive cancers in high-risk women in both retrospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/59-62\">",
"     59-62",
"    </a>",
"    ] and prospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/63-67\">",
"     63-67",
"    </a>",
"    ] studies. A systematic review included 11 studies comparing test performance of screening MRI to mammography in high-risk women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/68\">",
"     68",
"    </a>",
"    ]. The mean or median age of women in the studies ranged from 40 to 47 years. The women were at very high risk of breast cancer, with a prevalence of 2 percent (about 13 times the overall prevalence of approximately 0.15 percent in women of similar age). The following results were found:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sensitivity of MRI was better than mammography: 0.77 (95% CI 0.70-0.84) versus 0.39 (CI 0.37-0.41).",
"     </li>",
"     <li>",
"      Specificity of MRI was worse than mammography: 0.86 (CI 0.81-0.92) versus 0.95 (CI 0.93-0.97).",
"     </li>",
"     <li>",
"      Sensitivity of MRI and mammography together was 0.94 (CI 0.90-0.97) and specificity was 0.77 (CI 0.75-0.80).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A report of the largest cohort study to date (2,157 Dutch women aged 25 to 75) analyzed the effects of MRI and mammography screening according to subgroups of breast cancer risk: lifetime risks of 50 to 80 percent (BRCA1 mutations, BRCA2 mutations, and",
"    <span class=\"nowrap\">",
"     PTEN/TP53",
"    </span>",
"    mutations); 30 to 50 percent (based on family history); and 15 to 30 percent (based on family history) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/64,69\">",
"     64,69",
"    </a>",
"    ]. All women were screened annually with mammography and breast MRI and biannually with clinical breast examination (CBE), and those who developed breast cancer were followed for a median of five years after diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI was more sensitive (67 versus 47 percent) but less specific than mammography (89.5 versus 95 percent).",
"     </li>",
"     <li>",
"      At a median of five years of follow-up after cancer diagnosis, recurrent breast cancer developed in 11 of 93 patients, seven of whom were mutation carriers. Median overall survival for the women who developed breast cancer was higher than the survival rate for historical cohorts (83.9 versus 74.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another prospective cohort study, 496 women aged 25 to 65 years with BRCA 1 or BRCA 2 mutations (380 with no personal history of cancer) were screened annually between 1997 and 2009 with MRI and mammography and semi-annually with clinical breast examination, with individual women completing one to nine rounds of screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/70\">",
"     70",
"    </a>",
"    ]. Sensitivity and specificity of MRI was 86 and 90 percent, respectively, compared to 19 and 97 percent for mammography. Fifty-seven cancers were identified (53 screen-detected), including invasive cancer in 28 women without a prior history of cancer. At a median follow-up of 8.4 years, 24 of these 28 women were without distant metastasis; one died from relapsed breast cancer and three from other causes.",
"   </p>",
"   <p>",
"    The results of these studies support MRI screening for women at highest risk for breast cancer, although numbers are small and conclusions are subject to multiple biases (patient selection, lead time bias, treatment differences) affecting observational studies. A prospective randomized trial to evaluate whether MRI screening improves survival in women with BRCA mutations is unlikely to be feasible because of the large numbers of women it would require and the possibility that women at high risk would not consent to be assigned to a nonscreening arm.",
"   </p>",
"   <p>",
"    The combination of MRI and mammography is recommended by the American Cancer Society in women at high risk of breast cancer (&ge;20 to 25 percent lifetime risk), as defined by risk prediction models based primarily on family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/71\">",
"     71",
"    </a>",
"    ]. The cancer mortality risk in this population is assumed to be high enough to justify the increased cost and numbers of follow-up procedures that would be generated because of low specificity.",
"   </p>",
"   <p>",
"    The lack of evidence of mortality benefit, concerns about specificity and the high cost of MRI become more worrisome when there is a lower risk of breast cancer, because fewer women will benefit and more women will experience adverse effects. The 2007 guidelines from the American Cancer Society explicitly recommend against MRI screening in women with less than a 15 percent lifetime risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/71\">",
"     71",
"    </a>",
"    ]. For women with lifetime risks of breast cancer greater than 15 percent but less than those at very high risk, recommendations for screening breast MRI are less clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5145650\">",
"    <span class=\"h2\">",
"     Thermography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of thermography to detect occult breast cancer was based on the observation that patients have elevated breast skin temperatures over their breast cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/72\">",
"     72",
"    </a>",
"    ]. It was first investigated for screening in the Breast Cancer Detection Demonstration Project in the 1970s and was found to have poor test characteristics, with a false positive rate of 25 percent and a false negative rate of more than 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2004 a breast thermography device received approval from the US Food and Drug Administration (FDA) on the basis of prior approval for infrared imaging technology, because of demonstrated safety but not necessarily efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/72\">",
"     72",
"    </a>",
"    ]. The specificity of thermography remains very low, even with modern equipment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/72\">",
"     72",
"    </a>",
"    ]. Despite this, a number of thermography centers have been established in several US cities.",
"   </p>",
"   <p>",
"    No major organization making screening recommendations recommends thermography. Of those commenting on it, the American Cancer Society states, \"No study has ever shown that it is an effective screening tool for finding breast cancer early,\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/74\">",
"     74",
"    </a>",
"    ] and the American College of Radiology specifically states it does not endorse thermography for detecting clinically occult breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/75\">",
"     75",
"    </a>",
"    ]. The US FDA issued a safety communication in June 2011 notifying consumers that thermography is not a replacement for screening mammography and that thermography on its own is not an effective screening tool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/76\">",
"     76",
"    </a>",
"    ]. Patients should be advised that thermography is not recommended as a modality for breast cancer screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     BREAST PALPATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical breast examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because several randomized trials included both mammography and clinical examination, the extent of independent contribution of these methods is not clear. In these studies, mammography detected approximately 90 percent of screen-detected cancers and clinical breast examination approximately 50 percent. There is some but not total overlap.",
"   </p>",
"   <p>",
"    Only one study compared the effects of careful clinical breast examination (CBE) alone with CBE plus mammography on subsequent breast cancer mortality in women in their 50s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. After 13 years of follow-up, breast cancer mortality was the same in both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/78\">",
"     78",
"    </a>",
"    ]. The CBE used was standardized and took an average of 10 minutes, far different than typical clinical practice. A review of controlled trials and case-control studies in which CBE was at least part of the screening modality estimated CBE sensitivity to be 54 percent and specificity 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/79\">",
"     79",
"    </a>",
"    ]. A subsequent study found that CBE plus mammography (with CBE performed by trained nurses) had greater sensitivity than mammography alone, but a higher false positive rate (12.5 versus 7.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/80\">",
"     80",
"    </a>",
"    ]. Among 10,000 women screened with CBE and mammography, there were 55 additional false positive screens for each additional cancer detected by CBE. A 2009 literature review concluded that the effectiveness of CBE has not been proven by well-designed large trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A key factor is the quality of each examination: mammography is better standardized than CBE. The preferred technique for CBE includes: proper patient positioning (to flatten the breast tissue against the chest); examining in vertical strips beginning in the axilla and extending in a straight line down the midaxillary line to the bra line, with the fingers then moving medially and continuing up and down between the clavicle and the bra line; making circular motions with the pads of the middle three fingers and examining each breast area with three different pressures; examining each breast for at least three minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CBE sensitivity in community practice appears to be substantially lower than that reported in randomized trials. The National Breast and Cervical Cancer Early Detection Program, which studied the value of CBE in the community setting where procedural guidelines for performing the examination were not dictated, found that CBE still detected about 5 percent of cancers that were not visible on mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/81\">",
"     81",
"    </a>",
"    ]. Despite good specificity in women without symptoms (96.2 percent), the sensitivity was low (36.1 percent). In another community-based study, the specificity of screening CBE in average risk women was even higher (99.4 percent), suggesting a lower sensitivity; specificity was slightly lower in women at increased risk (97.1 percent) and for diagnostic, rather than screening, examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies suggest that CBE may modestly improve early detection of breast cancer, but at potential significant expense (in terms of clinician availability and time, as well as work-up of false positives) when performed as an adjunct to mammography. CBE alone may be a reasonably cost effective screening strategy, however, in developing countries where the relative cost of mammography is prohibitive for population screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breast self-examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few randomized trials of breast-self examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/84\">",
"     84",
"    </a>",
"    ]. One study performed in China randomly assigned 266,064 women to a breast self-examination instruction group or a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/85\">",
"     85",
"    </a>",
"    ]. The instruction group received initial instruction in breast self-examination, reinforcement sessions one and three years later, supervised self-examination every six months for five years, and ongoing reminders. Over ten years, there was no difference between the two groups in breast cancer deaths. More benign breast lesions were diagnosed in the self-examination group.",
"   </p>",
"   <p>",
"    A review of eight other studies also failed to show a benefit of regular breast self-examination in rates of breast cancer diagnosis, breast cancer death, or tumor stage or size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/86\">",
"     86",
"    </a>",
"    ]. In addition, several studies found the rate of breast biopsy for benign disease was significantly higher among women taught breast self-examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of two case-control studies suggest that technique is important in breast self-examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nested case-control study comparing Canadian women who died of breast cancer or had metastatic disease with control women found increased risk for death or metastatic disease (OR 2.20, 95% CI 1.30-3.71) in women who did not perform technically correct breast self-examination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case-control study showed no overall effect of breast self-examination on detecting breast cancer at an earlier stage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/89\">",
"       89",
"      </a>",
"      ]. The small number of women, however, reporting more thorough examinations had about a 35 percent decrease in advanced-stage breast cancer compared with women not performing breast self-examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26269818\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL TECHNIQUES FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active investigations, using proteomic technologies, are ongoing to identify reliable serum biomarkers for breast cancer that might be used for screening, as well as for disease treatment and surveillance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/90\">",
"     90",
"    </a>",
"    ]. Despite increasing evidence that epigenetic changes contribute to breast cancer pathogenesis, it may be many years before translating these scientific observations into clinically-reliable screening tests; none are currently available for clinical use. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PATIENT AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have shown that the sensitivity of mammography and clinical breast examination is higher in older, compared to younger, women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/32\">",
"     32",
"    </a>",
"    ]. It has been estimated that mammography detects about 75 percent of breast cancers in women in their 40s and 90 percent of breast cancers in women in their 50s and 60s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/91\">",
"     91",
"    </a>",
"    ]. A large prospective cohort study of 329,495 women confirmed that when controlling for breast density and postmenopausal hormone therapy use (HT), sensitivity and specificity of mammography were higher in women aged 80 to 89 years (83.3 and 94.4 percent, respectively) than in women aged 40 to 44 years (68.6 and 91.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performance characteristics of mammography are poor for women younger than 40. In a review of results of 73,335 initial screening mammograms in women aged 35 to 39 years, the recall rate was 12.7 percent and positive predictive value was 1.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/93\">",
"     93",
"    </a>",
"    ]. Nonetheless, 30.1 percent of US women aged 30 to 39 years from a 2005 nationally representative civilian sample reported they had had a mammogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Women in their 40s",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis of eight randomized trials found a 15 percent reduction of breast cancer mortality in women ages 39 to 48 who were randomly assigned to mammographic screening (RR 0.85, 95% CI 0.75-0.96) (",
"    <a class=\"graphic graphic_figure graphicRef65553 \" href=\"mobipreview.htm?20/12/20687\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the absolute benefits of screening, in terms of numbers of lives saved, are lower for women in their 40s than in older women because of both decreased incidence of breast cancer and sensitivity of mammography in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/95\">",
"     95",
"    </a>",
"    ]. Benefits for screening women in their 40s are more favorable when considered from the perspective of years of life saved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to older women, there is evidence that younger women have faster growing cancers for which mammographic screening would not be as beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/97\">",
"     97",
"    </a>",
"    ]. A rapidly growing tumor may be too small to detect at one screening, but already progressed to advanced stage by the subsequent screening.",
"   </p>",
"   <p>",
"    The Age trial in the United Kingdom evaluated the mortality effect of a screening intervention in which women at age 40 (n = 161,000) were randomly assigned to be invited for breast cancer screening (a two-view initial mammogram and annual single-view follow-up), or to a control group that received usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/98\">",
"     98",
"    </a>",
"    ]. Breast cancer mortality in the intervention group was decreased, though not significantly (RR 0.83, 95% CI 0.66-1.04), at a mean follow-up of 10.7 years. Risk reduction for breast cancer mortality was greater, though still not statistically significant, when only those women who actually attended the first screening were compared to the control group (RR 0.76, 95% CI 0.51-1.01). Previous trials of screening women in their 40s for breast cancer had included women who were up to age 49 years at the time of trial entry, and therefore in their 50s during the screening intervention; the Age trial was the first study to assess the effectiveness of screening restricted to women who had not yet passed age 50 years.",
"   </p>",
"   <p>",
"    Another useful way to interpret the available data on screening mammography in younger women is to look at the numbers needed to screen (NNS) to prevent one woman from dying of breast cancer. Published estimates vary somewhat according to the calculated relative risk, the baseline risk in the control group, and the length of follow-up. Pooling the data from eight trials, the US Preventive Services Task Force (USPSTF) estimated that 1904 women ages 39 to 49 (credible interval, CrI 929 to 6378 women) would need to be screened to prevent one death from breast cancer after at least 11 years of observation, compared to 1339 women in their 50s (CrI 322-7455) and 377 women in their 60s (CrI 230-1050) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost-effectiveness of screening mammography for women in their 40s has added to the controversy and difficulty of determining guidelines for this age group. One study, as an example, used a Markov model to compare the life expectancy of women undergoing different breast cancer screening strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/99\">",
"     99",
"    </a>",
"    ]. The cost-effectiveness ratios were $21,400 per year of life saved for women 50 to 69 years of age and $105,000 for women in their 40s. Thus, the cost of screening mammography in women in their 40s was almost five times that of older women, although both are within a generally accepted range for cost-effectiveness.",
"   </p>",
"   <p>",
"    Guidelines vary in regard to recommendations for screening women aged 40 to 49 years (see",
"    <a class=\"local\" href=\"#H37\">",
"     'Age to initiate'",
"    </a>",
"    below). Nonetheless, a representative survey conducted between 2006 and 2007 found that 93 to 97 percent of primary care physicians practicing in the United States would recommend mammogram screening for women in this age group, and more than 70 percent would recommend such screening annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/100\">",
"     100",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Clinicians should discuss breast cancer screening with all female patients starting at age 40 and the discussion and decision about screening should be recorded in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112701155\">",
"    <span class=\"h3\">",
"     Targeted screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;A modelling study, using data from large US databases of breast cancer, evaluated the",
"    <span class=\"nowrap\">",
"     harms/benefits",
"    </span>",
"    of breast cancer screening for women aged 40 to 49 years varying three parameters: breast cancer risk, screening frequency, and digital versus film mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/54\">",
"     54",
"    </a>",
"    ]. The study found that biennial screening starting at age 40 for women who had a twofold increased breast cancer risk had the same",
"    <span class=\"nowrap\">",
"     harms/benefits",
"    </span>",
"    ratio (false-positive findings per life-years gained) as biennial screening for women aged 50 to 74 years with average breast cancer risk. If screening were done annually starting at age 40, this threshold for increased relative risk to target screening rose from 2.0 to 4.3. The threshold risk was also higher for digital compared to film mammography because of the higher false-positivity rates for digital mammography.",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of risk factors identified two factors that were each associated with a twofold risk of breast cancer in women aged 40 to 49: a first-degree relative with breast cancer and extremely dense breasts (BI-RADS category 4 breast density) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/18\">",
"     18",
"    </a>",
"    ]. Combinations of other risks would also account for this risk threshold (",
"    <a class=\"graphic graphic_table graphicRef83694 \" href=\"mobipreview.htm?25/6/25709\">",
"     table 2",
"    </a>",
"    ). Since breast density would only be determined by a baseline mammogram at age 40, it is recognized that a strategy to target screening based on breast density would also lead to a significant number of false-positive findings in women undergoing baseline mammography at age 40 who were not found to be at increased risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening mammography may be less beneficial in women aged 70 and older. A shorter life expectancy decreases the potential for screening to prolong life. Screening mammography in older women may result in lower stage cancer at diagnosis, but the effect on mortality is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. In addition, the incidence of ductal carcinoma in situ (DCIS) increases with age and it is not clear that treatment of DCIS affects mortality. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Ductal carcinoma in situ'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data from randomized controlled trials in women older than 70 years are limited. In one analysis, mortality was unchanged for women 70 to 74 who were randomly assigned to mammogram screening (pooled RR 1.12, 95% CrI 0.73-1.72) but few women actually underwent screening in the studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/34\">",
"     34",
"    </a>",
"    ]. Two case-control studies involving the same population in Holland, but done slightly differently, found that screening women aged 65 to 74 decreased breast cancer mortality 55 percent (RR 0.45, 95% CI 0.20-1.02) or 66 percent (RR 0.34, 0.12-1.41); there was no protective effect beyond age 75 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. A cohort study of 2011 women 80 years and older found no difference in breast cancer rate, stage, or death comparing women who did and did not undergo mammography after age 80; 11 percent of the 1034 older women who underwent mammography screening had a false positive result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decision and cost-effectiveness analysis modeled three strategies in women over the age of 65: biennial mammography to 69 years; biennial mammography to 79 years; and determination of distal radial bone mineral density (BMD) at the age of 65 to decide need for ongoing screening after age 69 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/107\">",
"     107",
"    </a>",
"    ]. The inclusion of BMD data was based upon the increased risk of breast cancer among women with high BMD (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above). To prevent one death, the analysis found that 1064 women with high BMD would need to be screened routinely from age 69 to 79 years, compared with 7143 women with low BMD. Screening was cost-effective only in women with higher BMD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of cost-effectiveness analyses for the USPSTF concluded that extending biennial mammography screening to age 75 or 80 was estimated to cost $34,000 to $88,000 per life-year gained compared with stopping screening at age 65, and it was particularly likely to be cost-effective in women who were healthy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group presented a framework for guiding decision making in screening elderly women for various cancers that included life expectancy, risk of dying of cancer, and the number needed to screen over the remaining lifetime to prevent cancer death (",
"    <a class=\"graphic graphic_table graphicRef61593 \" href=\"mobipreview.htm?43/14/44268\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/109\">",
"     109",
"    </a>",
"    ]. As an example, 240 healthy 80-year-old women would need to have regular mammography screening to prevent one breast cancer-related death, compared with 642 70-year-old women with multiple medical problems and a life expectancy that is below the norm for that age group. Thus, age should not be the sole determining factor in determining indications for screening. Ideally, such decision-making should incorporate individual estimates of risk and benefit, and take into account patient preferences; decision aids are being investigated that may provide support for informed decision-making regarding screening mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that breast cancer screening with mammography be continued as long as a woman has a life expectancy of at least 10 years. In addition, the breast becomes easier to examine as a woman ages, with replacement of glandular tissue by fat. It is therefore likely that careful clinical breast examinations would be particularly useful in older women, although a study to confirm this hypothesis has not yet been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H614882\">",
"    <span class=\"h2\">",
"     Combining age with other variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk prediction tools combine multiple risk factors to improve breast cancer risk prediction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"     \"Risk prediction models for breast cancer screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, few risk tools have included breast density in their calculations. Furthermore, the risk of breast cancer is only one factor in deciding whom to screen. One study included breast density in the analysis of risk and conducted a cost-effective analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/111\">",
"     111",
"    </a>",
"    ].The authors estimated the risk of breast cancer, incorporating several breast cancer risk factors (age, mammographic breast density, family history of breast cancer in a first degree relative, and personal history of breast biopsy), and then performed a cost-effectiveness analysis (including estimates of benefits of screening along with estimates of false-positive mammograms and overdiagnosis harms) to determine quality-adjusted life-years, and cost of various mammography frequencies. Using such an approach, it was cost effective to screen subsets of women for breast cancer, at various frequencies, from age 40 to 79 (",
"    <a class=\"graphic graphic_figure graphicRef67061 \" href=\"mobipreview.htm?8/33/8725\">",
"     figure 2",
"    </a>",
"    ). &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FAMILY HISTORY OF BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a known genetic predisposition to breast cancer (ie, BRCA-1 or BRCA-2) should receive counseling for several preventive options, as well as more intensive screening for breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women without a known genetic syndrome, but who have a history of breast cancer in a first-degree relative, it has been suggested that screening mammography be initiated at an earlier age, particularly if the family member had premenopausal breast cancer. One study compared the performance of mammography in almost 390,000 women ages 30 to 69 years with and without a family history of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/112\">",
"     112",
"    </a>",
"    ]. More cancers were detected in women who had a first-degree relative with breast cancer than in those who did not (numbers of cancers found per 1000 women were 3.2 versus 1.6 for ages 30 to 39 years, 4.7 versus 2.7 for ages 40 to 49, 6.6 versus 4.6 for ages 50 to 59, and 9.3 versus 6.9 for ages 60 to 69 years).",
"   </p>",
"   <p>",
"    There are no data from randomized controlled trials on the efficacy of mammography in reducing mortality in younger women with a family history of breast cancer; a case control study showed a non-statistical trend towards greater protection among women in their 40s at increased risk, but no trend among older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative or adjunctive screening modalities for younger women at significantly increased risk for breast cancer, including magnetic resonance imaging and ultrasound, may improve screening sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/63,71,113,114\">",
"     63,71,113,114",
"    </a>",
"    ]. The combination of MRI and mammography is recommended by the American Cancer Society in women at high risk of breast cancer (&ge;20 to 25 percent lifetime risk), as defined by risk prediction models based primarily on family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Magnetic resonance imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GERMLINE PREDISPOSITION (BRCA1 OR BRCA2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a family history of breast cancer is common in women who develop breast cancer, only 5 to 6 percent of all breast cancers are associated with germline (inherited) genetic mutations. The majority of these involve two genes, BRCA1 and BRCA2, and testing for mutations in these genes is commercially available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who test positive for BRCA1 or BRCA2 mutations are at increased risk of both breast and ovarian cancer. Such women should be referred for appropriate counseling, to consider options for reducing risk and intensified surveillance. For women with an inherited predisposition, guidelines from major groups (including the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/115\">",
"     115",
"    </a>",
"    ]and the American Cancer Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/71\">",
"     71",
"    </a>",
"    ]) recommend a combination of annual mammography and breast MRI for breast cancer surveillance in women who are BRCA mutation carriers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link&amp;anchor=H15841803#H15841803\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Breast cancer screening in women'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER VARIABLES AFFECTING SCREENING ACCURACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors, in addition to age and genetic or family risk, influence screening test performance: the experience of the radiologist, availability of prior studies, patient body habitus, breast density, use of postmenopausal hormone therapy, and history of breast surgery. Ethnicity does not appear to affect the accuracy of mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/116,117\">",
"     116,117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119563887\">",
"    <span class=\"h2\">",
"     Radiologist",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to accurately interpret mammograms differs among individual radiologists. Studies conflict on whether accuracy is greater for radiologists who interpret a high volume of mammograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/118-121\">",
"     118-121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiologist experience does appear to be associated with interpretation of mammography. A study of the actual performance of 124 radiologists in interpreting 469,512 screening mammograms found that less experienced radiologists had higher sensitivity for breast cancer but also higher recall rates and lower specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/121\">",
"     121",
"    </a>",
"    ]. The effect of experience in this study was to shift the threshold for calling a mammogram positive rather than on the actual ability to detect cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119563894\">",
"    <span class=\"h2\">",
"     Prior studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparing a mammogram to one taken previously, especially one taken a year previously, improves specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119563901\">",
"    <span class=\"h2\">",
"     Body habitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammography may have lower sensitivity in thin women. In a multivariate analysis from a 12-month prospective study of 122,355 women ages 50 to 64, mammography had a lower sensitivity in women with a body mass index below 25 (86 versus 91 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119563919\">",
"    <span class=\"h2\">",
"     Breast density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced sensitivity of mammography in younger women is in part related to increased mammographic density, determined by a higher proportion of breast epithelial and stromal elements in younger breasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. Increased breast density not only impacts the interpretation of mammograms, but also increases the risk of breast cancer and is associated with more aggressive tumor characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]. The impact of breast density on mammogram interpretation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Digital mammography is more sensitive than film mammography for dense breasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/50\">",
"     50",
"    </a>",
"    ] and may be preferred, when available, for women with increased breast density. The role of ultrasound or MRI screening, as an adjunct to mammography, is uncertain, as there have been no randomized controlled trials evaluating the impact of these modalities on mortality or stage of diagnosed breast cancer in women with dense breasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Menstruating women have variable breast density during different phases of the menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Breast density is increased in the luteal compared with follicular phase, suggesting that mammographic sensitivity can be improved by obtaining mammograms during the first and second week after menstruation begins, particularly for women who have used oral contraceptives at some time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/129,130\">",
"     129,130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BI-RADS guidelines for mammogram interpretation recommend that breast density be reported in a sentence in every mammogram report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/131\">",
"     131",
"    </a>",
"    ]. The inter-observer reproducibility of BI-RADS breast density reports is only moderate, however [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/132\">",
"     132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119563926\">",
"    <span class=\"h2\">",
"     Postmenopausal hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal involution of breast tissue with age appears to be inhibited by postmenopausal hormone therapy (HT), which increases breast density and may decrease the sensitivity of mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/24,92,133,134\">",
"     24,92,133,134",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link&amp;anchor=H150019838#H150019838\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Mammographic density'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large prospective cohort study of 329,495 women found that HT prevented the usual improvement in mammographic accuracy with increasing age, and that this effect was mediated through increases in breast density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/92\">",
"     92",
"    </a>",
"    ]. Data from a subset of the Women's Health Initiative (WHI) trial show that among 413 postmenopausal women who were randomly assigned to combination",
"    <span class=\"nowrap\">",
"     estrogen/progesterone",
"    </span>",
"    therapy or placebo, mammogram density increased 6 percent at year one in the treatment group, compared to a 0.91 percent decrease in the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/135\">",
"     135",
"    </a>",
"    ]. Although breast density may not similarly increase with estrogen therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/134\">",
"     134",
"    </a>",
"    ], a reduction in mammographic sensitivity and a slight reduction in specificity has been seen in women taking preparations of either combination",
"    <span class=\"nowrap\">",
"     estrogen/progesterone",
"    </span>",
"    or estrogen alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the WHI trial, in addition to a higher rate of breast cancer, women on combination postmenopausal hormone therapy (HT) had a significantly higher rate of at least one abnormal mammogram (31.5 versus 21.2 percent on placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/24\">",
"     24",
"    </a>",
"    ]. The risk of having an abnormal mammogram at year one was four times greater in the HT group compared to the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/135\">",
"     135",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=see_link&amp;anchor=H7#H7\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Women's Health Initiative'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In another large cohort study, both combination HT and estrogen therapy alone increased the risk of recall after mammography in women who subsequently were found not to have breast cancer (false-positive recall) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/136\">",
"     136",
"    </a>",
"    ]. Short-term (one to two months) discontinuation of hormone therapy prior to mammography, however, had no effect on mammography recall rates in a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119563940\">",
"    <span class=\"h2\">",
"     Breast surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast augmentation surgery may reduce the sensitivity of screening mammography. A prospective cohort study found that mammogram sensitivity was lower in asymptomatic women with breast implants than in women without implants (45 versus 67 percent); specificity was slightly higher in women with implants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other breast surgery may also affect the sensitivity and specificity of mammography. In a study that did not distinguish between removal of benign breast lumps and other benign breast surgery, mammography in women with a history of such surgery had lower sensitivity and slightly lower specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     HARMS FROM SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from any risks of the screening procedure itself, screening for breast cancer can cause harm when false-positive results occur.",
"   </p>",
"   <p>",
"    Additionally, women may suffer harm if breast cancer is overdiagnosed. Overdiagnosis refers to the diagnosis of conditions that would not have become clinically significant, if not detected by screening. Overdiagnosis leads to unnecessary testing and treatment, and psychological and other consequences of being diagnosed with and treated for cancer.",
"   </p>",
"   <p>",
"    Women should understand the possibility of both benefits and harms from screening, as summarized in figures (",
"    <a class=\"graphic graphic_figure graphicRef76245 graphicRef56330 \" href=\"mobipreview.htm?24/27/25008\">",
"     figure 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69681 \" href=\"mobipreview.htm?35/61/36828\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     False-positive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although both sensitivity and specificity of tests are important, patients and clinicians are often most concerned by false-positive readings. While the definition of \"false- positive\" varies, for this discussion a false-positive reading is considered to be a mammogram that prompted a recommendation for additional workup (including further imaging or tissue sampling) in a woman who had no finding of breast cancer within one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/139\">",
"     139",
"    </a>",
"    ]. The clinical consequence of this error is recommendation for additional tests and procedures in a woman who does not have cancer. In the United States, for example, 11 percent of mammograms require additional evaluation; the lesion turns out to be benign in more than 90 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False-positive readings are more common in younger women, both because the tests are less specific and because breast cancer is less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. As a result, more follow-up procedures will be done in younger women even though fewer cancers will be found. In one report, although fewer biopsies were done for abnormal mammograms in younger, compared to older, women (9.3, 10.8, and 11.6 per thousand mammograms for women ages 40-49, 50-59, and 60-69 respectively), more of the biopsies were benign in younger women (6.7, 6.1, and 5.2 per thousand mammograms for women in their 40s, 50s, and 60s respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/34\">",
"     34",
"    </a>",
"    ]. Furthermore, because breast cancer screening occurs repeatedly, the risk of a false-positive study rises with repeated screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/143\">",
"     143",
"    </a>",
"    ] and will rise more quickly with annual, as compared to biennial, screening (",
"    <a class=\"graphic graphic_table graphicRef69681 \" href=\"mobipreview.htm?35/61/36828\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These points were illustrated in a 10-year retrospective cohort study of 2400 women who were 40 to 69 years of age at study entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/139\">",
"     139",
"    </a>",
"    ]. A median of four mammograms and five clinical breast examinations were performed per woman over the course of the study; 23.8 percent had at least one false-positive mammogram, 13.4 percent had at least one false-positive breast examination, and 31.7 percent had at least one false-positive result for either test. The estimated cumulative risk of a false-positive result was 49.1 percent after 10 mammograms and 22.3 percent after 10 clinical breast examinations. In another study, 10-year estimates of the percentage of women who would experience a false-positive mammogram reading ranged from 41 to 45 percent for women in their 50s and from 31 to 36 percent for women in their 60s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cumulative risk of a false-positive mammogram varied substantially according to both patient and radiology-related factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/145\">",
"     145",
"    </a>",
"    ]. The risk of a false-positive study at the first, and by the ninth screening mammogram, was 98 and 100 percent in those women with the highest risk variables (young age, prior breast biopsies, a family history of breast cancer, current estrogen use, three years between screenings, no comparison to prior mammograms, and the tendency of the radiologist to call mammograms abnormal [radiologist's random effect]). In contrast, those with the lowest risk variables had estimated risks of 0.7 and 4.6 percent for the first and ninth mammogram, respectively. The authors postulated that if women understood their relative risk of a false-positive study based on these factors, their anxiety might be less when an abnormal mammogram was reported.",
"   </p>",
"   <p>",
"    In addition to age and family or personal history of breast cancer, the frequency of mammography and degree of breast density also affected the percentage of women who will experience a false-positive mammogram over a ten-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/56,111\">",
"     56,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar concerns about false positive mammograms apply to elderly women. In a study of 23,000 women over the age of 65 undergoing one time screening mammography, 8 percent had an abnormal result that required additional evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/146\">",
"     146",
"    </a>",
"    ]. However, even in this group of women who were at high risk for breast cancer because of age, the majority with abnormal results (92 percent of abnormal mammograms in women ages 65 to 69 and 86 percent of abnormal mammograms in women age 70 or older) did not have cancer.",
"   </p>",
"   <p>",
"    Practice variation may contribute to the rate of false-positive mammograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/147\">",
"     147",
"    </a>",
"    ]. As an example, a study that compared results from large screening programs in the United States and the United Kingdom found that the rate of recommendations for further evaluation after a mammogram was twice as high in the United States as in the United Kingdom, but cancer detection rates were similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/144\">",
"     144",
"    </a>",
"    ]. These data suggest that it may be possible to reduce the rate of false-positive mammography results in the United States without significantly increasing the rate of false-negative results.",
"   </p>",
"   <p>",
"    Women have heightened anxiety about breast cancer and mammography for several months after a false-positive reading [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. One study evaluated 68 women with high-suspicion abnormal mammograms but negative subsequent work-ups: 47 percent reported substantial mammography-related anxiety and 41 percent worried about breast cancer three months later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/150\">",
"     150",
"    </a>",
"    ]. A meta-analysis found that anxiety, following a false-positive mammogram, was specific to breast cancer and mammography, and did not lead to a generalized anxiety disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/149\">",
"     149",
"    </a>",
"    ]. Anxiety associated with false-positive readings can be decreased by the immediate reading of screening mammograms, which allows for additional mammographic views or ultrasound to be performed during the same appointment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of a false positive mammogram on future screening behavior has been reported as variable. In a meta-analysis, women in the US were more likely to have routine screening following a false positive screen, while there was no effect on European women and Canadian women were less likely to return for routine screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/149\">",
"     149",
"    </a>",
"    ]. Having a false-positive mammogram result may to lead to increased utilization of health care services [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/152\">",
"     152",
"    </a>",
"    ], though further studies regarding the effects on trust and utilization are indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Overdiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cancers are slow-growing, and some even regress. Overdiagnosis refers to disease that is detected by screening that would not have caused morbidity or mortality if it had not been found. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ideal screening test would distinguish between cancers that carry significant or minimal risk, allowing targeted treatment depending on the tumor biology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/153\">",
"     153",
"    </a>",
"    ]. Such testing is not currently available. Overdiagnosis leads to some patients receiving treatment for a cancer that, if undiscovered, would not cause harm, thus causing adverse effects (both medical and psychological) without decreasing mortality.",
"   </p>",
"   <p>",
"    Overdiagnosis is identified when the number of cancers detected in a screened group exceeds the number of cancers in an unscreened (but otherwise similar) population over long-term follow-up. If there was no overdiagnosis, then one would expect that over time, the number of cancers in both screened and unscreened groups would equalize, although the cancers in the screened group would have been detected sooner and probably at an earlier stage.",
"   </p>",
"   <p>",
"    Multiple studies in breast cancer screening suggest that overdiagnosis is a concern, but a precise estimate of the number of screen-detected cancers that represent overdiagnosis is uncertain. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort study from Norway, based upon the staggered introduction of screening, reviewed data related to breast cancer detected by screening and compared this with concurrent breast cancer incidence in geographic areas where screening was not available and with historical data for the areas with and without screening to correct for time trends in breast cancer incidence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/154\">",
"       154",
"      </a>",
"      ]. The study included 39,888 patients with invasive breast cancer, with 7793 diagnosed after screening was introduced. The study estimated the rate of overdiagnosis to be between 15 and 25 percent.",
"     </li>",
"     <li>",
"      A review of data from five randomized trials in which the control group was not screened found that there was an excess of breast cancers in the intervention group in every study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/155\">",
"       155",
"      </a>",
"      ]. In the screened groups, between 0.07 and 0.73 excessive cancers (either invasive or in situ) per 1,000 women years could be attributed to overdiagnosis. This would account for approximately 4 to 32 percent of all breast cancers found by screening.",
"     </li>",
"     <li>",
"      A systematic review of breast cancer incidence trends in public mammography screening programs in five western countries compared incidence trends for seven years before and after screening introduction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/156\">",
"       156",
"      </a>",
"      ]. After taking into account the expected initial increase related to prevalence screening, as well as the background trends in breast cancer incidence, the authors estimated that one of every three breast cancers detected was due to overdiagnosis.",
"     </li>",
"     <li>",
"      A population-based cohort study found that as a result of screening, the recorded incidence of invasive breast cancer (not including ductal carcinoma in situ) in women ages 50 to 69 increased by 54 percent in Norway and 45 percent in Sweden without any corresponding decline in incidence after the age of 69 (when screening stopped) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/157\">",
"       157",
"      </a>",
"      ]. The study concluded that one-third of all invasive breast cancers in women ages 50 to 69 would not have been detected in the patients' lifetime, raising the possibility that mammographic screening leads to high rates of overdiagnosis of breast cancer. Potential differences in the use of hormone replacement therapy between the screened women and historical control groups have been cited as a possible confounder for these data. The authors subsequently examined data collected in the pre-hormone replacement era, comparing the incidence of breast cancer in women aged 40 to 69 years who participated in a screening program for six years with the incidence of breast cancer in women who were not screened for four years but subsequently underwent mammography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/158\">",
"       158",
"      </a>",
"      ]. The six-year cumulative incidence of breast cancer was greater among screened than non-screened women (RR 1.14, 95% CI 1.10-1.18), again suggesting overdiagnosis of some screen-detected breast cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Ductal carcinoma in situ",
"    </span>",
"    &nbsp;&mdash;&nbsp;As breast cancer screening has increased, the detection of ductal carcinoma in situ (DCIS) has risen dramatically, more than threefold in the 10-year period of 1983 to 1992 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/159\">",
"     159",
"    </a>",
"    ]. DCIS now accounts for approximately 21 percent of all new breast cancers diagnosed in the US, over 90 percent of which are detected only on imaging studies (most commonly by the presence of microcalcifications) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of DCIS is not clear, and many cases may not proceed to invasive cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/161\">",
"     161",
"    </a>",
"    ]. Concerns have been raised that detection of DCIS by mammography may lead to overdiagnosis of breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation increases the risk for breast cancer, but most cohort studies of the phenomenon have included women exposed to much larger radiation doses than the mean glandular dose for a two-view per breast film mammogram at American College of Radiology accredited facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/162,163\">",
"     162,163",
"    </a>",
"    ]. Excess risk of breast cancer, after a 10 year latent period, appears to be linearly dependent on [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/162\">",
"     162",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Radiation dose (higher doses increase risk)",
"     </li>",
"     <li>",
"      Age at onset of screening (younger age at exposure increases risk)",
"     </li>",
"     <li>",
"      Attained age or number of years since exposure (risk increases with increased time since exposure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two studies modelled the risk of increased breast cancer mortality from mammography radiation compared to the mortality benefit from mammogram screening, using data from studies of women with comparable radiation exposure and estimates extrapolated from risk models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/164,165\">",
"     164,165",
"    </a>",
"    ]. Both studies reported that screening was associated with a net positive benefit for onset of screening at age 40 or later. The earlier study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/164\">",
"     164",
"    </a>",
"    ] reported higher rates of radiation-induced cancer but factored in higher doses of radiation per mammogram than are used currently. The later study estimated that, per 100,000 women screened annually from 40 to 55 years and biennially until age 74, 136 woman-years would be lost due to radiation-induced cancer and 10,670 woman-years would be saved due to earlier detection of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/165\">",
"     165",
"    </a>",
"    ]. The assumptions used in this model may not be applicable to women with BRCA1 or BRCA2 mutations.",
"   </p>",
"   <p>",
"    In sum, radiation risk from mammography is low enough that a screening mammogram program for average risk women over age 40 saves lives.",
"   </p>",
"   <p>",
"    While the risk of radiation-associated breast cancer from breast imaging for average risk women is felt to be small or nonexistent, women at high genetic risk may be more susceptible to radiation-induced carcinogenesis because of the role of BRCA proteins in DNA repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'Gene function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies differ on the effect of diagnostic radiation in this group of women, with growing evidence that the effect depends on the age when exposure occurs and the total dose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 1993 carriers of",
"      <span class=\"nowrap\">",
"       BRCA1/BRCA2",
"      </span>",
"      mutations, any exposure of diagnostic radiation before age 30 was associated with an increased risk of breast cancer (hazard ratio [HR] 1.90, 95% CI 1.20-3.00), with a dose-response pattern [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/166\">",
"       166",
"      </a>",
"      ]. A history of having a mammogram before age 30 in BRCA mutation carriers was associated with an insignificant increased risk of breast cancer (HR 1.43, CI 0.85-2.40). Increased risk of breast cancer among women in this study occurred at radiation dose levels considerably lower than that among women without BRCA. There was no association between breast cancer risk and radiation exposure from ages 30 to 39. The authors concluded that the study supported use of non-ionizing radiation imaging (such as MRI) in young women with",
"      <span class=\"nowrap\">",
"       BRCA1/BRCA2",
"      </span>",
"      mutations. Further data are needed, however, to determine whether such an approach is optimal; current recommendations by most groups support screening these women with a combination of mammography and MRI scanning. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link&amp;anchor=H15841803#H15841803\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Breast cancer screening in women'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other studies evaluating the effect of chest x-rays on BRCA mutation carriers found a significantly elevated risk of breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/167,168\">",
"       167,168",
"      </a>",
"      ]. In one study, individuals who reported any exposure were 54 percent more likely to develop breast cancer compared to individuals without any exposure (HR 1.54) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/167\">",
"       167",
"      </a>",
"      ]. The risk was highest for women who reported having more than five chest x-rays (HR 2.69) and for those who were exposed before the age of 20 (HR 5.21).",
"     </li>",
"     <li>",
"      In a report that was based upon a questionnaire sent to known BRCA mutation carriers, exposure to mammographic screening (mean age at first screening mammogram 35 years of age) was not associated with an increased risk of breast cancer when adjusted for parity, oral contraceptive use, family history, and ethnicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/169\">",
"       169",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Discomfort",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammographic screening can be uncomfortable or painful, as the breast needs to be compressed to achieve adequate images. There are few high quality studies examining methods to reduce discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/170\">",
"     170",
"    </a>",
"    ]. One well-designed study found that patient-controlled breast compression reduced patient discomfort while achieving good image quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/171\">",
"     171",
"    </a>",
"    ]. Another randomized trial in women with high expectation of pain from the procedure found that topical application of 4%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    gel to the breast and chest wall reduced discomfort but premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/172\">",
"     172",
"    </a>",
"    ]. Reduced discomfort correlated with increased intent to return for another screening examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     TRADE-OFFS BETWEEN BENEFITS AND HARMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies and commentaries have emphasized the trade-offs between benefits and harms of breast cancer screening, demonstrating that the trade-offs vary by age, frequency, and type of screening. A table summarizes the findings of an estimate of mammography screening consequences, while varying frequency and age at which screening starts and ends (",
"    <a class=\"graphic graphic_table graphicRef69681 \" href=\"mobipreview.htm?35/61/36828\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefits in terms of numbers of lives saved and life-years gained per 1000 women are greatest when the widest age range is screened annually. However, including women in their 40s substantially increases the number of mammograms and unnecessary biopsies. Trade-offs in terms of numbers of lives saved in relation to false-positive results and breast biopsies are shown in figures (",
"    <a class=\"graphic graphic_figure graphicRef76245 graphicRef56330 \" href=\"mobipreview.htm?24/27/25008\">",
"     figure 3A-B",
"    </a>",
"    ). The table (",
"    <a class=\"graphic graphic_table graphicRef69681 \" href=\"mobipreview.htm?35/61/36828\">",
"     table 5",
"    </a>",
"    ) and figures make explicit the fact that many women will experience harms for each woman whose life is saved by mammography.",
"   </p>",
"   <p>",
"    The benefits and harms of screening for breast cancer should be discussed with all women. Discussing risks and benefits of mammography for women aged 40 to 50 is especially important because the absolute benefits of screening are smaller and the associated risks associated are greater than in older women. Sharing the information in the accompanying table and figure (",
"    <a class=\"graphic graphic_table graphicRef69681 \" href=\"mobipreview.htm?35/61/36828\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76245 graphicRef56330 \" href=\"mobipreview.htm?24/27/25008\">",
"     figure 3A-B",
"    </a>",
"    ) may be helpful. The decision to perform mammography should be determined with shared decision making about risks and benefits and by individual patient values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/173\">",
"     173",
"    </a>",
"    ]. The discussion should be noted in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR SCREENING BY EXPERT GROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Screening with mammography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Age to initiate",
"    </span>",
"    &nbsp;&mdash;&nbsp;All major North American groups making recommendations about breast cancer screening recommend routine screening with mammography with or without clinical breast examination for women age 50 and older. There is controversy, however, about routine screening for women in their 40s, with some groups recommending shared decision making because of trade-offs of benefits and harms (",
"    <a class=\"graphic graphic_table graphicRef53551 \" href=\"mobipreview.htm?12/50/13101\">",
"     table 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Cancer Society [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/174\">",
"       174",
"      </a>",
"      ], American College of Radiology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/75\">",
"       75",
"      </a>",
"      ], American Medical Association [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/175\">",
"       175",
"      </a>",
"      ], the National Cancer Institute [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/176\">",
"       176",
"      </a>",
"      ], the American College of Obstetricians and Gynecologists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/96\">",
"       96",
"      </a>",
"      ] and the National Comprehensive Cancer Network (NCCN) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/177\">",
"       177",
"      </a>",
"      ] recommend starting routine screening at age 40. The American Academy of Family Physicians recommends screening mammography every one to two years for women ages 40 and older [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/178\">",
"       178",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United States Preventive Services Task Force (USPSTF), the American College of Physicians and the Canadian Task Force on the Periodic Health Examination recommend beginning routine screening at age 50 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179-181\">",
"       179-181",
"      </a>",
"      ]. The Canadian Task Force in 2011 revised its recommendations to recommend against screening for women under age 50 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/181\">",
"       181",
"      </a>",
"      ]. These groups advise individual risk assessment and shared decision-making with patients regarding mammogram screening for women 40 to 49 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179,180\">",
"       179,180",
"      </a>",
"      ]. For women who do not wish to participate in shared decision-making, the ACP suggests mammograms every 1 to 2 years for women age 40 to 49 years. The USPSTF advises screening every two years for women who elect to be screened. In December 2009, after professional and public reaction, the USPSTF revised their November 2009 recommendation, dropping the comment not to routinely screen women aged 40 to 49 with mammography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179\">",
"       179",
"      </a>",
"      ], but continuing to recommend \"The decision to start regular biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/182\">",
"       182",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 2000, the Advisory Committee on Cancer Prevention in the European Union recommended women between the ages of 50 and 69 be offered mammogram screening in the context of an organized screening program with quality assurance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/183\">",
"       183",
"      </a>",
"      ]. Women aged 40 to 49 should be advised of potential harms of screening, and if mammograms are offered to these women, they should be performed with strict quality standards and double reading.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Age to discontinue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several groups do not explicitly state at what age breast cancer screening should stop. The USPSTF recommends mammography screening to age 74, as does the Canadian Task Force of Preventive Health Care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179,181\">",
"     179,181",
"    </a>",
"    ]. They state that there is insufficient evidence beyond age 74. The American College of Radiology recommends screening until life expectancy is &lt;five to seven years, on the basis of age or comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/75\">",
"     75",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists recommend that women aged 75 years and older should consult with their physician to decide whether to continue screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The USPSTF recommends biennial mammography screening for women who are screened. Most other North American groups recommending screening for women in their 40s have tended to shift towards annual examinations because of the evidence of more rapid tumor growth in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/96,184\">",
"     96,184",
"    </a>",
"    ]. However, the benefit of detecting more tumors in earlier stage needs to be balanced against the increased harms associated with an increased rate of false-positive mammograms for women in their 40s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended frequency of mammography is variable among organizations (",
"    <a class=\"graphic graphic_table graphicRef53551 \" href=\"mobipreview.htm?12/50/13101\">",
"     table 7",
"    </a>",
"    ). The World Health Organization recommends mammography every one to two years for women aged 50 to 69 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/185\">",
"     185",
"    </a>",
"    ]. There has been a tendency for recommendations to extend the interval to two years for older women. The Advisory Committee on Cancer Prevention in the European Union has recommended mammograms be performed at intervals of two to three years for women 50 to 69 and, if performed for women 40 to 49, at intervals of 12 to 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/183\">",
"     183",
"    </a>",
"    ]. In 2011, the Canadian Task Force recommended screening intervals of two to three years, whereas previous recommendations had been for one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/181\">",
"     181",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Screening with clinical breast examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Cancer Society recommends clinical breast examination every three years from age 20 to 39, and annually thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/174\">",
"     174",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists recommends clinical breast examination every one to three years from age 20 to 39, and annually thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/96\">",
"     96",
"    </a>",
"    ]. The US Preventive Services Task Force concludes that evidence is insufficient to assess additional benefits of clinical breast examination beyond mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179\">",
"     179",
"    </a>",
"    ], and the Canadian Task Force on Preventive Health Care recommends against clinical breast examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/181\">",
"     181",
"    </a>",
"    ]. The World Health Organization does not recommend clinical breast examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/185\">",
"     185",
"    </a>",
"    ]. No group recommends clinical breast examination alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Screening with breast self-examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less consensus among expert groups about teaching and promoting breast self-examination (BSE).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Canadian Task Force on Preventive Health Care recommends not advising women to routinely practice self-breast examination, on the basis of no evidence of a reduction in mortality, but evidence of increased harm with BSE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/181\">",
"       181",
"      </a>",
"      ]. The US Preventive Services Task Force recommends against teaching women the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179\">",
"       179",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 2003, the American Cancer Society changed its previous recommendation in favor of monthly BSE to a recommendation that women be educated about the benefits and limitations of BSE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/186\">",
"       186",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American College of Obstetricians and Gynecologists recommends breast self-awareness, which &ldquo;can include breast self-examination&rdquo; [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Advisory Committee on Cancer Prevention in the European Union states that there is \"no convincing evidence for the effect of screening based on breast self-examination or clinical breast examination\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/183\">",
"       183",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The World Health Organization recommends against BSE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179\">",
"       179",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The National Comprehensive Cancer Network (NCCN) recommends that women maintain \"breast awareness\" but revised 2009 guidelines no longer recommend instruction in breast self examination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/177\">",
"       177",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Screening with breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most groups issuing guidelines about breast cancer screening have not commented on breast MRI.",
"   </p>",
"   <p>",
"    The 2007 American Cancer Society (ACS) recommends offering annual MRI, in addition to mammography, to women within certain high-risk groups including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Known BRCA mutation carriers",
"     </li>",
"     <li>",
"      First degree relatives of known BRCA mutation carriers",
"     </li>",
"     <li>",
"      Women with an approximate lifetime risk of breast cancer from 20 to over 25 percent, according to risk prediction models primarily using family history (",
"      <a class=\"graphic graphic_table graphicRef54270 \" href=\"mobipreview.htm?11/57/12188\">",
"       table 8",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ACS recommends against MRI screening for women with less than a 15 percent lifetime risk and states that evidence is insufficient to support recommendations for women with risks between 15 and 20 percent.",
"   </p>",
"   <p>",
"    Guidelines from the National Comprehensive Cancer Network (NCCN) recommend annual breast MRI in addition to mammography for women with a strong family history or genetic predisposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/177\">",
"     177",
"    </a>",
"    ]. The criteria specified include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BRCA 1 or 2 mutation carriers",
"     </li>",
"     <li>",
"      Untested women who have a first degree relative with a BRCA 1 or 2 mutation",
"     </li>",
"     <li>",
"      Lifetime risk of breast cancer of 20 to 25 percent or more, defined by models that are largely dependent on family history (eg, BRCAPRO and others) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"       \"Risk prediction models for breast cancer screening\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Received radiation treatment to the chest between ages 10 and 30",
"     </li>",
"     <li>",
"      Genetic mutation in the TP53 (Li-Fraumeni syndrome) or PTEN genes (Cowden syndrome) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=see_link\">",
"       \"Li-Fraumeni syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29530?source=see_link\">",
"       \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Institute for Health and Clinical Excellence (NICE) guidelines recommends offering annual MRI in addition to mammography to the following high risk groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/187\">",
"     187",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      BRCA1 and BRCA2 mutations carriers, starting at age 30",
"     </li>",
"     <li>",
"      TP53 mutation carriers, starting at 20",
"     </li>",
"     <li>",
"      Women in their 30s with a 10-year risk &gt;= 8 percent",
"     </li>",
"     <li>",
"      Women in their 40s with a 10-year risk &gt;= 20 percent",
"     </li>",
"     <li>",
"      Women in their 40s with dense breasts and a 10-year risk &gt;= 12 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The USPSTF concluded that evidence is insufficient to determine benefits and harms of digital mammography or MRI for breast cancer screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179\">",
"     179",
"    </a>",
"    ]. Recommendations of other groups vary, but many predate the publication of several key studies on the utility of breast MRI in high-risk women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     FOLLOW-UP OF DETECTED ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of abnormalities detected by screening mammography, clinical breast examination, or breast self-examination is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=see_link\">",
"       \"Patient information: Breast cancer screening (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/40/36481?source=see_link\">",
"       \"Patient information: Breast cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An approach to breast cancer screening should incorporate an individual's level of breast cancer risk, established by history and by use of a risk prediction model. The model most commonly used is the Breast Cancer Risk Assessment Tool (Gail model), available online at",
"      <a class=\"external\" href=\"file://www.cancer.gov/bcrisktool/\">",
"       www.cancer.gov/bcrisktool/",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=see_link\">",
"       \"Risk prediction models for breast cancer screening\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Breast cancer risk prediction tools'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should discuss breast cancer screening with all female patients starting at age 40, and the decision about screening should be recorded in the medical record. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Women in their 40s'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Lifetime breast cancer risk below 15 percent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable approach to breast cancer screening in average risk women is summarized below (",
"    <a class=\"graphic graphic_table graphicRef63099 \" href=\"mobipreview.htm?30/17/31004\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that women between the ages of 50 and 70 be screened with mammography (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Information about the risk of breast cancer and the benefits and harms of screening should be reviewed (",
"      <a class=\"graphic graphic_figure graphicRef76245 graphicRef56330 \" href=\"mobipreview.htm?24/27/25008\">",
"       figure 3A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef69681 \" href=\"mobipreview.htm?35/61/36828\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mammography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest discussion of the risks and benefits of mammography between women age 40 to 50 and their clinician; the decision to perform mammography should be determined by individual patient risk and values through shared decision making (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Women in their 40s'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Trade-offs between benefits and harms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that women over the age of 70 be screened with mammography if their life expectancy is at least 10 years (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Frameworks have been developed that may assist with decision making in older women (",
"      <a class=\"graphic graphic_table graphicRef61593 \" href=\"mobipreview.htm?43/14/44268\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Older women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ideal interval for screening mammography is not known, but we suggest screening every one to two years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend that women being screened for breast cancer also undergo clinical breast examination (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Clinical breast examination may be particularly useful in older women. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical breast examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of breast self-examination (BSE) is unproven. We suggest that BSE",
"      <strong>",
"       not",
"      </strong>",
"      be performed except by women who express a desire to do so and who have received careful instruction to differentiate normal tissue from suspicious lumps (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). BSE should only be performed as an adjunct to mammography and clinical breast examination, not as a substitute for these screening methods. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Breast self-examination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Lifetime breast cancer risk 20 to 25 percent or higher",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women at high risk for breast cancer (lifetime risk &ge;20 to 25 percent) should be referred for genetic counseling to determine the likelihood of a BRCA mutation and to decide on management options. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with a lifetime risk of breast cancer &ge;20 to 25 percent (mutation carriers and others) who choose intensified surveillance for breast cancer, we suggest annual mammography and MRI, as well as clinical breast examinations every three to six months and monthly breast self-examinations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The appropriate age to begin annual screening is not established. Until further data are available, we suggest that screening be initiated at age 25 for these women (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Germline predisposition (BRCA1 or BRCA2)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Mild to moderately increased lifetime breast cancer risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is not known whether increased screening, either by beginning at an earlier age or by adding breast MRI, would result in greater benefits than harms for women with mild to moderately elevated lifetime breast cancer risks (15 percent or greater and less than 20 to 25 percent). We suggest that women with mild to moderately increased breast cancer risk follow the recommendations for women at average risk (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Family history of breast cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/1\">",
"      Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/3\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD 2007. Available at: file://seer.cancer.gov/csr/1975_2004/ (Accessed on January 12, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/5\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/6\">",
"      McNeil C. Breast cancer decline mirrors fall in hormone use, spurs both debate and research. J Natl Cancer Inst 2007; 99:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/7\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/8\">",
"      Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/9\">",
"      Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/10\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/11\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/12\">",
"      Smith-Bindman R, Miglioretti DL, Lurie N, et al. Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med 2006; 144:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/13\">",
"      Mittra I. Screening for breast cancer: is it globally applicable? Nat Clin Pract Oncol 2008; 5:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/14\">",
"      Wong IO, Kuntz KM, Cowling BJ, et al. Cost effectiveness of mammography screening for Chinese women. Cancer 2007; 110:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/15\">",
"      Smith RA, Caleffi M, Albert US, et al. Breast cancer in limited-resource countries: early detection and access to care. Breast J 2006; 12 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/16\">",
"      Arslan AA, Formenti SC. Mammography in developing countries: the risks associated with globalizing the experiences of the Western world. Nat Clin Pract Oncol 2009; 6:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: Colorectal cancer screening, incidence, and mortality--United States, 2002-2010. MMWR Morb Mortal Wkly Rep 2011; 60:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/18\">",
"      Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 2012; 156:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/19\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/20\">",
"      King MC, Rowell S, Love SM. Inherited breast and ovarian cancer. What are the risks? What are the choices? JAMA 1993; 269:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/21\">",
"      Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/22\">",
"      Hulka BS, Stark AT. Breast cancer: cause and prevention. Lancet 1995; 346:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/23\">",
"      Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997; 336:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/24\">",
"      Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289:3243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/25\">",
"      Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/26\">",
"      Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/27\">",
"      Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007; 99:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/28\">",
"      Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/29\">",
"      Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/30\">",
"      Berg WA. Tailored supplemental screening for breast cancer: what now and what next? AJR Am J Roentgenol 2009; 192:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/31\">",
"      Weaver DL, Rosenberg RD, Barlow WE, et al. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 2006; 106:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/32\">",
"      Fletcher SW, Black W, Harris R, et al. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993; 85:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/33\">",
"      Elwood M, Cox B, Richardson A. The effectiveness of breast cancer screening by mammography in younger women: correction. Online J Curr Clin Trials 1994; Doc No 121:[385 words; 4 paragraphs].",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/34\">",
"      Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/35\">",
"      Nystr&ouml;m L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/36\">",
"      Freedman DA, Petitti DB, Robins JM. On the efficacy of screening for breast cancer. Int J Epidemiol 2004; 33:43.",
"     </a>",
"    </li>",
"    <li>",
"     Breast cancer screening. In: IARC Handbook of cancer prevention, Vainio H, Bianchini F (Eds), Lyon IARC Press, Lyon, France 2002. Vol 7.",
"    </li>",
"    <li>",
"     National Cancer Institute. Breast Cancer (PDQ&reg;): Screening. Available at: file://cancer.gov/cancertopics/pdq/screening/breast/healthprofessional (Accessed on November 15, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/39\">",
"      Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer 2009; 45:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/40\">",
"      G&oslash;tzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011; :CD001877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/41\">",
"      Autier P, Koechlin A, Smans M, et al. Mammography screening and breast cancer mortality in Sweden. J Natl Cancer Inst 2012; 104:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/42\">",
"      Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/43\">",
"      Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/44\">",
"      Otto SJ, Fracheboud J, Verbeek AL, et al. Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2012; 21:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/45\">",
"      Elmore JG, Reisch LM, Barton MB, et al. Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 2005; 97:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/46\">",
"      Pisano ED, Yaffe MJ. Digital mammography. Radiology 2005; 234:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/47\">",
"      Lewin JM, D'Orsi CJ, Hendrick RE, et al. Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. AJR Am J Roentgenol 2002; 179:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/48\">",
"      Skaane P, Young K, Skjennald A. Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading--Oslo I study. Radiology 2003; 229:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/49\">",
"      Skaane P, Skjennald A. Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial in a population-based screening program--the Oslo II Study. Radiology 2004; 232:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/50\">",
"      Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005; 353:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/51\">",
"      Skaane P, Hofvind S, Skjennald A. Randomized trial of screen-film versus full-field digital mammography with soft-copy reading in population-based screening program: follow-up and final results of Oslo II study. Radiology 2007; 244:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/52\">",
"      Kerlikowske K, Hubbard RA, Miglioretti DL, et al. Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States: A Cohort Study. Ann Intern Med 2011; 155:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/53\">",
"      Pisano ED, Hendrick RE, Yaffe MJ, et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 2008; 246:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/54\">",
"      van Ravesteyn NT, Miglioretti DL, Stout NK, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med 2012; 156:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/55\">",
"      Hofvind S, Vacek PM, Skelly J, et al. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst 2008; 100:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/56\">",
"      Hubbard RA, Kerlikowske K, Flowers CI, et al. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med 2011; 155:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/57\">",
"      Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/58\">",
"      Moore SG, Shenoy PJ, Fanucchi L, et al. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res 2009; 9:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/59\">",
"      Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/60\">",
"      Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 2000; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/61\">",
"      Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/62\">",
"      Stoutjesdijk MJ, Boetes C, Jager GJ, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001; 93:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/63\">",
"      Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/64\">",
"      Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/65\">",
"      Lehman CD, Isaacs C, Schnall MD, et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007; 244:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/66\">",
"      Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/67\">",
"      Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/68\">",
"      Warner E, Messersmith H, Causer P, et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/69\">",
"      Rijnsburger AJ, Obdeijn IM, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010; 28:5265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/70\">",
"      Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012; 107:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/71\">",
"      Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/72\">",
"      Brenner RJ, Parisky Y. Alternative breast-imaging approaches. Radiol Clin North Am 2007; 45:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/73\">",
"      Moskowitz M, Milbrath J, Gartside P, et al. Lack of efficacy of thermography as a screening tool for minimal and stage I breast cancer. N Engl J Med 1976; 295:249.",
"     </a>",
"    </li>",
"    <li>",
"     www.cancer.org/acs/groups/cid/documents/webcontent/003178-pdf.pdf. (Accessed on December 29, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/75\">",
"      Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 2010; 7:18.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm257707.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/77\">",
"      Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 1992; 147:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/78\">",
"      Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000; 92:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/79\">",
"      Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA 1999; 282:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/80\">",
"      Chiarelli AM, Majpruz V, Brown P, et al. The contribution of clinical breast examination to the accuracy of breast screening. J Natl Cancer Inst 2009; 101:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/81\">",
"      Bobo JK, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000; 92:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/82\">",
"      Fenton JJ, Rolnick SJ, Harris EL, et al. Specificity of clinical breast examination in community practice. J Gen Intern Med 2007; 22:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/83\">",
"      Okonkwo QL, Draisma G, der Kinderen A, et al. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst 2008; 100:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/84\">",
"      K&ouml;sters JP, G&oslash;tzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003; :CD003373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/85\">",
"      Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002; 94:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/86\">",
"      Baxter N, Canadian Task Force on Preventive Health Care. Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 2001; 164:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/87\">",
"      Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a meta-analysis. Br J Cancer 2003; 88:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/88\">",
"      Harvey BJ, Miller AB, Baines CJ, Corey PN. Effect of breast self-examination techniques on the risk of death from breast cancer. CMAJ 1997; 157:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/89\">",
"      Newcomb PA, Weiss NS, Storer BE, et al. Breast self-examination in relation to the occurrence of advanced breast cancer. J Natl Cancer Inst 1991; 83:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/90\">",
"      Qin XJ, Ling BX. Proteomic studies in breast cancer (Review). Oncol Lett 2012; 3:735.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement Jan 21-23,1997. National Institutes of Health. Available at: file://consensus.nih.gov/1997/1997BreastCancerScreening103html.htm (Accessed on October 26, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/92\">",
"      Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003; 138:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/93\">",
"      Yankaskas BC, Haneuse S, Kapp JM, et al. Performance of first mammography examination in women younger than 40 years. J Natl Cancer Inst 2010; 102:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/94\">",
"      Kapp JM, Ryerson AB, Coughlin SS, Thompson TD. Racial and ethnic differences in mammography use among U.S. women younger than age 40. Breast Cancer Res Treat 2009; 113:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/95\">",
"      Armstrong K, Moye E, Williams S, et al. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 2007; 146:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/96\">",
"      American College of Obstetricians-Gynecologists. Practice bulletin no. 122: Breast cancer screening. Obstet Gynecol 2011; 118:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/97\">",
"      Rajkumar SV, Hartmann LC. Screening mammography in women aged 40-49 years. Medicine (Baltimore) 1999; 78:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/98\">",
"      Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006; 368:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/99\">",
"      Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 1997; 127:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/100\">",
"      Meissner HI, Klabunde CN, Han PK, et al. Breast cancer screening beliefs, recommendations and practices: primary care physicians in the United States. Cancer 2011; 117:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/101\">",
"      Randolph WM, Goodwin JS, Mahnken JD, Freeman JL. Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med 2002; 137:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/102\">",
"      McCarthy EP, Burns RB, Freund KM, et al. Mammography use, breast cancer stage at diagnosis, and survival among older women. J Am Geriatr Soc 2000; 48:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/103\">",
"      Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J. Is screening mammography effective in elderly women? Am J Med 2000; 108:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/104\">",
"      van Dijck JA, Holland R, Verbeek AL, et al. Efficacy of mammographic screening of the elderly: a case-referent study in the Nijmegen program in The Netherlands. J Natl Cancer Inst 1994; 86:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/105\">",
"      Van Dijck JA, Verbeek AL, Beex LV, et al. Mammographic screening after the age of 65 years: evidence for a reduction in breast cancer mortality. Int J Cancer 1996; 66:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/106\">",
"      Schonberg MA, Silliman RA, Marcantonio ER. Weighing the benefits and burdens of mammography screening among women age 80 years or older. J Clin Oncol 2009; 27:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/107\">",
"      Kerlikowske K, Salzmann P, Phillips KA, et al. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA 1999; 282:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/108\">",
"      Mandelblatt J, Saha S, Teutsch S, et al. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 139:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/109\">",
"      Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/110\">",
"      Mathieu E, Barratt A, Davey HM, et al. Informed choice in mammography screening: a randomized trial of a decision aid for 70-year-old women. Arch Intern Med 2007; 167:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/111\">",
"      Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med 2011; 155:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/112\">",
"      Kerlikowske K, Carney PA, Geller B, et al. Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 2000; 133:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/113\">",
"      Liberman L. Breast cancer screening with MRI--what are the data for patients at high risk? N Engl J Med 2004; 351:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/114\">",
"      Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008; 299:2151.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/116\">",
"      Kerlikowske K, Creasman J, Leung JW, et al. Differences in screening mammography outcomes among White, Chinese, and Filipino women. Arch Intern Med 2005; 165:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/117\">",
"      Gill KS, Yankaskas BC. Screening mammography performance and cancer detection among black women and white women in community practice. Cancer 2004; 100:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/118\">",
"      Esserman L, Cowley H, Eberle C, et al. Improving the accuracy of mammography: volume and outcome relationships. J Natl Cancer Inst 2002; 94:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/119\">",
"      Smith-Bindman R, Chu P, Miglioretti DL, et al. Physician predictors of mammographic accuracy. J Natl Cancer Inst 2005; 97:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/120\">",
"      Beam CA, Conant EF, Sickles EA. Association of volume and volume-independent factors with accuracy in screening mammogram interpretation. J Natl Cancer Inst 2003; 95:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/121\">",
"      Barlow WE, Chi C, Carney PA, et al. Accuracy of screening mammography interpretation by characteristics of radiologists. J Natl Cancer Inst 2004; 96:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/122\">",
"      Sumkin JH, Holbert BL, Herrmann JS, et al. Optimal reference mammography: a comparison of mammograms obtained 1 and 2 years before the present examination. AJR Am J Roentgenol 2003; 180:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/123\">",
"      Banks E, Reeves G, Beral V, et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 2004; 329:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/124\">",
"      Baines CJ, Dayan R. A tangled web: factors likely to affect the efficacy of screening mammography. J Natl Cancer Inst 1999; 91:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/125\">",
"      Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/126\">",
"      Tice JA, Cummings SR, Smith-Bindman R, et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008; 148:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/127\">",
"      Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst 2011; 103:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/128\">",
"      Corsetti V, Houssami N, Ferrari A, et al. Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer 2008; 44:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/129\">",
"      White E, Velentgas P, Mandelson MT, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998; 90:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/130\">",
"      Baines CJ, Vidmar M, McKeown-Eyssen G, Tibshirani R. Impact of menstrual phase on false-negative mammograms in the Canadian National Breast Screening Study. Cancer 1997; 80:720.",
"     </a>",
"    </li>",
"    <li>",
"     D'Orsi CJ, Bassett LW, Berg WA, et al.. BI-RADS: Mammography, 4th edition. In: Breast Imaging Reporting and Data System: ACR BI-RADS &ndash; Breast Imaging Atlas, D'Orsi CJ, Mendelson EB, Ikeda DM, et al. (Eds), American College of Radiology, Reston, VA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/132\">",
"      Ciatto S, Houssami N, Apruzzese A, et al. Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. Breast 2005; 14:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/133\">",
"      Kaufman Z, Garstin WI, Hayes R, et al. The mammographic parenchymal patterns of women on hormonal replacement therapy. Clin Radiol 1991; 43:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/134\">",
"      Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003; 95:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/135\">",
"      McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005; 97:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/136\">",
"      Banks E, Reeves G, Beral V, et al. Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study. BMJ 2004; 328:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/137\">",
"      Buist DS, Anderson ML, Reed SD, et al. Short-term hormone therapy suspension and mammography recall: a randomized trial. Ann Intern Med 2009; 150:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/138\">",
"      Miglioretti DL, Rutter CM, Geller BM, et al. Effect of breast augmentation on the accuracy of mammography and cancer characteristics. JAMA 2004; 291:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/139\">",
"      Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/140\">",
"      Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol 1995; 165:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/141\">",
"      Kerlikowske K, Grady D, Barclay J, et al. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 1993; 270:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/142\">",
"      Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ 1996; 312:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/143\">",
"      Eddy DM. Screening for breast cancer. Ann Intern Med 1989; 111:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/144\">",
"      Smith-Bindman R, Chu PW, Miglioretti DL, et al. Comparison of screening mammography in the United States and the United kingdom. JAMA 2003; 290:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/145\">",
"      Christiansen CL, Wang F, Barton MB, et al. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 2000; 92:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/146\">",
"      Welch HG, Fisher ES. Diagnostic testing following screening mammography in the elderly. J Natl Cancer Inst 1998; 90:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/147\">",
"      Elmore JG, Nakano CY, Koepsell TD, et al. International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst 2003; 95:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/148\">",
"      Tyndel S, Austoker J, Henderson BJ, et al. What is the psychological impact of mammographic screening on younger women with a family history of breast cancer? Findings from a prospective cohort study by the PIMMS Management Group. J Clin Oncol 2007; 25:3823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/149\">",
"      Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 2007; 146:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/150\">",
"      Lerman C, Trock B, Rimer BK, et al. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 1991; 114:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/151\">",
"      Barton MB, Morley DS, Moore S, et al. Decreasing women's anxieties after abnormal mammograms: a controlled trial. J Natl Cancer Inst 2004; 96:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/152\">",
"      Barton MB, Moore S, Polk S, et al. Increased patient concern after false-positive mammograms: clinician documentation and subsequent ambulatory visits. J Gen Intern Med 2001; 16:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/153\">",
"      Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009; 302:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/154\">",
"      Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/155\">",
"      Moss S. Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 2005; 7:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/156\">",
"      J&oslash;rgensen KJ, G&oslash;tzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339:b2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/157\">",
"      Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004; 328:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/158\">",
"      Zahl PH, G&oslash;tzsche PC, M&aelig;hlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol 2011; 12:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/159\">",
"      Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/160\">",
"      Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/161\">",
"      Welch HG, Woloshin S, Schwartz LM. The sea of uncertainty surrounding ductal carcinoma in situ--the price of screening mammography. J Natl Cancer Inst 2008; 100:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/162\">",
"      Preston DL, Mattsson A, Holmberg E, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002; 158:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/163\">",
"      Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/164\">",
"      Berrington de Gonz&aacute;lez A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits. Br J Cancer 2005; 93:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/165\">",
"      Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology 2011; 258:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/166\">",
"      Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012; 345:e5660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/167\">",
"      Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 2006; 24:3361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/168\">",
"      Gronwald J, Pijpe A, Byrski T, et al. Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat 2008; 112:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/169\">",
"      Narod SA, Lubinski J, Ghadirian P, et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006; 7:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/170\">",
"      Miller D, Martin I, Herbison P. Interventions for relieving the pain and discomfort of screening mammography. Cochrane Database Syst Rev 2002; :CD002942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/171\">",
"      Kornguth PJ, Rimer BK, Conaway MR, et al. Impact of patient-controlled compression on the mammography experience. Radiology 1993; 186:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/172\">",
"      Lambertz CK, Johnson CJ, Montgomery PG, Maxwell JR. Premedication to reduce discomfort during screening mammography. Radiology 2008; 248:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/173\">",
"      Nekhlyudov L, Braddock CH 3rd. An approach to enhance communication about screening mammography in primary care. J Womens Health (Larchmt) 2009; 18:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/174\">",
"      Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59:27.",
"     </a>",
"    </li>",
"    <li>",
"     www.ama-assn.org/ama/no-index/about-ama/9060.shtml (Accessed on May 10, 2009).",
"    </li>",
"    <li>",
"     www.cancer.gov/cancertopics/pdq/screening/breast/HealthProfessional/page2 (Accessed on May 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/177\">",
"      Bevers TB, Anderson BO, Bonaccio E, et al. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009; 7:1060.",
"     </a>",
"    </li>",
"    <li>",
"     Periodic Health Examinations: Summary of AAFP Policy Recommendations &amp; Age Charts. Available at: www.aafp.org/exam.xml (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/179\">",
"      US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/180\">",
"      Qaseem A, Snow V, Sherif K, et al. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 146:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/181\">",
"      Canadian Task Force on Preventive Health Care, Tonelli M, Connor Gorber S, et al. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ 2011; 183:1991.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Preventive Services Task Force. Screening for Breast Cancer. Available at: www.ahrq.gov/clinic/USpstf/uspsbrca.htm (Accessed on January 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/183\">",
"      Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention. Eur J Cancer 2000; 36:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/184\">",
"      Feig SA, D'Orsi CJ, Hendrick RE, et al. American College of Radiology guidelines for breast cancer screening. AJR Am J Roentgenol 1998; 171:29.",
"     </a>",
"    </li>",
"    <li>",
"     Screening for Breast Cancer, Geneva: World Health Organization, 2009. Available at: file://www.who.int/cancer/detection/breastcancer/en/index.html (Accessed on November 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/49/41754/abstract/186\">",
"      Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003; 53:141.",
"     </a>",
"    </li>",
"    <li>",
"     www.nice.org.uk/guidance/CG41 (Accessed on February 03, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7564 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41754=[""].join("\n");
var outline_f40_49_41754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age/Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Estrogen exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Breast cancer risk prediction tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Film mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Full-field digital mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Computer-aided detection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Frequency of mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5145650\">",
"      Thermography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      BREAST PALPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical breast examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breast self-examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26269818\">",
"      INVESTIGATIONAL TECHNIQUES FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PATIENT AGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Women in their 40s",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112701155\">",
"      - Targeted screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Older women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H614882\">",
"      Combining age with other variables",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FAMILY HISTORY OF BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GERMLINE PREDISPOSITION (BRCA1 OR BRCA2)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER VARIABLES AFFECTING SCREENING ACCURACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119563887\">",
"      Radiologist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119563894\">",
"      Prior studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119563901\">",
"      Body habitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119563919\">",
"      Breast density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119563926\">",
"      Postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119563940\">",
"      Breast surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      HARMS FROM SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      False-positive tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Overdiagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Ductal carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Discomfort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      TRADE-OFFS BETWEEN BENEFITS AND HARMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      RECOMMENDATIONS FOR SCREENING BY EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Screening with mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Age to initiate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Age to discontinue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Screening with clinical breast examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Screening with breast self-examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Screening with breast MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      FOLLOW-UP OF DETECTED ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Lifetime breast cancer risk below 15 percent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Lifetime breast cancer risk 20 to 25 percent or higher",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Mild to moderately increased lifetime breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7564|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/12/20687\" title=\"figure 1\">",
"      Pooled relative risk mammog",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/33/8725\" title=\"figure 2\">",
"      Cost-effective mammography screening strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/9/22686\" title=\"figure 3A\">",
"      Outcome of screening I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/22/34158\" title=\"figure 3B\">",
"      Outcome of screening II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/52/16205\" title=\"table 1\">",
"      Risk factors breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/6/25709\" title=\"table 2\">",
"      Risk factors breast ca 40 to 49",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/17/31004\" title=\"table 3\">",
"      Strategy breast ca screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/29/6620\" title=\"table 4\">",
"      Risk of false-pos result by freq of mammography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/61/36828\" title=\"table 5\">",
"      Chances bc related outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/14/44268\" title=\"table 6\">",
"      Breast ca screening over50",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/50/13101\" title=\"table 7\">",
"      Soc and govt recs mamm scrn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/57/12188\" title=\"table 8\">",
"      Recs breast MRI screen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_49_41755="History in musculoskeletal CP";
var content_f40_49_41755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important features of the history in musculoskeletal chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Features suggestive of visceral causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Middle aged or elderly patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk factors for coronary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exertional pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Features suggestive of musculoskeletal cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insidious onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent repetitive unaccustomed activity (trunk and arms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positional component",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent and prolonged (lasting hours-days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Features suggestive of associated condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck, thoracic, or shoulder pain (pain referred to chest)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic low back pain, young patient (ankylosing spondylitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocular inflammation (ankylosing spondylitis or related disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse musculoskeletal pain/sleep disturbance (fibromyalgia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral joint pain and swelling (rheumatoid arthritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin lesions (psoriasis), (psoriatic arthritis)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41755=[""].join("\n");
var outline_f40_49_41755=null;
var title_f40_49_41756="Brucella postexposure recs";
var content_f40_49_41756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for surveillance and postexposure prophylaxis (PEP) after laboratory exposure to",
"    <em>",
"     Brucella",
"    </em>",
"    isolates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Evaluate all workers exposed to",
"        <em>",
"         Brucella",
"        </em>",
"        isolates* and classify exposures as either high risk or low risk.&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Recommend PEP for workers with high-risk exposures to",
"        <em>",
"         Brucella",
"        </em>",
"        isolates. PEP should be offered as soon as",
"        <em>",
"         Brucella",
"        </em>",
"        exposure has been identified, up to the end of the 6-month incubation period.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Administer doxycycline 100 mg twice daily and rifampin 600 mg once daily for 3 weeks or doxycycline alone if exposed to",
"        <em>",
"         Brucella abortus",
"        </em>",
"        RB51 strain, which is resistant to rifampin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Trimethoprim-sulfamethoxazole (160 mg/800 mg) should be considered for patients with contraindications to doxycycline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Pregnant workers with high-risk exposures should be considered for PEP in consultation with their obstetricians.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discuss potential PEP with workers who have low-risk exposures to",
"        <em>",
"         Brucella",
"        </em>",
"        isolates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain baseline serum samples from all workers exposed to",
"        <em>",
"         Brucella",
"        </em>",
"        , unless exposed to",
"        <em>",
"         B. abortus",
"        </em>",
"        RB51 strain, which does not elicit a measurable serologic response using available assays.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrange for serologic testing on all workers exposed to",
"        <em>",
"         Brucella",
"        </em>",
"        (eg, 2, 4, 6, and 24 weeks postexposure) using agglutination testing (eg, tube or",
"        <em>",
"         Brucella",
"        </em>",
"        microagglutination testing) at the state public health laboratory or CDC; serologic testing is not recommended for workers exposed to",
"        <em>",
"         B. abortus",
"        </em>",
"        RB51 strain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arrange for regular (eg, weekly) active surveillance for febrile illness among all workers exposed to",
"        <em>",
"         Brucella",
"        </em>",
"        isolates for 6 months after last exposure.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A",
"     <em>",
"      Brucella",
"     </em>",
"     -exposed worker is defined as any worker present in the microbiology laboratory during workup and identification of a",
"     <em>",
"      Brucella",
"     </em>",
"     isolate, from the time the culture is first manipulated until all culture isolates are destroyed or removed from the laboratory.",
"     <br>",
"      &bull; A high-risk exposure is defined as 1) having direct personal exposure to",
"      <em>",
"       Brucella",
"      </em>",
"      (eg, sniffing bacteriologic cultures, direct skin contact, pipetting by mouth, inoculation, or spraying into the eyes, nose, or mouth), 2) performing work on an open bench (ie, outside of biosafety level 3 containment equipment) with an open culture plate containing a",
"      <em>",
"       Brucella",
"      </em>",
"      isolate or being in close proximity to such work (eg, across an open bench top or within 5 feet), or 3) presence in the laboratory during any procedure conducted on a",
"      <em>",
"       Brucella",
"      </em>",
"      isolate that might result in generation of aerosolized organisms and inhalational exposure (eg, vortexing or catalase testing). A low-risk exposure is defined as being present in the laboratory during an exposure but not meeting the definition for a high-risk exposure.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: MMWR Surveill Summ 2008; 57:39.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41756=[""].join("\n");
var outline_f40_49_41756=null;
var title_f40_49_41757="Mortality beta blocker amio";
var content_f40_49_41757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benefit of beta blocker plus amiodarone after myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 231px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pooled analysis of patients in the EMIAT and CAMIAT trials shows that all-cause mortality, arrhythmic death, rescucitated cardiac arrest, and non arrhythmic cardiac death were reduced in patients taking beta blocker; the decrease was most prominent in those treated with the combination of beta blocker and amiodarone.",
"    <div class=\"footnotes\">",
"     Pl: placebo; Am: Amiodarone.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Boutite F, Boissel JP, Connolly SJ, et al, and the EMIAT and CAMIAT Investigators. Circulation 1999; 99:2268.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41757=[""].join("\n");
var outline_f40_49_41757=null;
var title_f40_49_41758="Diagnosis and treatment of intestinal ischemia I";
var content_f40_49_41758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnosis and treatment of intestinal ischemia I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 607px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate accepted management plan; dashed lines indicate alternate management plan.",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; SMA: superior mesenteric artery.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Gastroenterological Association. Brandt, LJ, Boley, SJ, Gastroenterology 2000; 118:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41758=[""].join("\n");
var outline_f40_49_41758=null;
var title_f40_49_41759="Bronchoscopic image of stent through bronchial wall";
var content_f40_49_41759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchoscopic image of a stent through the bronchial wall revealing lung parenchyma with severe emphysema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cardoso, PFG, Snell, GI. Hopkins, P, et al. Clinical application of airway bypass with paclitaxel-eluting stents: Early results. J Thorac Cardiovasc Surg 2007; 134:974. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_49_41759=[""].join("\n");
var outline_f40_49_41759=null;
